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This thesis presents an investigation into gene expression profiling, using microarray and 
next generation sequencing (NGS) datasets, in relation to multi-category diseases such as 
cancer. It has been established that if the sequence of a gene is mutated, it can result in the 
unscheduled production of protein, leading to cancer. However, identifying the molecular 
signature of different cancers amongst thousands of genes is complex. This thesis investigates 
tools that can aid the study of gene expression to infer useful information towards 
personalised medicine.  
For microarray data analysis, this study proposes two new techniques to increase the 
accuracy of cancer classification. In the first method, a novel optimisation algorithm, COA-GA, 
was developed by synchronising the Cuckoo Optimisation Algorithm and the Genetic Algorithm 
for data clustering in a shuffle setup, to choose the most informative genes for classification 
purposes. Support Vector Machine (SVM) and Multilayer Perceptron (MLP) artificial neural 
networks are utilised for the classification step. Results suggest this method can significantly 
increase classification accuracy compared to other methods.   
An additional method involving a two-stage gene selection process was developed. In this 
method, a subset of the most informative genes are first selected by the Minimum Redundancy 
Maximum Relevance (MRMR) method. In the second stage, optimisation algorithms are used 
in a wrapper setup with SVM to minimise the selected genes whilst maximising the accuracy 
of classification. A comparative performance assessment suggests that the proposed algorithm 
significantly outperforms other methods at selecting fewer genes that are highly relevant to 
the cancer type, while maintaining a high classification accuracy.  
In the case of NGS, a state-of-the-art pipeline for the analysis of RNA-Seq data is 
investigated to discover differentially expressed genes and differential exon usages between 
normal and AIP positive Drosophila datasets, which are produced in house at Queen Mary, 
University of London. Functional genomic of differentially expressed genes were examined 
and found to be relevant to the case study under investigation. Finally, after normalising the 
RNA-Seq data, machine learning approaches similar to those in microarray was successfully 
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A basic question in regulatory biology is ‘how is it possible that all humans can have a 
99.9% identical genome, but still be different?’ Each individual has a 100% identical genome 
in different organs, but each organ has a different shape and functionality.  The answer is 
that different cells types express a different set of genes through a phenomenon known as 
gene expression, in which the information from the DNA is transcribed to RNA, and then 
translated to proteins that form the cell shapes and their functionalities.  
Many studies have shown that if the sequence of a gene is mutated, it can result in an 
unscheduled production of protein, which can lead to diseases such as cancer [1]. 
Furthermore, recent research suggested that cancer could also form without any change 
happening in the underlying gene sequence itself, through epigenetic modifications such as 
histone modification and DNA methylation [2]. The invention of microarray technology paved 
the way to quantify the gene expressions of thousands of genes simultaneously. More 
recently, a more sophisticated technology known as Next Generation Sequencing (NGS) has 
improved gene expression quantification and allowed investigation of epigenetic modifications 
on a wide scale in genomes.  
Microarray technology can be used in a range of scientific fields and can contribute to the 
diagnoses of diseases. Although cancer is a complex disease that arises from multiple genetic 
factors, it is known that the level of gene expression could carry a signature for a disease. A 
vast majority of fatal diseases have a unique gene expression profile that can be observed 
using microarray technology. The main field that microarray gene expression is applied in is 
profiling cancerous tissue. Measuring the gene expression of diseased tissue enables 
researchers to understand tumours and discover possible markers for them.  For example, 
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some prognostic markers were discovered based on gene expression profiles by Sorlie et al 
[3] which are used for overall survival in breast cancer. 
Analyses of gene expression data produced by microarray technology can be classified into 
two different types; namely supervised and unsupervised learning (clustering). Clustering 
divides data sets into several groups such that the similarity within a group is greater than 
that among groups. Since copious amounts of gene expression data is produced with 
microarrays, it is useful to group genes such that genes with similar expression patterns are 
put into one cluster, where the genes within the cluster are known as co-expressed genes. 
Research suggests that genes in one cluster have related functions [4–6]. In machine learning, 
procedures that use annotated samples are referred to as supervised learning [7]. Therefore, 
in supervised learning, classes are predefined and the objective is to train a set of data to 
form a classifier for classification of future observations. 
Recently, microarray technology has been used to determine subtypes of certain cancers 
based on differences in the expression level of key genes [8–10]. This approach has become 
known as cancer classification, and provides detailed information on the genetic makeup of 
each individual cancer patient, thereby potentially improving the accuracy of treatment 
decisions made by doctors [11]. During microarray analysis, the number of genes is 
significantly higher than the number of samples [12,13] and classification with a high degree 
of accuracy is challenging, due to the phenomenon of the so called curse of dimensionality 
[14,15]. In order to overcome this problem, gene selection mechanisms have been introduced, 
by which only the most important genes are selected and used for classification purposes [16–
19]. There are several advantages to this process of minimising the number of genes and only 
selecting the meaningful genes that are more predictive during classification, and this will be 
explained in detail in chapter 3.  
Whilst microarray technology is widely used and has greatly contributed in gene expression 
research over the years, it does have its limitations, such as the noise produced during the 
experiments [20]. Therefore, over the last few years, new sequencing technologies have been 
developed including next generation sequencing (NGS) technology. The arrival of NGS 
technologies in the marketplace has changed the scientific perspective on basic, applied and 
clinical research. NGS technologies have the ability to produce millions of sequence reads in 
each run, which makes it possible to sequence the whole genome easily. As a result, it allows 
large-scale evolutionary and comparative studies to be performed. NGS technologies have 
been used in different projects, such as RNA expression profiling, mutation discovery, defining 
DNA-protein interaction, and whole-genome sequencing [20]. 
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RNA expression profiling, which utilises NGS technology, can provide gene expression 
quantification on a genome-wide scale, providing a tool to not only discover differentially 
expressed genes between conditions, but also one that enables researchers to investigate 
differentially expressed isoforms, and differential exon usage across different conditions. 
Furthermore, RNA-Seq data can be used to discover novel transcripts using statistical analysis 
[21].  
1.2: Motivations  
Over the last 20 years, there has been a revolution in biological sciences and technologies 
like microarray and NGS, which provide an overwhelming volume of data that requires 
computational tools to sift through this data to provide useful information for more informed 
treatment decisions. Most types of cancers are treatable if they can be detected at an early 
stage. The determination of cancer type and stage is also crucial when choosing an 
appropriate treatment. Therefore, the development of computational tools is an important 
topic, and more research is needed to make the most out of the available data.  
Although several methods have been proposed to increase the accuracy of classification 
[22,23], more research is still needed to propose new models that can further increase the 
prognosis and classification accuracy of diseases such as cancer. Achieving high classification 
accuracy is of the utmost importance for personalised medicine, as it would lead to more 
informed decisions by doctors and subsequently save patients’ lives. Since the invention of 
NGS and RNA-Seq, there have been numerous pipelines to investigate the analysis of such 
data. Nevertheless, due to the rapid development of statistical methods for RNA-Seq, the 
proposed pipelines have undergone several changes to improve the results. Hence, it is 
essential to provide a state-of-the-art pipeline to enhance scientific discoveries and their 
implementation into clinical practice.  
1.3: Aim and Objectives 
This thesis presents an investigation into the analysis of gene expression using microarray 
and next generation sequencing data for multi-category diseases like cancer, in order to create 
useful information towards personalised medicine. The objectives of this thesis are described 
below: 
 
• Explore different methods for analysing gene expression data   
• Incorporate machine learning techniques to cluster and classify gene expression data  
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• Assess optimisation-based algorithms for data clustering to enhance the accuracy of cancer 
classification 
• Investigate the impact of data clustering prior to gene selection on classification accuracy 
• Develop novel gene selection models to select the highly informative genes using 
microarray data 
• Identify differential gene expression and differential exon usage using RNA-Seq 
1.4: Contributions 
In this study, different approaches are adopted to improve prognosis and classification of 
multi-category diseases such as cancer using microarray and NGS data towards more 
personalised medicine. The main contributions of this investigation are as follows: 
 
• An innovative gene selection approach using the shuffle method prior to cancer 
classification is proposed. It is noted that in cancer classification using clustering based 
gene selection, changing the number of clusters results in the selection of different sets of 
genes due to the random initialisation of centroid protocol for clustering methods. This 
results in a variation in the accuracy of classification. In order to overcome this problem, 
the shuffle method is proposed, in which genes with a higher rate of repetition are selected 
after six runs of the clustering algorithm. 
 
• A novel optimisation algorithm, COA-GA, has been developed by integrating the Cuckoo 
Optimisation Algorithm (COA) [24] and the Genetic Algorithm (GA) [25] to enhance 
classification performance. The proposed algorithm (COA-GA) not only outperforms COA, 
GA and Particle Swarm Optimisation (PSO) at achieving a better classification performance, 
but also reaches a better minimum with only few iterations.  
 
• It is additionally confirmed that traditional clustering does not have any impact on gene 
selection and classification performance. However, optimisation based clustering is shown 
to enhance the accuracy of gene selection and classification. 
 
• The performances of two well-known classification methods, SVM and MLP, are assessed. 
To examine the performance of these two methods, different cancer datasets including 
leukaemia, prostate, and lymphoma were utilised in different setups. Higher classification 
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accuracy is observed in all cases, with the SVM classifier being compared to MLP when 
analysing gene expression datasets. 
 
• A novel optimisation algorithm, COA-HS, has been developed to enhance gene selection. 
This optimisation algorithm was then used in a two-stage gene selection method, MRMR-
COA-HS, in order to select a few genes that could provide high accuracy in cancer 
classification. Comparative performance assessment of the proposed method with other 
evolutionary algorithms, suggest that the proposed algorithm significantly outperforms 
other methods in selecting a lower number of genes, while maintaining the highest 
classification accuracy. The functions of all selected genes using this method were 
investigated further, and it was confirmed that the selected genes are biologically relevant 
to each type of cancer. 
 
• A state-of-the-art pipeline for RNA-Seq data is proposed. This pipeline was used to analyse 
a set of RNA-Seq data, which was produced at the Genome Centre of Queen Mary 
University. In the proposed pipeline, differential gene expression, and differential exon 
usage were investigated in detail. Furthermore, functional genomics of differentially 
expressed genes were investigated, and some key genes were identified for the case study 
under investigation that can be used as biomarkers. Finally, the application of data 
classification for RNA-Seq data was explored, and methods similar to those in microarray 
classification were successfully implemented. 
1.5: Outline of the Thesis 
Chapter 2 presents a review of recent developments. Initially, a brief overview of the 
biological aspects of the thesis such as gene expression phenomena is given. Then, it explores 
different types of microarray technologies like cDNA and oligonucleotide microarray. Different 
NGS technologies are then investigated, and a unique method for each technique is explained. 
At the end of the chapter, the techniques that incorporate NGS technology such as RNA-Seq 
are assessed.  
Chapter 3 describes the main steps required for microarray analysis, including pre-
processing, clustering, and classification. In this chapter, several clustering methods such as 
K-means, C-means, Hierarchical clustering, self-organising map, Bi-CoPaM and UNCLES are 
investigated. Then the most widely used classification methods such as SVM and MLP artificial 
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neural networks are briefly explained. Afterwards, the importance of gene selection before 
classification is investigated 
Chapter 4 concerns the effect of gene clustering prior to gene selection on the classification 
performance. Initially, the effects of traditional data clustering methods on the classification 
performance are investigated. Then, the effect of optimization based clustering algorithms on 
the performance of SVM and MLP classifiers is investigated and compared to conventional 
methods. 
Chapter 5 presents the development of a two-stage gene selection process, using MRMR 
and the COA-HS algorithm. In this chapter, the MRMR method is described first. Then the use 
of optimization algorithms for gene selection as well as the proposed objective function are 
explained. To this end, different optimization algorithms such as GA, PSO, COA, and HS are 
investigated. The use of the Leave-One-Out Cross-Validation (LOOCV) method to evaluate the 
performance of our proposed method is then explained.  
Chapter 6 is divided into two main sections. The first section describes the main steps 
required for RNA-Seq analysis, including experimental considerations in design, pre-processing 
and quality assessment, alignment, building a count table, and normalisation. Then the 
concept of differential expression at the gene and transcripts levels are examined, and some 
of the well-known software for such analyses are identified. In the second section of this 
chapter a state-of-the-art pipeline for RNA-Seq analysis is presented. In this chapter, RNA-
Seq data from AIP deficient Drosophila is used as the case study (6 samples). Initially, different 
pre-processing steps are explained in order to eliminate biological and technical noises that 
present in RNA-Seq data. Approaches used to create a count table after mapping the samples 
to a reference genome are then explained. Finally, downstream analysis and classification are 
explored. 
Chapter 7 consists of conclusions, discussion, and future work. 
1.6: Publications 
Publications extracted from this thesis are outlined below. 
• Elyasigomari, V., Mirjafari, M. J., Screen, H R C., and Shaheed, M H. (2015), Cancer 
classification using a novel gene selection approach by means of shuffling based on data 
clustering with optimization, Journal of Applied Soft Computing. 35(1), pp 43-51.  
• Elyasigomari, V., Lee, D., Shaheed, M H. (2017), Development of a two-stage gene 
selection method that incorporates a novel hybrid approach using the cuckoo optimization 
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algorithm and harmony search for cancer classification. Journal of Biomedical Informatics. 
67(1), pp 11-20. 
1.7: Utilised microarray datasets throughout this thesis 
In respect to cancer gene expression studies, there are several benchmark microarray data 
sets including leukaemia, lymphoma, and prostate cancer data sets which are also used in this 
research. Brief explanation on these datasets are given in following subsections.   
1.7.1: Leukaemia dataset 
This dataset was taken from a collection of leukaemia samples by Golub et al., (1999). In 
total 72 patients participated in their study. As a result, 72 samples were obtained from bone 
marrow (63 samples) or peripheral blood (9 samples) of these patients and the gene 
expression for these samples were measured using Affymetrix high-density oligonucleotide 
arrays (Affymetrix Hgu6800 chips) that contained 7129 genes. From 72 patients, 47 were 
associated with acute lymphoblastic leukaemia (ALL) and 25 were diagnosed with acute 
myeloblastic leukaemia (AML) [26].  
Although the original study was designed for leukaemia classification in the case of two 
class classification, the 47 samples from ALL could be further categorised into ALL B-CELL (38 
samples), ALL T-CELL (9 samples) which made it possible for some studies to use this dataset 
for multiclass classification. It is noted that this dataset has been used by many authors to 
test the accuracy of their techniques. Golub and his colleagues normalised this dataset such 
that overall intensities for each chip became equivalent by re-scaling intensity values [27]. 
The original dataset available from the Broad institute can be accessed using the link: 
http://portals.broadinstitute.org/cgi-bin/cancer/publications/pub_paper.cgi?mode=view&paper_id=43 
 
1.7.2: Lymphoma dataset 
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of mature B 
lymphocytes. The DLBCL dataset provided by Alizadeh et al., (2000) consists of 47 samples 
and each sample contains 4,026 genes. 24 samples were obtained from germinal centre B-
like DLBCL, and the remaining 23 samples were acquired from activated B-like DLBCL. For the 
measurement of gene expression levels, specialised cDNA microarray was used which 
consisted of genes that had known to have immunologic/oncologic importance or had 
expressed in lymphoid cells [28]. 
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In the process of hybridization, a tumour mRNA sample was used for the fluorescent cDNA 
targets (labelled with dye Cy5) and for the fluorescent cDNA reference a mRNA sample was 
used from lymphoma cell lines and labelled by Cy3. Then the GenePix 4000 microarray scanner 
was used to obtain the fluorescent images. In order to calibrate the fluorescent ratios for all 
arrays a single scaling factor was calculated such that on each array the median fluorescence 
ratio of well-measured spots was 1.0 [28].  This scaling factor was applied to all fluorescence 
ratio for each array. It is noted that fluorescent intensities above 1.4 times of background was 
considered as well measured. The fluorescent ratios then were log-transformed (base 2). In 
order to eliminate the effect of the amount of RNA in the reference pool each data point was 
centred by subtracting the median value for all genes [29]. The original dataset available from 
Lymphoma/Leukemia Molecular Profiling Project can be accessed using following link 
https://llmpp.nih.gov/lymphoma/index.shtml. 
1.7.3: Prostate dataset  
Prostate cancer is one the most common heterogeneous cancer among humans. Singh et 
al., (2002) used microarray expression analysis to investigate important genes and 
pathological features that underlie global biological differences in prostate cancer. In their 
experiment, total RNA was isolated from 55 samples that were obtained from patient with 
prostate cancer and 53 samples that were acquired from healthy individuals. These samples 
were labelled by biotin and hybridized to HU95Av2 microarrays that contained 12,600 genes 
and expressed sequence tags [30].  
Affymetrix GeneChip software was used to calculate the average differences. The average 
pixel mean and standard deviation values for each probe set and the standard deviation of 
the average difference for all genes were calculated. Based on these calculations some 
samples which had high standard deviation were removed from the experiment and 102 
samples including 50 healthy and 52 cancerous samples were chosen as high quality samples. 
These samples then were scaled to a reference sample. Afterwards, the relative variation of 
expression for each gene was computed using the minimum and maximum expression values 
of the gene across all samples. The original dataset available from the Broad institute can be 
















All living organisms are composed of cells.  All cells are characterised by a plasma 
membrane, which encapsulates the cytoplasm and provides internal space where important 
functions are carried out (see Figure 2.1). In this internal compartment, different components 
are present, such as ribosomes and the nucleus. Ribosomes are organelles that process the 
cell’s genetic information to create protein. In the nucleus, the heredity information is stored 
in the form of Deoxyribonucleic Acid (DNA).  Most DNA molecules are double-stranded helices 
consisting of four different nucleotides which are: guanine (G), adenine (A), thymine (T) and 
cytosine (C) [31].  
 
Figure 2.1: Cell structure [32]. 
In humans, the complete set of genetic information that is required for normal functioning 
of the body consists of 3 billion base pairs of DNA packaged into 23 chromosomes. Each cell 
contains almost 2 meters of DNA, and each human roughly consists of 50 trillion cells. If all 
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of the DNA was uncoiled, it would wrap around the Earth’s equator 2.5 million times [33]. So 
the question is: how is this incredible amount of DNA stored in a nucleus?  
The answer to this question lies in the fact that certain proteins compact chromosomal DNA 
into the microscopic space of the eukaryotic nucleus. These proteins are called histones, and 
the resulting DNA-protein complex is called chromatin.    
As can be seen in Figure 2.2 point A, at the simplest level chromatin is a double-stranded 
helical structure of DNA. At point B, DNA is wrapped around eight histones 1.65 times to form 
a nucleosome. Histones are positively charged proteins named H1, H2A, H2B, H3, and H4 
[34]. Since DNA is negatively charged, histones bind with DNA very tightly.  A nucleosome 
with the H1 histone is known as a chromatosome (point C). At point D, it is illustrated how 
nucleosomes fold up to form a 30-nm fibre. This 30-nm fibre folds up more to form loops 
averaging 300-nm in length. Afterwards, the 300-nm fibres are compressed and folded to 
produce a fibre that is 250-nm in width and 700-nm in length (point E). Finally, tight coiling 
of the 250-nm fibre produces the chromatid of a chromosome [33]. 
 
Figure 2.2: Chromatin structure adapted from [33]. 
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2.1: Gene Expression 
Gene expression refers to all the processes that convert genetic information from the DNA 
sequence of genes into gene products. These products can range from proteins to functional 
RNAs that result from protein and non-protein coding genes respectively. A gene is a segment 
of DNA that consists of information used to code for a protein. The genetic information that 
codes for the production of amino acids is stored as three-letter codes, called codons, and the 
sequence of codons defines the primary structure of the final proteins [35]. 
Gene expression involves two steps: the first step is “transcription”, which refers to the 
synthesis of a ribonucleic acid (RNA) molecule using DNA, which occurs within the cell nucleus. 
In this step, the transcription factor connects to the part of DNA referred to as the TATA box 
(also called the Goldberg-Hogness box). Afterwards, the RNA polymerase binds to the 
transcription factor, thereby adding energy (adenosine triphosphate (ATP)) to the process. At 
this point, the transcription starts, and then finally the process is terminated by the RNA 
polymerase, and the newly formed RNA is released from the DNA (see Figure 2.3). Then it 
travels in the form of messenger RNA (mRNA) to the edge of the nucleus, where it gains 
access to the cytoplasm through a tiny hole called a nuclear pore [36]. 
The second step is “translation”, which is carried out in the cytoplasm. This step refers to 
the process of facilitating the codon within the mRNA for the synthesis of a special protein. In 
this step, two important components are utilised: the ribosome (rRNA) and transfer RNA 
(tRNA). After mRNA is exported to the cytoplasm, it is attached to the ribosome. Amino acids 
are carried by tRNA, and can only be added to the chain of growing protein if the tRNA aligns 
to its complementary mRNA codon. Therefore, as the name suggests, the genetic information 
translates into chain of proteins [36]. 
 
Figure 2.3: Process of transcription and translation adapted from [37]. 
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2.2: DNA Microarray 
Microarray technology is a powerful way to quantify gene expression. By using microarray, 
it is possible to examine the expression level of thousands of genes in one experiment. It can 
be used to compare the expression of many genes under different conditions, such as 
cancerous cells versus normal cells. Although there are several microarray technologies that 
exist to date like exon arrays [38], high resolution tiling arrays [39], and Illumina bead arrays 
[40],  two technologies are specifically used in practice, cDNA and oligonucleotide microarray 
[41]. 
2.2.1: cDNA Microarrays   
In the case of cDNA microarrays, the production of arrays begins with the selection of total 
or partial fragments of cDNA to be printed on the array. Partial fragments of cDNA are known 
as expressed sequence tags (ESTs). cDNA clones are usually selected from available 
databases, including Unigene [42], dbEST [43], and GeneBank [44]. The chosen cDNA clones 
are then amplified using polymerase chain reaction (PCR), and purified before using high-
speed robots to print them on a coated glass surface. These immobilised cDNA clones on the 
glass are known as microarray probes, and each probe represents a specific gene (see Figure 
2.4).  
 
Figure 2.4: Microarray glass [45] 
When comparing the gene expressions of two samples, the first step is extracting RNA from 
the cells and amplifying it using a polymerase chain reaction (PCR). After the PCR products 
are cleaned, they are reverse transcribed into cDNA by using an enzyme reverse transcriptase 
and nucleotides labelled with different fluorescent dyes by chemically attaching the dye 
molecules to the ends of the corresponding cDNA strands [46]. For example, cDNA from cells 
grown in cancerous conditions are labelled with a red dye (Cy5) and cDNA from cells grown 
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in healthy conditions are labelled with a green dye (Cy3). Once the samples have been labelled 
with different fluorescent dyes known as probes, they can be hybridised onto the same glass 
slide of the array, where any cDNA sequence attaches to its complementary sequence on the 
glass. Unattached materials are gently removed and the glass is left to dry. The spots are then 
excited by a laser and scanned afterwards. Specifically, two scans are required for each 
microarray. The first scan is for the red fluorescent and the second scan is to detect the green 
fluorescent.  After these two scans, a three-colour image is typically composed, containing 
red, yellow, and green spots, which refers to highly expressed, equal expressed and less 
expressed genes correspondingly [41]. It is shown in Figure 2.5 that some spots are shown 
in black, which can be explained by the fact that none of the samples contain significant 
amounts of the corresponding type of RNA, or a mistake in the hybridisation process.  
 
 
Figure 2.5: DNA microarrays technology modified from [47]. 
Once the image is generated, it is analysed to identify the spots using special software, 
where the background hybridisation can be estimated and the intensity is calculated for each 
spot. Afterwards, the expression ratio is calculated as a primary comparison tool to relate the 







where  𝑇" ,  𝑅" and 𝐺" are the expression ratio, the intensity of the sample and the intensity 
of the reference (healthy) samples respectively.  
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2.2.2: Oligonucleotide Microarray 
In contrast to the cDNA microarray that uses the complete gene sequence as targets, 
oligonucleotide microarrays (single-channel) use a number of short oligonucleotide sequences 
(usually 20-70 nucleotides long) that represent a specific gene. These oligonucleotide 
sequences can be either spotted or synthesised on the array surface. Although there are 
varieties of oligonucleotide arrays, Affymetrix GenChip is the most widely used technique [48]. 
In Affymetrix GenChip, a short stretch of oligonucleotide strands is used, and the spots are 
synthesised through photolithography. The fabrication of the array is based on the sequential 
addition of nucleotides to the microarray surface (wafer), which is chemically protected from 
nucleotide additions until exposure to UV light. Photolithographic masks are used to place 
nucleotides on specific probe sites, and the sequential addition of lithographic masks 
determines the order of sequential synthesis on the array (Figure 2.6). In this method, each 
gene is represented by 25 pairs (25-mer) of oligonucleotide [49].  
 
 
Figure 2.6: Affymetrix GenChip lithography [50]. 
One strand of the 25-mer sequence is known as a perfect match (PM) and the other is 
referred to as a mismatch. The sequence of the nucleotide in the perfect match probe is 
exactly complimentary to a particular gene, and thus measures the expression of the gene. 
However, the mismatch probe differs from the perfect match probe by a single base nucleotide 
at the centre position of the probe, which prevents the target from binding to the gene 
transcript (see Figure 2.7). The main reason for using the mismatch probe is to determine the 
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background and nonspecific hybridisation that contributes to the measured signal for the 
perfect match oligonucleotide probe [36].  
 
 
Figure 2.7: Affymetrix expression array design adapted from [51]. 
In the process of achieving expression, RNA is extracted from the sample and after 
amplification, is labelled with chemical biotin. Then the labelled RNA is added to the Affymetrix 
array to bind with the relevant oligonucleotide probe. After washing the unattached materials, 
fluorescent stain that is capable of attaching to the biotin on the RNA is added to the array. 
The array is then scanned to obtain an image. In contrast to cDNA, Affymetrix arrays use a 
single dye colour (one channel), and therefore each sample should be added to a separate 
array and cannot be hybridised (see Figure 2.8) [41]. The hybridisation intensity of the perfect 
match and the mismatch is computed and subtracted from each probe by Microarray Suite 
software. As a result, the absolute intensity value for each probe is acquired.  Afterwards the 
intensity of the perfect match is subtracted from the intensity of the mismatch probe. 
Therefore, the average intensity for each gene can be calculated. Then the intensity is 
converted into a ratio. Eventually, as in cDNA, the data is stored in the form of the gene 
expression ratio [52]. 
 
 
Figure 2.8: Affymetrix GenChip microarray modified from [53]. 
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2.3: Next Generation Sequencing Technology (NGS) 
DNA sequencing refers to the precise identification of the order of nucleotides (A, G, T and 
C) in a DNA sample. Over the last 4 decades, there have been major advancements in DNA 
sequencing technologies. In 1975, DNA sequencing by primed synthesis with DNA polymerase 
was investigated by Sanger and Coulson [54], and this method was then improved by utilising 
chain-terminating inhibitors [55]. The automated readout of the sequence was successful 
when fluorescent tags were added to the chain terminator [56]. This innovation is known as 
First Generation Sequencing technology or Automated Sanger Sequencing. Over the last 
decade, technological advancements in the field of sequencing have introduced Second 
Generation Sequencing also known as Next Generation Sequencing (NGS) [57]. Not only has 
the cost of sequencing with the new methods been significantly reduced, but this technology 
is also capable of producing a significant amount of data in a shorter time [20,58]. 
Although there are several next generation sequencing platforms available, three platforms 
are more widely used: Roche 454, Illumina, and SOLiD [59]. The amount of reads and the 
length of each read (base pair) are varied across different platforms [60], but each platform 
has their own advantages and disadvantages [58], which are listed in Table 2.1. 
 












capability of samples 




Fast run times; 
Longer reads  
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rates in homo-polymer 
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correction by two-
base encoding  
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All NGS platforms detect the order of nucleotides through 3 primary steps. The first step is 
the random fragmentation of DNA and ligation with some custom adaptors, known as sample 
preparation. Then the amplification step follows in which the fragments are amplified to 
produce a detectable signal. The last step is to perform sequencing reaction and detection of 
nucleotides in a sequential order one by one. In the following sections, the details of Roche 
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454 FLX Pyrosequencer, Illumina genome analyser, and SOLiD Applied Biosystems are 
analysed. 
2.3.1: Roche/454 FLX Pyrosequencer  
In this method, DNA is converted into sequence data through three main steps which are: 
DNA sample preparation, loading DNA samples onto beads, and finally sequencing DNA with 
the Genome Sequencer FLX instrument. Sample preparation starts with random fragmentation 
of DNA (400-600 bp), then the adaptors are attached to these fragments. Finally, the double-
stranded DNA fragments are separated into single strands (see Figure 2.9). 
 
 
Figure 2.9: Sample preparation in Roche/454 [61]. 
In the second step, the fragments that are attached to adaptors are put onto micron-sized 
beads, which have a complimentary sequence to the adapter, then through using emulsion-
based PCR, around ten million copies of each DNA fragment that is immobilised on the capture 
beads are produced (see Figure 2.10). Emulsion refers to a method where a single DNA 
molecule is isolated in aqueous micro-reactors by utilising water and oil emulsion. This 
amplification is required to generate sufficient signals that are detectable in the sequencing 
step [20].  
 
 
Figure 2.10: Amplification step in Roche/454 [61]. 
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The last step is sequencing through synthesis. For this step, the beads are put into a well 
on a PicoTiter Plate along with an enzyme that helps the sequencing reaction (see Figure 
2.11).   
 
 
Figure 2.11: Sequencing by synthesis step in Roche/454 [61]. 
To accomplish this objective, starting from one end of the single-stranded fragment and 
based on the order of nucleotides in the strand, the enzyme synthesises the complimentary 
fragment through the sequential adding of nucleotides. Each time a nucleotide is added, a 
light is emitted which is then recorded by a camera (see Figure 2.12). 
 
 
Figure 2.12: Sequencing by synthesis step in Roche/454 [62]. 
2.3.2: Illumina Genome Analyser 
The Illumina Genome analyser converts DNA into sequenced data through three steps: 
sample preparation, cluster generation, and sequencing. After the random fragmentation of 
DNA, the ends of these fragments need to be repaired by adding the complementary 
nucleotides to the appropriate end of the fragment.  Afterwards the ends of the fragment are 
phosphorylated, and a single A base is added to its 3’ ends. Finally the adapters are ligated 





Figure 2.13: Sample preparation for Illumina sequencer [64]. 
In the second step, the prepared fragments are attached to a flow cell on a solid surface 
that has their complementary adapters. Once they are attached, the other side of the fragment 
also attaches to the solid surface and forms a bridge. Then a replica of the fragments forms, 
and they detach from each other. This cycle, known as bridge amplification, continues until 
clusters are formed [20].  
 
 





The final step is the detection of nucleotide sequences through sequence by synthesis. For 
this reason, DNA polymerase is added to the clusters on the slide and flooded by nucleotides. 
These nucleotides are engineered to have different colours corresponding to the base, and 
modified in such a way that the polymerase can extend by one base at a time through the 
use of a terminator. Once a nucleotide is attached to the fragment, the remaining unattached 
nucleotides are removed and a camera detects which nucleotide (C, A, G or T) is attached. 
Then the terminator is removed, and the slides are flooded by nucleotides again, and this 
process is repeated until the whole fragment is sequenced (see Figure 2.15). Although the 
sequencing and detection of nucleotides is done for one base at a time for each fragment, it 
is done for millions of fragments at the same time (see Figure 2.16) [64].  
 
 
Figure 2.15: Sequencing by synthesis step in Illumina sequencer [64]. 
 
 
Figure 2.16: Pseudo colour enhanced image [65]. 
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2.3.3: Applied Biosystems SOLiD Sequencer 
The process of detecting the order of nucleotides by SOLiD (Sequencing by Oligonucleotide 
Ligation and Detection) technology is carried out through three steps:  sample preparation, 
amplification and sequence by ligation. The sample preparation step is similar to other NGS 
platforms and consists of DNA fragments that are ligated to oligonucleotide adapters [66]. 
These ligated fragments are then amplified using emulsion based PCR as explained in Section 
2.3.1 for Roche 454.  
The sequencing by synthesis step in SOLiD technology is different from other NGS 
platforms, as this is done by DNA ligase (see Figure 2.17) as opposed to using a polymerase 
[64,67]. Initially a sequencing primer is hybridised to the P1 adaptor, which is attached to the 
bead. A mixture of Di-base probes that is labelled with four different fluorescent dyes races 
to ligate to the sequencing primer. After ligation, the fluorescent dyes are excited, and 
subsequently an image is taken. Afterwards, unextended strands are capped and fluorophores 
are cleaved. A new cycle starts 5 bases away from the priming site, by attaching another Di-
base probe, and this is repeated for 7 cycles. Then the first sequencing primer is detached, 
and a new primer is attached to the temple sequence (reset), and another 7 cycles is repeated 
for the new primer.  In total, 5 rounds of this primer reset is performed (n, n-1, n-2, n-3, and 
n-4). As can be seen in Figure 2.17, eventually 35 bases are sequenced twice, thus improving 








2.3.4: NGS Raw Data File Formats and Quality Scores for Detected 
Nucleotides  
The RNA-Seq experiment generates tens of millions of sequence tags, known as short 
reads, which can be encoded into different file formats depending on the NGS platforms such 
as the FASTQ [68] and FASTA/QUAL [69] formats. While encoding the short reads, not only 
the sequence of each read is preserved, but the quality value of detected nucleotides for each 
read is also determined. Although the quality scores across different platforms cannot be 
compared, all NGS platforms use a Phred-like score [70,71], which is logarithmically related 
to the probability that a base call is incorrectly identified (P). 
 
 𝑄'()*+ = −10× log34 𝑃 (2.2) 
 
There are three types of quality scores that are used. The first scoring method is known as 
the Sanger quality score, which is used in Sanger FASTQ formats, and uses ASCII values from 
33-126 to encode Phred scores from 0-93. Later by using logarithmic mapping, Solexa, Inc. 
(Illumina, Inc.), introduced another quality scoring method in which Solexa scores were used, 
ranging from -5 to 62 and represented by ASCII characters from 59 to 126 [68]. Solexa scores 
can be calculated by Equation 2.3. 





Equations 2.4 and 2.5 are used to convert Phred scores to Solexa-scale quality scores and 
vice versa.   
 𝑄'()*+ = 10× log34( 10
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More recently, Illumina, Inc. introduced a new format used from Genome Analyser Pipeline 
1.3 onwards.  In this format, the Phred scores ranging from 0-62 are represented by ASCII 













FASTQ format uses 4 lines to encode each read (see Figure 2.18). The first line begins with 
the character ‘@’ and is followed by a sequence identifier and an optional description. The 
second line contains the order of nucleotides for the read. Line 3 begins with the ‘+’ character 
and is optionally followed by the same sequence identifier. Lastly, line 4, which has the same 
length as line 2, indicates the quality of detected nucleotides for the read using ASCII 










Figure 2.18: FASTQ format 
FASTA format uses 2 lines to encode each read. The first line begins with the character ‘>’ 
and is followed by a sequence identifier and an optional description. The second line contains 




> Sequence Identifier 
ACCCCAGGATCAACACTTCACATGCATTAGCAGAGAGAGATAAATCAA 
Figure 2.19: FASTA format 
Illumina encodes the reads and corresponding quality scores in the FASTQ format. Roche 
454 encodes the reads in FNA format, which is a type of FASTA format, and also encodes the 
corresponding quality scores in a separate QUAL format which is also similar to FASTA format 
[73]. In contrast, since SOLiD output is based on colour space and not sequence space, this 
technology uses the CSFASTA (Colour Space FASTA) format to encode the sequence of a read, 





ASCII characters Quality scores 
Range Offset Type Range 
Sanger standard 33-126 33 Phred 0 to 93 
Solexa 59-126 64 Solexa -5 to 62 
Illumina 64-126 
 
64 Phred 0 to 62 
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2.4: Gene Expression Profiling Using NGS Technology (RNA-Seq) 
The importance of mRNA in gene expression and its role in identifying the informative 
genes that cause disease was investigated in Section 2.1 and 2.2, where microarray was used 
to determine the expression of genes. Microarray is a reliable and robust method which has 
been proven over decades, and even considering the drop in cost of NGS technology, 
microarray is still more economical. However, microarray technology has several limitations. 
For instance, since microarrays are designed by hybridisation probes for which the sequence 
of the probes is already known, this means that this technology is ineffective at finding new 
genes, detecting structural variations, discovering transcripts, and analysing isoform 
composition. However, RNA-Seq technology can overcome these limitations [75]. Whilst 
comparative studies of microarray gene expression and RNA-Seq [21,76,77] suggest that the 
results of both platforms correlate well, a wider spectrum of gene expression levels could be 
obtained when RNA-Seq is used, resulting in a more detailed insight into gene expression. 
Further studies, prove that RNA-Seq outperforms microarray at discovering new isoforms 
[78,79], and at transcriptome profiling [80,81]. 
RNA-Seq or the Whole Transcriptome Shotgun Sequencing workflow consists of several 
steps (see Figure 2.20). First, the total RNA consisting of messenger RNA (mRNA), ribosomal 
RNA (rRNA), and other small RNAs is extracted from a cell. The next step is the isolation of 
RNA content. In this step, due to the fact that over 90% of total RNA is made of rRNA, which 
can hinder the detection of mRNA, it is necessary to remove rRNA. One solution for this issue 
is to use poly (A) to enrich mRNA, which can only be used if the interest is in analysing mRNA 
alone, as this method eliminates all other non-poly RNAs. Another solution is to use rRNA-
depletion technique, such as using exonuclease to digest rRNA, or using subtractive 
hybridisation [82–84]. Furthermore, if a study is interested in other small RNAs, several 
strategies are available to enrich such small RNAs, either by using commercially available kits 
or performing size selection by using polyacrylamide gel electrophoresis [85]. 
The next step is fragmentation of RNA to reduce the chance of secondary structure 
formation, and to provide a homogeneous coverage of entire transcripts [75]. The final step 
is to convert single stranded RNAs to double stranded cDNAs by utilising a reverse 
transcriptase. This last step is done because most sequencing technologies are currently 
unable to sequence RNA itself. Once the cDNA libraries are formed, various NGS platforms 




Figure 2.20: RNA-Seq procedure [86]. 
2.5: Analytical challenges for microarray and NGS data in respect 
to profiling and understanding diseases  
Although gene expression profiling is a viable tool for diagnosis and prognosis of diseases, 
the analysis of microarray and NGS data is characterised as being very challenging [87]. In 
regard to microarray data, although only few samples are used, the expressions of thousands 
of genes are measured. This creates a challenge as the methods that could be implemented 
for analysis of microarray data needs to account for the nature of high dimensionality of such 
data [88]. To overcome this challenge and extract useful information among the pool of 
microarray data, machine learning techniques and various statistical approaches have been 
facilitated. These methods range from finding differentially expressed genes via statistical 
40 
 
methods to clustering and classification of diseases through machine learning techniques [46]. 
It is noted that over that last decade, the use of machine learning to classify diseases have 
become an area of intensive research [22]. However, high classification accuracy of diseases 
such as cancer is still highly challenging and more research is required where new methods 
could be implemented to further increase the classification accuracy. 
With regard to NGS data, although the exploration of gene expression through RNA-Seq 
technique is more feasible, the analysis of such data is more computationally challenging when 
compared to microarray data [89]. For instance, a significant number of the short reads that 
are produced from a RNA-Seq experiment are map across splice junctions so that the task of 
mapping these reads to a reference genome is very challenging. Furthermore, after mapping 
these reads, the process of counting these reads over genomic locations inherits a significant 
challenge and one required to apply some statistical modelling such as discrete distributions 
to model these counts [90]. There exist several main challenges when analysing RNA-Seq as 
addressed in Chapter 6 later. 
2.6: Summary  
In this chapter a review of recent developments in measuring gene expression was 
presented. Initially, a brief overview of the biological aspects of the thesis such as gene 
expression phenomena was given. Afterwards, different types of microarray technologies such 
as cDNA and oligonucleotide microarray were explored. Then, different NGS technologies were 
investigated and a unique approach for each technique was explained in order to have a good 
understanding of how NGS data is produced. The common formats of NGS data such as 
Sanger, Solexa, and Illumina were then explained. Finally, the RNA-Seq technique utilising 


















Chapter 3: Overview of Machine Learning 





There are several steps for a successful microarray data analysis including design, pre-
processing, inference, classification, and validation. Since each step plays an important role in 
the final results, there have been numerous studies to optimise each step. The design step is 
vital, as it determines the initial quality and quantity of the information to work with, and this 
step is carried out in a wet laboratory. Pre-processing is usually the first step for the analysis 
of microarray data, during which the images from microarray chips are processed and 
systematic variations are removed, followed by the transformation and normalisation steps. 
After pre-processing, depending on the purpose of the experiment, inference and/or 
classification of the data follows. Finally, the results from the previous steps are validated 
[46].  
3.2: Design 
Research suggests that the design of microarray experiments directly affects the efficiency 
and validity of the information obtained [91,92]. There are 2 factors that are essential to take 
into consideration when designing a microarray experiment. 
The first factor is related to the importance of having biological replicates in the experiment. 
In general, there are two types of replicates, technical and biological replicates.  Biological 
replicates refer to the replicates that are produced from different biological samples. In 
contrast, technical replicates are obtained from the same sample, but processed in a different 
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microarray experiment. One advantage of biological replicates compared to technical 
replicates is that the latter can only estimate the measurement variation between samples 
from different experiments. However, biological replicates not only can be used for this 
purpose, but they can also measure the variation between different biological samples. For 
instance, they can be used to find out which genes are differentially expressed between 
different samples [46].  
The second factor is related to the number of required samples for a microarray experiment 
to provide enough information for a valid analysis. Several studies confirm that for a 
differential expression analysis using statistical inference, at least 5 biological replicates for 
each sample group are required [93,94]. With regards to a number of replicates for a 
classification purpose, a study by Dobbin and Simon [95] proposed a formula to calculate this 
number based on the relative sizes of different sources of variability.  
3.3: Pre-Processing  
As was discussed in Sections 2.2.1 and 2.2.2, as a result of microarray experiments, several 
images in TIFF format are produced that contain intensity signals. The first action towards a 
meaningful analysis is the pre-processing of these images and extraction of useful information 
to form a gene expression matrix [96,97]. Figure 3.1 shows the important steps for pre-
processing microarray data.  
 
Figure 3.1: Pre-processing of microarray data. 
Image analysis is the first step in the pre-processing of microarray data, and deals with the 
process of extracting information from images. This provides the basis for further microarray 
analysis. This step involves quantifying spots on the microarray.  To this end after identifying 
the spots on the microarray, first spot signal and background intensity are measured. Then 
based on these measurements, the initial intensity for each spot is calculated by subtracting 
the spot signal from the background intensity [98]. 
In the second step, the expression ratio for each gene is calculated. This is done by utilising 
the spot intensities of two samples and relating them by using a metric called expression ratio 



















   
where 𝑇" is the expression ratio of gene 𝑘, 𝑅" is the spot intensity of sample 1, and 𝐺" is the 
spot intensity of sample 2. The expression ratio is a relevant way to represent expression 
differences. For example, genes that have equal levels of expression in two experimental 
conditions will have an expression ratio of 1. However, the interpretation of data from this 
method can be confusing when a gene has a higher or lower expression. For example, a gene 





  has an expression 
ratio of 4. However, if it has a lower expression by a factor of 4, the expression ratio becomes 





 ). Thus lower expression is mapped between 0 and 1 while higher 
expression is mapped between 1 and infinity. Logarithmic transformation is used to eliminate 
this inconsistency in the mapping intervals, where higher expression and lower expression are 
treated equally. For instance, if the expression ratio is 1, then log2 (1) equals 0 represents no 
change in expression. If the expression ratio is 4, then log2 (4) equals +2 and for an expression 
ratio of log2 (1/4) equals -2. 
The next step is the normalisation of data. In the human genome, there are some genes 
known as housekeeping genes. The expression level of these genes should not change across 
different conditions. However, in some cases the data from the expression ratio suggests that 
an average expression ratio of such genes deviates from 1. This implies some sources of 
systematic variation that affect the measured expression levels of genes. In order to overcome 
this problem, the data needs to be normalised. There are several methods of normalisation, 
like total intensity normalisation, mean log centring, and linear regression.  In these methods, 
a normalisation factor is calculated and then it is used to rescale the intensity of each gene 
[99].  
After these pre-processing steps, the data can be represented in the form of a matrix, and 
each row in the matrix (see Figure 3.2) corresponds to a particular gene, while each column 
either corresponds to an experimental condition or a specific time point at which expression 




Figure 3.2: Gene expression matrix. 
3.4: Unsupervised Classification 
Data clustering, which also refers to unsupervised classification, is a way of finding 
similarities in data when no prior information on the structure of data is available [100]. In a 
clustering task, data is divided into groups in which data points within each group (cluster) 
are very similar to each other, yet different from other clusters. Microarray gene expression 
data can be clustered based on genes (row), samples (column), or both genes and samples 
which provides useful information for data visualisation and the interpretation of experimental 
results. Clustering based on both genes and samples referred to as bi-clustering [101] which 
is useful in uncovering functionally linked gene sets under different experimental conditions. 
Since genes that have similar expression pattern are grouped together in clustering methods, 
one can hypothesise that if two genes are within a similar cluster, the respective genes can 
be co-expressed and have a related function. 
Despite the fact that there are several clustering methods available such as K-means, Fuzzy 
C-means and Hierarchical, all methods use a similarity measure to calculate the distance 
between data points, so that similarities and dissimilarities of all data points can be quantified 
and clustered respectively [102]. Among the several similarity measuring methods like 
Covariance, Manhattan Distance, Average Dot Product, Pearson Correlation Coefficient, and 
Euclidian Distance, the latter two are most commonly used. 
In the Pearson Correlation, the linear association between gene 𝑎 and 𝑏 is calculated by 
Equation 3.2.  
 
𝑃𝑎𝑏 =
(𝑥R; − 𝑥;)(𝑥RS − 𝑥S)
T
RU3







where 𝑥R; and 𝑥RS are respectively the gene expression for gene 𝑎 and 𝑏 in sample 𝑚 and 
45 
 
𝑥; and 𝑥S are the mean expression of genes 𝑎 and 𝑏 from all samples. The value of correlation 
between gene 𝑎 and 𝑏, (𝑃𝑎𝑏) can range from -1, which means a perfect negative correlation, 
to 1 which means a perfect positive correlation. If both genes appear to be independent of 
each other, the correlation value will be assigned to zero.  
In Euclidian distance method, the distance between gene 𝑎 and 𝑏 is calculated by Equation 
3.3. 




where 𝑥R; and 𝑥RS are respectively the gene expression for gene 𝑎 and 𝑏 in sample 𝑚. The 
Euclidian distance between gene 𝑎 and 𝑏, (𝐸𝑎𝑏) can range from 0 to ∞.  
3.4.1: K-means  
K-means clustering is a simple and fast method that aims to partition	𝑛 genes into 𝑘 
clusters, where data within a cluster is nearer to the centre of their cluster than other clusters. 
It is noted that the number of clusters (𝑘) should be specified in advance. The means of 
clusters are updated, along with iterations. If that microarray data contains 𝑛 genes with 
expression	(	𝑥3, 𝑥V, … , 𝑥]), and each 𝑥 is a d-dimensional factor, 𝑛 genes will be separated into 
𝑘 subsets with unknown centres (	𝜇3, 𝜇V, … , 𝜇"), under the condition that 𝑘	 ≤ 𝑛. The objective 
of the K-mean algorithm is to minimise the cost function 𝐻 (see Equation 3.4), such that the 
centre of each cluster has the minimum aggregation distance between the centre of a cluster 
and the points within that cluster [103].  






where 𝑥a − 𝜇b
V is the Euclidian distance between the 𝑖𝑡ℎ gene (	𝑥a), and the centroid for the 
𝑗𝑡ℎ cluster; 𝑎ab is the membership value which is either one if 𝑥a is assigned to 𝑗𝑡ℎ cluster or 
zero otherwise. The K-mean algorithm clusters the data through the following iterative 
procedure: 
 





Step 2: Assign each point (	𝑥a) to its nearest cluster centre. This is done by determining 





𝑖𝑓		 𝑥a − 𝜇b
V




Step 3: Compute the cost function 𝐻 using Equation 3.4. 
 









Step 5: Steps 2, 3 and 4 are cycled through continuously until they coincide with set values 
(e.g. the number of iterations). 
3.4.2: Fuzzy C-means  
Fuzzy C-means clustering relies on the basic idea behind K-mean clustering, with the 
difference that in the C-means method, each data point belongs to a cluster with a degree of 
membership grade. In K-means, each data point either belongs to a certain cluster or not. In 
other words, in fuzzy C-means, each data point can belong to more than one cluster with a 
degree of belonging specified by membership grades between 0 and 1. Fuzzy C-means also 
utilise a cost function and similar to K-means, its objective is to minimise the cost function 
[104]. The fuzzy C-means algorithm clusters the data by the following iterative procedure: 
 
Step 1: Initialise the membership matrix 𝑎a,b
p with random values between 0 and 1, such 
that the constraint in Equation 3.7 is satisfied. 
 𝑎a,b















where 𝑓 > 1	is the exponent of the membership values, and it is a real-valued number 




Step 3:  Compute the cost function according to Equation 3.9: 
 𝐻 = 𝑎a,b


















Step 5: Steps 2, 3 and 4 are cycled through continuously until they coincide with set values.  
3.4.3: Hierarchical Clustering 
There are two types of hierarchical clustering approaches: agglomerative and divisive, both 
of which involve building some type of dendrogram or tree that reveals the relationships 
between the data objects. The agglomerative approach starts by assuming that each object 
belongs to its own cluster. Afterwards, it identifies which clusters are the closest to others 
using a distance metric. Each iteration of this approach creates bigger and bigger clusters at 
each level, until all data objects are put into one big cluster. In contrast, the divisive approach 
works exactly the opposite, where at the start all objects belong to one big cluster (see Figure 
3.3). When the iteration starts, it finds the best division of the data objects, so that there is 
the highest similarity among objects within clusters, and the most dissimilarity between 
clusters. This process continues, until all objects are in their own clusters [5,105]. 
 
 






























Hierarchical clustering partitions genes based on the measurement of distance. The most 
commonly used method for measuring distance in this context is Euclidean distance. The 
calculation of distance between a pair of sub-clusters depends on linkage criteria, which is a 
way of defining the similarity of clusters based on the similarities of cluster members. There 
are four linkage methods that can be used: single, average, complete, and the distance 
between centroids (see Figure 3.4), in which clusters are linked based on the similarity of the 
closest members, the average similarity, and the similarity of the furthest members [106]. 
 
 
Figure 3.4: Linkage methods 
3.4.4: Self-Organising Map 
The Self-Organizing Map (SOM) which is based on neural network was developed by 
Kohonen [107]. SOM utilises a competition and cooperation means to attain unsupervised 
learning using winner takes all (WTA) algorithms. A SOM network consists of two layers 
including a Kohonen layer and an input layer (see Figure 3.5). In the Kohonen layer, neurons 
are organised in a geometric pattern, usually 2-dimentional lattice. Each neuron in the input 
layer is fully coupled with all neurons in the Kohonen layer and each has a weight vector, 
𝑤a, 𝑖 = 1,2, . . , ℎ which is randomly initialised. ℎ represents the number of neurons in the 
Kohonen layer. Also, each neuron in the Kohonen layer is linked to adjacent neurons by a 
neighbourhood relation. The objective of SOM is to discover a suitable mapping from the 𝑛 




Figure 3.5: SOM neural network adapted from [108]. 
 
To this end, the Euclidean distances between input data and weight vectors are calculated. 
Then for each data vector the best match unit (BMU) is obtained through Equation 3.11, which 
refers to the unit that minimises the Euclidean distance between the input data and weight 
vectors [109].  
 
 𝐵𝑀𝑈 = 𝑎𝑟𝑔minb 𝑥a − 𝑤b  (3.11) 
 
Once the BMU is chosen, this unit is then allowed to update its weight vector. Since in the 
Kohonen layer neurons are linked to adjacent neurons, when the BMU is chosen, all 
neighbouring neurons within a width and radius of BMU also will be updated. By defining a 
set of activated neuron adjacent to BMU as 𝑁~, the activated neurons can update their weights 
at time 𝑡	using Equation 3.12 [109]. 
 
 𝑤b 𝑡 + 1 =
𝑤a 𝑡 + ℎ 𝑡 	[𝑥a − 𝑤a 𝑡 ], 𝑖 ∈ 𝑁6		
𝑤b 𝑡 , 𝑖 ∉ 𝑁6
 (3.12) 
 
where ℎ 𝑡  is the neighbourhood function and can be calculated as below:  
 







where 𝑟a denotes the location of neuron 𝑖 on the grid map, 𝛼 𝑡  is the learning rate, and 
𝜎 𝑡  is the kernel width function around BMU. Both 𝛼 𝑡  and 𝜎 𝑡  are monotonically shrinking 
over time. As the process continuous and new input vectors are given to the map, the 
neighbourhood radius and the learning rate progressively shrink to zero so that only BMU can 
be updated. The SOM algorithm clusters the data by the following iterative procedure [109]: 
 
Step 1: The topology of SOM is defined and the weight of each neuron is randomly  
initialised (𝑤a(0), 𝑖 = 1,2, . . , ℎ). 
 
Step 2: The distance between the input vector and the weights of each neuron is calculated   
and BMU is identified using Equation 3.11.  
 
Step 3: The active radius around BMU is calculated which is then decreases over time. 
 
Step 4: The weights of the BMU and the neurons within the active radius are updated using  
Equation 3.12.  
 
Step 5: Steps 2, 3 and 4 are cycled through continuously until convergence.  
 
3.4.5: Binarisation of Consensus Partition Matrices (Bi-CoPaM) 
In order to improve reliability and robustness of clustering procedure, ensemble clustering 
methods such as graph-based and hypergraph-based methods [110], kernel-based methods 
[111], relabelling and voting [112], and non-negative matrix factorization [113] have been 
proposed.  In these methods, the results of various clustering algorithms for the same dataset 
are merged to build a consensus clustering outcome.  
More recently, the binarisation of consensus partition matrices (Bi-CoPaM) that is a 
tuneable consensus clustering method was proposed by Abu-Jamous et. al [114,115]. This 
clustering method takes into account various datasets while employs several single clustering 
algorithms to detect the subset of features which incessantly correlate among many clustering 
results [116]. This method outperforms conventional clustering algorithms in that each feature 
can be assigned to multiple clusters at the same time or not assigned to any clusters at all 
[117]. 
Assuming time series microarray datasets, Bi-CoPaM performs clustering independently for 
each dataset in the first stage and datasets are not combined. This means within each dataset 
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all features are homogenous as they have the same experimental design. However, in the 
next stages the created clusters from each dataset are merged in respect to memberships 
which is not influenced by the time profiles of the feature in their datasets to create one set 
of partitions. This method provides the infrastructure for multiple heterogeneous datasets to 
be analysed together [118]. Figure 3.6 illustrates the Bi-CoPaM flowchart.   
 
 
Figure 3.6: Flowchart of Bi-CoPaM adapted from [115] 
 
Bi-CoPaM performs clustering through four main steps as follow: 
 
Step 1: Partitions generation. In this step, R partition results, 𝑈3, 𝑈V, … , 𝑈) , are 
created by facilitating R different clustering algorithms. Each 𝑈 matrix consists of 𝐾 rows 
corresponding to number of clusters and 𝑀 columns corresponding to the number of genes. 
Each element in the matrix, 𝑈ab , denotes the membership of the 𝑖𝑡ℎ gene in the 𝑗𝑡ℎ cluster 
based on the 𝑟𝑡ℎ partition.  
 
Step 2: Relabelling. The objective of relabelling is to make sure that the 𝑖𝑡ℎ cluster in 
each generated partition correspond to each other by means of rearranging the clusters. The 





A) First a dissimilarity matrix, 𝐷6×6 , is composed. In this matrix, each element (𝐷ab) 
denotes the dissimilarity between the 𝑖𝑡ℎ row of the partition 𝑈 and the 𝑗𝑡ℎ row of the 
reference partition 𝑈9p. 
B) Then in the 𝐷 matrix the minimum of each column is calculated.  
C) Afterwards, the maximum value from the calculated minimums is selected by which the 
clusters from 𝑈 and 𝑈9p that have this maximum are coordinated to correspond to 
each other.  
 
D) Then the selected row that was used for matching the clusters in step C is removed 
from 𝐷 matrix.  
 
 
E) Steps B to D are repeated till 𝐷 matrix is empty and all clusters from 𝑈 and 𝑈9p are 
matched.	
	
After relabelling the rearranged matrix of 𝑈 is shown by 𝑈 which is presented as follow.  
 
 
𝑈 = 	𝑎𝑟𝑔𝑚𝑎𝑥	∀9R  Γ(	𝑈9p, 𝑝𝑒𝑟𝑚(𝑈)) 
 
(3.14) 
where 𝑝𝑒𝑟𝑚(𝑈) denotes the permutation of the rows of 𝑈 and Γ() is the similarity measure 
[114]. 
 
Step 3: CoPaM generation.   
The R relabelled partition matrices are utilised to create a single fuzzy CoPaM in which each 
single element represents a fuzzy membership of a gene in a cluster based on the number of 
times that the genes appeared in that cluster. The membership value ranges from 0, 
representing absolutely no consistency to 1 which denotes absolute consistency. It is noted 
that the summation of fuzzy membership values for each given element across all clusters 
should be 1. To generate the CoPaM matrix the values of the first partition are used to 
instantiate an intermediate fuzzy CoPaM,	𝑈a]. The remaining partitions are then fused to the 
	𝑈a] one after another and in each step when a partition is fused, this partition is relabelled 
according to the 	𝑈a]. Once all partitions are fused, the 	𝑈a] is assigned as the CoPaM 
matrix	𝑈∗.  If 	𝑈a]() denotes the intermediate matrix after 𝑔 partition is fused, the generation 
of CoPaM can carried out by the following three steps [115]:  
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a) 	𝑈a](3) = 	 	𝑈3 
b) 𝑓𝑜𝑟	𝑘 = 2	𝑡𝑜	𝑅 
1. 𝑈" = 𝑅𝑒𝑙𝑎𝑏𝑒𝑙𝑒𝑑	(	𝑈", 	𝑈a]("s3)) 





c) 	𝑈∗ = 	 	𝑈a] )  
 
Step 4: Binarisation.   
In general, the binarisation is performed in CoPaM so that each gene is included only in 
one cluster and excluded from other clusters. However, Bi-CoPaM generates a pseudo-
partition matrix, 𝐵∗, with 𝐾 rows corresponding to the number of clusters and 𝑀 column which 
allows a gene to be included in multiple clusters, not assigned to any clusters or assigned to 
only one cluster by assigning a multiple 1s, no 1, or a unique 1 in columns accordingly. Several 
techniques have been proposed to generate the Bi-CoPaM including intersection binarisation 
(IB), maximum value binarisation (MVB), top binarisation (TB), different thresholding 
binarisation (DTB) [119]. In all methods, the binarisation status is monitored using two 
measurements namely 	𝑀] which denotes the number of genes that belongs to none of the 
clusters and 	𝑀R8a that denotes the number of genes that belongs to multiple clusters. For 
instance, in IB approach binarisation leads to 	𝑀R8a= 0 and 	𝑀] ≥ 0 where a gene is 
assigned to a cluster if all partitions map this gene to all that cluster which can be 
mathematically expressed as follow:  
 𝑏a,b∗ =




In TB method, each gene is not only assigned to the maximum membership value cluster, 
but also assigned to other clusters where its membership values are within a definite variance 
𝛿 less than the maximum which leads to 	𝑀R8a ≥ 0 and 	𝑀] = 0. TB method mathematically 
expressed as follow: 
 𝑏a,b∗ =




In DTP method, each gene is assigned to the maximum membership value cluster on a 
condition that the value of nearest candidate cluster is as far from the maximum as a minimum 
of a definite variance 𝛿. This technique leads to 	𝑀R8a = 0 and 	𝑀] ≥ 0 when 𝛿 > 0 and 









3.4.6: Unification of clustering results from multiple datasets using 
external specifications (UNCLES) 
Abu-Jamous, et al., [118] proposed a method to examine multiple gene expression datasets 
at once by unifying the clustering results in order to discover a subset of genes that are co-
expressed across all datasets while taking into account one of two types (type A and B) 
external specifications. Type A, is similar to that in Bi-CoPaM where the objective is to identify 
a subset of genes that are consistently co-expressed in all datasets. In contrast, type B allocate 
all datasets into two subsets of datasets, the negative subset,		𝑆s, and the positive subset, 
	𝑆. The objective of type B is to identify a subset of genes that are poorly co-expressed in 
	𝑆s, while a consistent co-expression of the selected subset of genes can be observed in 	𝑆 
(See Figure 3.7).  
 
Figure 3.7: UNCLES flowchart with type B of external specifications adapted from [118]  
 
Type B UNCLES is performed in several steps as follow. In the first step, Bi-CoPaM (type 
A) that utilises DTP binarisation with parameters 	𝛿 and 	𝛿s is performed on both subsets of 
datasets 𝑆 and 	𝑆s respectively. Afterwards, the selected genes that resulted from Bi-CoPaM 
on the 𝑆 subset are excluded from the result of 𝑆s. It can be noted that type B take 
advantages of two parameters (	𝛿 and 	𝛿s) compared to one parameter in type A. The 
parameter 	𝛿	regulates the tightness of clusters in 𝑆 subsets so that the co-expressed genes 
in this subset can be included in the final results and 	𝛿s controls the how tight the clusters 
in	𝑆s subset can be so that its co-expressed genes could be excluded from the final results. 
For instance, at a pair of (𝛿 and 0) will result in creating empty clusters as 	𝛿s = 0 means all 
the genes will be excluded from the final results [120].  
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3.5: Supervised Classification  
In supervised classification, the objective is to design a class predictor to distinguish two 
or more classes of samples from each other (e.g. healthy vs cancerous). The class predictor 
is designed based on the currently available data from different diagnostic classes, which 
refers to training or learning samples. In this procedure, first the classifier is trained, and then 
the classifier is used to find the diagnostic class of new samples [7]. When designing a 
classifier, based on the available information within the training set of data, one needs to 
develop decision rules and mathematical formulas with a particular classifier design strategy, 
so that the classifier can make diagnostic or prognostic predictions. There exists several 
classifier design approaches that can be used for microarray gene expression classification, 
including Linear Discriminate Analysis (LDA) [7], k Nearest Neighbours (k-NN) [121], Support 
Vector Machines (SVM) [122], Multilayer perceptron (MLP) [123], and other types of Artificial 
Neural Networks [7]. 
LDA classification is based on the identification of linear combinations of features that are 
able to best distinguish between two classes of samples. This classification method is closely 
related to the analysis of variance method (ANOVA), and its objective is to maximise the ratio 
of between-class variance for datasets whereby a maximum separability between different 
diagnostic classes can be achieved [7]. k-NN classification is based on the concept of similarity 
measurement (e.g. Euclidian distance or Pearson’s correlation) in which the distances between 
unknown samples (test samples) and known samples is calculated. Subsequently, the class 
membership of unknown samples is assigned based on 𝑘, the closest known samples. One of 
the advantages of k-NN is low computational consumption compared to other classification 
methods [124]. In this thesis, two of the most widely used classifiers, SVM and the MLP neural 
network are investigated in detail. 
3.5.1: Support Vector Machine 
SVM is an efficient classification method typically used for a two-class classification 
problem. SVM chooses a hyperplane, which provides the maximum separation distance in two 
classes [125]. Given some training data, a set of 𝑁 points of the form (𝑋a, 𝑦a): 
 𝐷 = 𝑋a, 𝑦a |	𝑋a ∈ ℝ, 𝑦a ∈ −1, 1 	 aU3  (3.18) 
where 𝑦a is either 1 or −1, indicating the class to which the point 𝑋a belongs. Each 𝑋a is a p-
dimensional real vector. The objective is to find a maximum margin hyperplane that divides 
the points having 𝑦a = 1 from those having 𝑦a = −1. A hyperplane can be written by 
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expression 𝑊𝑋a +𝑏 = 0, where 𝑊 is the normal vector to the hyperplane, 𝑋a is the input 
vector (𝑋a = 𝑋3, 𝑋V, … , 𝑋), and 𝑏 is the bias. 
If the data is linearly separable, two hyperplanes can be selected, which provides the 
maximum separation distance for two classes (see Figure 3.8). The selection of the hyperplane 
is done in such a way that data is separated into two sections with a defined gap (margin) 
between separated data. The main objective is to maximise this gap to provide better 
classification results [126] .  
 
Figure 3.8: Support vector machine classifier. 
In Figure 3.8, the blue lines are margin lines, and can be mathematically presented by 
Equations 3.19 and 3.20. The red line is the maximum-margin hyperplane that is 
mathematically formulated by Equation 3.21, whose position is in the middle of both margin 
hyperplanes. By using geometry, the distance between margin hyperplanes can be calculated 
by Equation 3.22. 
 𝑊 𝑋a + 𝑏 = −1 (3.19) 
 𝑊 𝑋a + 𝑏 = +1 (3.20) 






As it was discussed earlier, the objective is to maximise the distance between two margin 















It is also crucial to prevent data points from falling into the margin. For this reason, the 
following constraint needs to be added: 
 
 
𝑊𝑋a + 𝑏	 ≥ 1,												𝑦 = 1
	
	𝑊𝑋a + 𝑏	 ≤ −1, 𝑦 = −1
 (3.24) 
 
Equation 3.25 can be obtained by rewriting the above constraint: 
 
 𝑦a	(𝑊𝑋a + 𝑏) 	≥ 1, 1 ≤ 𝑖 ≤ 𝑛 (3.25) 
 
In order to solve this optimisation problem that has such a constraint, the Lagrange method 
is utilised so that the constrained become unconstrained [127]. To this end, the problem can 
be stated in the Lagrange format as follows: 
 
 𝐿(𝑊, 𝑎, 𝑏) =
𝑊 V
2





Gradient with respect to 𝑊 and derivation with respect to 𝑏 will result in: 
 












Afterwards, these are substituted in the Lagrange formula as shown by the following 
equation. 






















In Equation 3.29, by using a quadratic program, vector 𝛼a = (𝛼3, 		𝛼V, … , 		𝛼) is created. It 
is noted that the majority of the 𝛼a values are zero, and the value for 𝛼 is only positive for 
support vectors. This means that one only needs to sum the equation over the support vectors. 
It is important to note that when classifying with SVM, at the same time the dimension of data 
is significantly reduced. As can be seen in Figure 3.8, the data has 15 dimensions while after 
using SVM the data effectively has 3 dimensions (pointed out by filled circle and squares 
shapes). Once the alphas that meet the criteria for support vectors are defined, they can be 
used and plugged into Equation 3.27 to calculate 𝑊. Then, the value for 𝑏 can be calculated 
by the following expression:  
 𝑦]	(	𝑊	. 𝑋a 	+ 𝑏) = 1 (3.31) 
 
Finally, the classifier can be designed as shown below:   
 





where	𝑠𝑣 is the number of support vectors, 𝑋a	. 𝑋]9¤ is the dot products of the input vector 
sample and the unknown vector.  
If the data is not linearly separable, then the nonlinear SVM is utilised by applying kernel 
trick [128]. In general, when kernel trick is applied on a pair of data, it can implicitly map this 
data to a higher dimensional space so that a linear classifier can be used to separate highly 
non-linear data. Training and classification process in nonlinear SVM is similar to that in linear 
SVM. The only difference between linear and nonlinear methods is that the nonlinear kernel 
function is used in nonlinear SVM. It is noted that when kernel trick is used the coordinates 
of the data in the higher dimensional space is not computed but rather the inner products of 
the data pairs is calculated which eliminates the computational power required for explicit 
computation of the coordinates [128,129]. In the case of non-linearly separable data the 
classifier can be designed as follows:  
 







where 𝑘 𝑋a	. 𝑋]9¤  is a kernel function such as a polynomial, Gaussian or Hyperbolic tangent 
[130].    
3.5.2: Multilayer Perceptron (MLP) Artificial Neural Network 
• Single layer perceptron: 
 
Artificial neural networks mimic biological neural networks like that of the human brain 
[131]. In biology, the fundamental unit of a biological neural network is a neuron, and in 
artificial neural networks the fundamental unit is an artificial neuron. One of the widely used 
models for an artificial neuron is McCulloch-Pitts (MP) model [132]. The model is constructed 
in such a way that it has one input layer of MP neurons feeding forward one output layer of 
neurons, referred to as a perceptron (see Figure 3.9). Each input has a weight (𝑤). In a 
perceptron, an initially weighted sum of all its inputs is calculated and fed to a single variable 
function, which is also known as the activation function. The activation function then uses the 
information from the weighted sum to decide to fire or otherwise [133]. In other words, in its 
simplest form a perceptron is a network that can classify linearly separable patterns. To this 
end, initially the network should be trained in order to learn the values of the weights and 
biases to correctly respond to each input vector with the corresponding target classes.  
Figure 3.9 shows a perceptron with 𝑚 inputs (𝑥 3, 	𝑥 V, 	𝑥 §, … , 𝑥 R), and corresponding 
synaptic weight for each input (	𝑤3, 	𝑤V, 	𝑤§, … , 	𝑤R), a bias (𝑏), activation function (𝑓), and 𝑦 
is the output and can be mathematically presented by Equation 3.34.  
 
 𝑦 = 𝑓 𝑥a	𝑤a
R
aU3
+ 𝑏 = 𝑓(𝑥𝑤 + 𝑏) (3.34) 
 
Figure 3.9: A perceptron with m inputs and a bias. 
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Table 3.1 depicts some commonly used activation functions, as well as their formulations, 
and the illustrations of the signal shapes.  
Table 3.1 Activation functions 
Function 
name 






































For classification purposes, initially the network should be trained in order to learn the 
values of the weights and biases in order to minimise the error rate (error rate = desired 
output - actual output) [7]. A perceptron convergence algorithm can be used to train a single 
layer perceptron (SLP). In this algorithm the problem is solved in several steps that use the 
following parameters [134].   
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Input vector                    𝑥 𝑛 = [+1, 𝑥 3(𝑛), 	𝑥 V(𝑛), 	𝑥 §(𝑛), … , 𝑥 R(𝑛)]
 
Weight vector                 	𝑤 𝑛 = [𝑏, (𝑤3 𝑛 , 	𝑤V 𝑛 , 	𝑤§ 𝑛 , … , 	𝑤R 𝑛 ]       
Actual output                  𝑦(𝑛) = 𝑓 	𝑤a 𝑛 	𝑥a 𝑛RaU4 = 𝑓(𝑤 𝑛 𝑥(𝑛)) 
Desired output                 𝑑 𝑛 = +1, 𝑥 𝑛 ∈ 𝑐𝑙𝑎𝑠𝑠1−1, 𝑥 𝑛 ∈ 𝑐𝑙𝑎𝑠𝑠2  
where 𝑛 denotes the epoch number for applying the algorithm. It is noted that the input for 
bias (𝑏) is equal to +1, and referred to as a synaptic weight of 𝑏 in the weight vector. In the 
output, the summation operator starts at zero and 	𝑤4 𝑛  represents the weight of bias. The 
task of learning is done through four or five steps as follow: 
 
1. Initialisation of weight vector in which 𝑤 𝑛 = 0. Define the number of epochs to be 
performed (𝑛 = 1,2, 3… , ℎ). 
2. Activation of perceptron using input vector 𝑥	(𝑛) 
3. For each instance in the input vector (with known class), the activation output of the 
signum function is computed using 𝑦	(𝑛) 
4. Updating the weight vector using 𝑤 𝑛 + 1 = 𝑤 𝑛 + 𝜂 𝑑 𝑛 − 𝑦 𝑛 𝑥 𝑛 , where 𝜂 is 
the learning rate parameter.  
5. If the epoch number is less than ℎ, increment epoch by one and go to step 2, otherwise 
stop.  
 
• Multilayer perceptron: 
 
The feedforward connection of at least two perceptrons leads to the formation of a 
multilayer perceptron (MLP) which can be used for classification of data even if the data is not 
linearly separable [135].  Each perceptron is fully connected to all perceptrons in the next 
layer, and a bias presents for each perceptron. In the MLP structure, the first and last layers 
are called input and output layers respectively, because they represent inputs and outputs of 
the overall network. The remaining layers are called hidden layers. Figure 3.10 illustrates a 
typical MLP configuration with two hidden layers. In this configuration, the input layer consists 
of 𝑁 input features. The first hidden layer consists of 2 perceptrons, and each receives 𝑁 
inputs from the input features. The second hidden layer consists of 3 perceptrons, and each 
perceptron is fed by 2 inputs which are the outputs from the first hidden layer. Finally, the 
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output layer consists of one perceptron that has 3 inputs from the second hidden layer’s 
outputs. All perceptrons have bias 𝑏. 
 
Figure 3.10: MLP Artificial neural network. 
An activation function should meet several criteria, including being differentiable, 
monotonic, and continuous in order to be used in MLP learning [136]. This criterion is 
important because in later stages of training, one can apply gradient descent to find an 
optimum solution. Therefore, it is important to remember that both step and sign activation 
functions cannot be used. Between the hyperbolic tangent and sigmoid functions, the latter 
one is most widely used [137].  
The training (learning) is usually done by error back propagation algorithms, which are 
based on error correcting learning rules [138]. Compared to SLP, where all inputs are directly 
connected to the neuron that produces the output, in MLP the inputs have indirect effects on 
the output. The main idea in MLP is to calculate the error rate at the output layer (layer L) 
and then back propagate them to the perceptron in the previous layer (L-1), after which the 
weight is updated accordingly to minimise the errors. The back propagation algorithm is 
performed through several steps. Initialisation of weight vectors is the first step, and the 
number of epochs to be performed (𝑛 = 1,2, 3… , ℎ) is also defined at this step. The second 
step is the forward computation step, where the output activation functions for each layer and 
the error for the output layer is calculated. In this respect, we denote 𝑙 for layer (1 ≤ 𝑙 ≤ 𝐿), 
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𝑖 for inputs (0 ≤ 𝑖 ≤ 𝑑8s3), and 𝑗 for outputs (0 ≤ 𝑗 ≤ 𝑑8). For the first step the objective is to 
determine the parameters of 𝑤ab
(8) as the synaptic weight of neuron	𝑖 in layer 𝑙 [134]. The 
function that is used to calculate the output signal for each layer (𝑥b




(8) 𝑛 = 𝜃(𝑠b







where 𝜃 is the activation function (sigmoid), 𝑛 is the epoch number and 𝑦a
(8s3) is the output 
activation function of neuron	𝑖 in the previous layer 𝑙 − 1. To solve the problem, the stochastic 
gradient decent (SGD) method can be applied. The error can be defined as a function of 
weight vector 𝑒(𝑤ab
(8)).  Therefore, to apply SGD we need the gradient of 𝑒(𝑤ab
(8)) as follows: 
 
 ∇𝑒 𝑤ab
8 = ∇𝑒 𝑊 =
𝜕𝑒 𝑊
𝜕𝑤ab
8  (3.36) 
 


















(8s3), the value of which is already calculated by Equation 3.35. Therefore, 
one only needs to calculate ´9 ¡
´~µ
@ = 𝛿b
(8). To calculate the 𝛿 for the final layer where 𝑙 = 𝐿 






·  (3.38) 
 
For the final layer, it is noted that using the mean squared error, 𝑒 𝑊 = (𝑥3
(·) − 𝑦")V, 
where 𝑦3
(·) = 𝜃(𝑠3
· ) and 𝑦" is a constant and presents the desired value. Therefore, 𝛿	for the 
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where 𝜃¸ is the derivative of the sigmoid activation function [134].  
The third step, backward computation, aims to calculate the error of previous layers 





































8  (3.42) 
 
This step terminates an epoch, so that if the number of epochs is less than ℎ, steps 2 and 
3 are repeated, otherwise the final value of 𝑤ab
8  is returned as the final weights.  
Although there are several training algorithms based on back-propagation, such as gradient 
descent [139] , conjugate gradient [140], Bayesian regularisation [141], resilient [142], scaled 
conjugate gradient [143], and Levenberg-Marquardt [144], the last one is the most widely 
used. 
3.6: Feature Selection  
During microarray analysis, the number of genes is significantly higher than the number of 
samples [12,13] and classification to a high level of accuracy is challenging, due to large 
number of genes and small sample size [14,15]. This concept refers to as the course of 
dimensionality which is a term that was introduced by Belham to explain the challenge initiated 
by the exponential expansion in volume related to adding extra dimension to Euclidian space 
[145]. In order to overcome this problem, gene selection mechanisms have been introduced, 
by which only the most important genes are selected and used for classification purposes [16–
19]. There are several advantages to this process of minimising the number of genes, and 
only selecting the meaningful genes which are more predictive during classification. By having 
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fewer genes, not only is the processing time for classification significantly decreased, but the 
chance of misclassification is also reduced. Furthermore, inputting a high number of genes 
into the classifier can cause the classifier to be over-fitted [146].  
Gene selection methods, based on their interaction with the classifier, can be categorised 
into three approaches: filter methods, wrapper methods, and embedded methods [146,147]. 
Filter methods assess the relevance of genes by only looking at the general characteristics of 
the data, and ignoring the impact of selected genes on the classification performance [148]. 
Wrapper gene selection initiates a search procedure in the space of possible gene subsets. 
The selected genes are then evaluated based on their power to improve classification accuracy 
[149–151]. In the embedded gene selection method, feature selection is linked to the 
classification stage, but this connection is much stronger than in the wrapper method. This is 
because gene selection in embedded methods is included in the classifier construction, and 
the classifier is used to provide a criterion for feature selection [152,153] (see Figure 3.11). 
More recently, evolutionary algorithms have been utilised for gene selection within the 
framework of wrapper methods [154,155].  
 
Figure 3.11: Feature selection methods. 
Each gene selection approach has advantages and disadvantages [146]. For instance, 
although the filter method is simple and computationally efficient, its performance lags behind 
other approaches. This is because the classifier performs independently, and is not involved 
in the selection of genes [156]. Conversely, while the wrapper and embedded methods, which 
incorporate the gene selection task into the classification task, can achieve higher classification 
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accuracy, they suffer from scalability problems due to their high computational cost and are 
not practical for large datasets [157,158]. 
3.7: Overfitting  
As discussed in Section 3.5, in a classification task there exist two main phases namely 
training and testing.  In the training phase, the classifier model is build using training data 
and in the second phase the model is evaluated using test data. It is important to note that 
the test data should not be used in the training phase, otherwise the result of validation would 
be optimistic. The main aim when building a classifier model is not only to perform well on 
the training data, but to be able to generalise this model to perform well on the test data and 
other unseen data [159]. Overfitting is a phenomenon that occurs when a model is too 
complex (too many parameters) that the model memorises the training data rather than learn 
to generalise from the data. In other word, overfitting happens when fitting the data in the 
model more than it is warranted [160].  
As illustrated in Figure 3.12, initially as the number of parameters in a model increases the 
error rate of classifier decreases for both training and test data. However, after the 5th 
parameter is included in the model, the error rate for test data starts to increase while the 
training data exhibits a low classification error. Therefore, if overfitting takes place the model 
performs very well on the training data, however this model would have a poor prediction 
power when applied to the test data due to the lack of generalisation [161].  The impact of 
overfitting could be in a higher magnitude on the classification performance for unseen data 
if the training data consists of stochastic noise.  
 
Figure 3.12: Train and test performance when changing the number of parameters in the classifier 
model adapted from [162]. 
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Overfitting can be prevented if methods such as hold out validation, k-fold cross validation, 
or leave one out cross validation (LOOCV) are implemented in the model. These methods 
basically determine the point where further training will not result in enhancing the 
generalisation power of the classifier.  In general, in a cross validation task the data is split 
into two parts where the training is done on one part and validation is performed on the other 
part. Therefore, the principle of cross validation emphasis on separating a part of data from 
the training stage to validate the performance of the model on this part of data which is not 
seen by the model before. Cross validation is widely accepted in machine learning society 
where it is being use for model selection [163].  
In holdout validation, the data is split into two parts (e.g. 70% - 30%). The training is 
usually performed on the higher chunk of data (70% of data), then the model is evaluated on 
the remaining part (30 % of data). Since splitting the data is a random process, one usually 
tend to repeat the splitting several times and consequently repeating training and evaluation 
several times. Then report the final accuracy as the average accuracies that obtained from all 
repetitions [164].   
K-fold cross validation is commonly used technique for assessing the prediction 
performance of a classifier model. In this method data is split into k equal chunks where the 
training is performed on k-1 chunks and the testing is carried out on the remaining chunk. 
This process is repeated k times, where each time a new chunk is chosen for test phase and 
the remaining k-1 chunks for training. Therefore, testing is performed on all chunks separately. 
The final accuracy of the model is determined by averaging the accuracies in each iteration. 
Similar to hold out validation, to acquire a robust estimate of the classification performance 
the k-fold cross validation should be ran multiple times while reshuffle the data each time. 
Then the final estimate is reported as the average accuracies obtained in each iteration. 
LOOCV is a special case of k-fold cross validation where k is equal to the number of samples 
[164]. 
The K-fold cross validation can be used for model selection. In the above, the cross 
validation using k-fold cross validation was discussed. In a model selection task using k-fold 
the task is somewhat similar to holdout method whilst here the splitting of data refers to a 
“three-way holdout”.  In this approach, the data initially is split into two parts namely test and 
training set. The test set is preserved for the final evaluation of the model. The training set is 
then used for k-fold cross validation. Once the training and validation is done, the performance 





In this chapter, the steps required for microarray analysis were described including: pre-
processing, clustering, and classification (see Figure 3.13). It was explained that the design 
step is a crucial step towards a successful analysis. Then the importance of pre-processing of 
microarray data was explored, and it was concluded that, first, systematic variation of 
microarray images should be removed; and the importance of transformation and 
normalisation of the data before starting the main analysis was pointed out. Furthermore, 
unsupervised and supervised classification methods were described. It was elaborated that 
unsupervised analysis can provide useful information for data visualisation and the 
interpretation of experimental results; several clustering methods such as K-means, C-means, 
hierarchical, SOM, Bi-CoPam and UNCLES clustering methods were investigated. Then the 
importance of supervised classification methods in class prediction was mentioned, and 
methods such as SVM and the MLP artificial neural network were briefly explained. Afterwards, 
the vital role of feature selection before classification was investigated. Finally, the pitfalls of 
overfitting and how to account for it were discussed  
 
 



















Chapter 4: Effects of Data Clustering Prior to Gene 






In order to enhance classification performance, two main areas including gene selection 
and classifier design are important to be investigated. Furthermore, it is referenced from the 
literature that grouping data (clustering) has also been implemented for microarray data 
analysis in a number of investigations [165]. The main characteristic of such approaches is 
that there is no prior information on the group structure of the data, and frequently used in 
microarray analysis to facilitate the visual display of experimental results.  
In this chapter, the effects of gene clustering prior to gene selection on classification 
accuracy is investigated. In this context, the aim of clustering applications is to partition	𝑛 
genes (total number of genes) with 𝑚 dimension (𝑚 sample) into a given number of clusters. 
Once the data is clustered, a set of genes is selected based on gene ranking across all clusters 
for classification purposes. In order to fully investigate the effects of clustering on classification 
accuracy, not only are conventional clustering methods such as K-means, fuzzy C-Means and 
hierarchical methods used, but some optimisation algorithms are also utilised including PSO, 
GA, and COA for clustering purposes. Furthermore, a novel optimisation algorithm called COA-
GA is proposed for clustering tasks.  
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4.2: Optimisation Based Clustering Techniques  
In order to investigate the effects of optimisation based clustering methods on classification 
performance, three optimisation algorithms, specifically GA [25], PSO [166], and COA [24] 
were used. A new hybrid optimisation algorithm, COA-GA, was also developed, merging the 
recently invented COA and the traditional GA algorithms for data clustering. In the following 
subsections, first the design of the cost function for clustering tasks will be given. Then, details 
of optimisation algorithms including GA, PSO, COA will be described. Finally, the newly 
proposed hybrid COA-GA algorithm are explained.  
4.2.1: Proposed Cost Function  
In an optimisation problem, the optimisation algorithm iterates until a fitness function (cost 
function) conforms to a threshold set beforehand. Therefore, in order to use the optimisation 
algorithm for the purpose of clustering microarray gene expression data, a cost function needs 
to be defined with the objective to minimise the distance between data within each cluster, 
while maximising the distance between clusters. The design of the cost function is depicted 
below. 
 







where 𝑚 is the population size which is supplied by evolutionary algorithm, and 𝑝 is 
the product of number of samples (𝑠) in the data set and number of clusters (c). 
2. For each row of the POP matrix steps 3 to 9 are repeated. 
3. Candidate centres are acquired by reshaping a row of the POP matrix with dimension 






4. Then the distances between each increment of data (gene) and candidate cluster 








       where 𝑖 is the number of genes. 
5. “Minimum values” for each gene in the 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 matrix is found, thereby a gene will 
be assigned to the cluster which has the minimum value for that gene. 
6. Distance between all clusters is calculated and assigned to variable B. 
7. Distance between all clusters is calculated as follow. First by using “dist” function of 
MATLAB the Euclidian distance between all clusters are calculated. This produce a 
distance matrix whose dimension is 𝑐	×	𝑐. Then the upper triangular part of this matrix 
is selected and the sum of columns is calculated which results in a vector that has 𝑐 
elements. Finally, the sum of this vector is computed which results in a single value. 
This value is assigned to variable 𝐵. 
8. In order to ensure each suggested cluster centre contains at least one gene, a term 
called “𝑝𝑒𝑛𝑎𝑙𝑡𝑦” is defined. If a cluster contains at least one gene, this term will 
become zero, otherwise it will be 10e4 (essentially to skip unsuitable cluster centres). 
9. Finally, the cost for the selected row is calculated as below: 
 𝐶𝑜𝑠𝑡 = 𝑠𝑢𝑚 𝑚𝑖𝑛𝑖𝑚𝑢𝑚	𝑣𝑎𝑙𝑢𝑒𝑠 +
1
𝐵
+ 𝑝𝑒𝑛𝑎𝑙𝑡𝑦 (4.1) 
10. Since steps 3-9 are repeated 𝑚 times, a matrix containing cost values whose dimension 
is 𝑚×1 will be acquired and return. 
 
The objective is to supply this cost function to an evolutionary algorithm whereby the 
chosen population by the algorithm can be examined in terms of their profit value. The cost 
function will be updated by each iteration of algorithm. Through some initial experiments, it 
was observed that the cost function could be minimised up to 100 iterations beyond which no 
further cost minimisation was observed. Therefore, in order to control the computational time, 
it was decided to run all optimisation algorithms 100 times in this research and compare their 
performances.  
4.2.2: Genetic Algorithm (GA) 
The genetic algorithm is an evolutionary computing method that was first introduced by 
John Holland in 1975 [25]. Since then, this algorithm has been used for solving many 
computational problems that require searching through a huge number of possibilities for 
solutions. By using a genetic algorithm, many different possibilities are explored 
simultaneously in an efficient way. The foundation for the method comes from the behaviour 
of living organisms in nature. In biology, an enormous set of possibilities lies in a set of possible 
genetic sequences, and the desired solutions are highly fit organisms that can survive and 
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reproduce in their environments. In a genetic algorithm, a potential solution to the problem is 
named as a chromosome. In the first step of this algorithm, an initial set of chromosomes, 
referred to as initial population is selected. From this population, some individuals are 
randomly opted to transfer to the next generation without any change occurring to them 
through a natural selection process [167]. 
In the selection method, a fitness function (cost function) is used for evaluating the quality 
of every chromosome. According to the principles of evolution, chromosomes with higher 
fitness scores tend to remain for producing offspring [168]. Therefore, the probability that an 
individual is transferred to the next generation is defined by how good its fitness function is. 
Each gene in the chromosome represents a specific characteristic. If all the chromosomes are 
transferred to the next generation, the next generation’s properties will be identical to the 
previous generation’s properties. However, in reality, this is not the case. In fact, two events 
take place in chromosomes. The first event is mutation, where the random substitution of 
some nucleotides within each chromosome occurs. The role of mutation is to increase the 
possibility of exploring untouched areas of the design space, preventing premature 
convergence. The number of genes that undergo mutation is very low (less than 10%). 
However, this random variation is really important. The second event is crossover, where the 
beginning of one chromosome sticks to the end of another chromosome (genetic 
recombination). The number of genes that undergo crossover is higher than that for mutation 
[169]. The cost minimisation plot is acquired to visualise how GA minimises the cost function 
over 100 iterations. The pseudo-code of GA is given below.  
 
1. Initialise population. 
2. Calculate fitness. 
3. Sort fitness value of the population. 
4. Choose the best fit solution to be the parental pair for reproduction. 
5. Crossover the chromosomes at a random position using single point crossover. 
6. Mutation. 
7. Evaluate cost for the new offspring’s chromosomes and mutated chromosomes. 
8. If the number of iterations is less than 100, go to step 2. 
9. Save the best profit so far as the ‘best answer’. 
4.2.3: Particle Swarm Optimisation (PSO) 
Particle Swarm Optimisation was first introduced by Eberhart in 1995, and was intended 
for simulating the social behaviour of the movement of organisms in a bird flock or fish school. 
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This kind of action is an automatic and interactively updated system [166]. PSO has already 
been implemented in many research areas, such as function optimisation, artificial neural 
networks, and fuzzy system control.  
Particle swarm optimisation (PSO) is a method that optimises an issue by iteration, which 
tries to achieve the best result for a given function. In PSO algorithms, a population (or swarm) 
consists of several particles or candidate solutions. These particles are moved around in the 
search space based on its own memory and information received from other particles in order 
to find the best solution [170]. Like genetic algorithm, a fitness function is used for 
determining the fitness value of each particle. The fitness value also needs to be optimised. 
In the progress of movement, the position of each particle is adjusted by the change of 
velocity, which is based on its own experience and particles around it. The velocity represents 
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where, 𝑣 and 𝑥	are the velocity and position of 𝑖𝑡ℎ particle; 𝑘 represents irritation level; 𝑝 is 
the best position found by 𝑖𝑡ℎ particle (personal best); 𝐺 accounts for the best position found 




2𝑖 are random numbers on the interval [0,1] applied 
to 𝑖𝑡ℎ particle. The above movement iteration will stop after a set number of times [171]. The 
cost minimisation plot is acquired to visualise how PSO minimises the cost function over 100 
iterations. The pseudo-code of PSO is given below.  
 
1. Initialise population (n particles).  
2. Calculate the fitness of each particle. 
3. Position of the best-fit particle is chosen as the global best position.  
4. Move all of the particles towards the global best position.  
5. For each particle, if (fitness of current position < fitness of personal best) then personal 
best = current position.  
6. Update personal best position for each particle.  
7. Global best fitness value is retained.  
8. If number of iteration is less than 100, go to step 2. 
9. Save the global best from 100 iterations as the ‘best answer’. 
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4.2.4: Cuckoo Optimisation Algorithm (COA) 
COA is a population-based optimisation algorithm that was proposed by Rajabion in 2011 
[24] that was inspired by the life of the cuckoo bird. The cuckoo’s behaviour in laying eggs is 
unique in the sense that a cuckoo never builds its own nest when laying eggs, and instead 
uses other birds’ nests to lay its eggs. In doing so, if the cuckoo’s eggs are similar to the host’s 
eggs, it is likely that the cuckoo’s eggs will hatch and become mature cuckoos. If the cuckoo’s 
eggs are discovered by the host bird, the foreign eggs will be destroyed. In the COA algorithm, 
each egg in a nest represents a potential solution and each cuckoo represents a successful 
new solution. The objective of the COA is to find the nest with the highest probability of an 
egg’s survival. Therefore, the more eggs that survive after being placed in a host nest, the 
greater the level of profit assigned to that nest. When the time comes for the migration of the 
newly matured cuckoos, they will move towards the best nest with the highest survival rate, 
and lay eggs within a radius of it. This radius is known as the egg laying radius (ELR), and 
can be calculated by Equation 4.4. 
 







low  (4.4) 
 





are respectively the minimum and maximum values in the gene expression dataset.  
Around 10 % of the laid eggs are sufficiently dissimilar to the nest’s eggs and are killed by 
the host bird; the rest would remain until they turn into mature cuckoos and form societies. 
Each society has its own habitat area to live in [172]. When the time for egg laying approaches 
for newly matured cuckoos, they migrate towards the best habitat among all societies (goal 
point). As illustrated in Figure 4.1, when cuckoos move towards the goal point they can deviate 




, in which case they can only fly λ amount of 
the distance between the current habitat and the goal point (d) in that iteration, where 𝜆 is a 





Figure 4.1: Immigration of a cuckoo towards goal habitat. 
When all cuckoos have migrated toward the goal point and new habitats have been 
specified, each cuckoo is allocated some eggs. Then after the number of eggs dedicated to 
each bird is considered, an egg laying radius (ELR) is calculated for each cuckoo, and this step 
concludes one iteration in the algorithm. In the new iteration, the new egg laying process 
starts. Due to the fact that there is always equilibrium in any birds’ population, a number 
𝑁
	
𝑀𝑎𝑥	is provided in the COA algorithm to control and limit the maximum number of live 
cuckoos in the environment [173]. After some iterations, all the cuckoo populations move to 
the optimum habitat. This habitat will produce the maximum profit, and there will be the least 





𝐶𝑢𝑟𝑟𝑒𝑛𝑡ℎ𝑎𝑏𝑖𝑡𝑎𝑡 + 𝐹×(𝑋𝑔𝑜𝑎𝑙𝑝𝑜𝑖𝑛𝑡 − 𝑋
	
𝐶𝑢𝑟𝑟𝑒𝑛𝑡ℎ𝑎𝑏𝑖𝑡𝑎𝑡)  (4.5) 
 
where 𝐹 is a parameter that causes deviation. The cost minimisation plot is acquired to 
visualise how COA minimises the cost function over 100 iterations [174]. The COA algorithm 
follows the steps listed below [24].  
1. Initialise cuckoo habitats with some random points in the profit function.  
2. Dedicate some eggs to each cuckoo.  
3. Define ELR for each cuckoo.  
4. Allow cuckoos to lay eggs inside their corresponding ELR.  
5. Kill the eggs that are recognised by host birds (if two eggs are in the same position).  
6. Let eggs hatch and chicks grow.  
7. Evaluate the position of each newly grown cuckoo (profit value). 
8. Limit cuckoos' maximum number in the environment, and kill those who live in the 
worst habitats.  
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9. Assign the current maximum profit using the cuckoo with highest profit value. 
10. Cluster cuckoos (using k-mean), find the best group, and select goal habitat.  
11. Let new cuckoo population immigrate toward goal habit.  
12. Get the position of all cuckoos and their profit values and update maximum profit. 
13. If the number of iteration is less than 100, go to step 2. 
14. Save the positions of cuckoo with highest profit value as the ‘best answer’. 
 
In the COA algorithm like other optimisation algorithms there are few parameters that are 
important to set as follow. Default values are used.   
• Number of initial population. 
• Maximum number of cuckoos to control how many cuckoos can live at the same 
time in each iteration. 
• Minimum number of eggs for each cuckoo. 
• Maximum number of eggs for each cuckoo. 
• λ variable to controls distance between the current habitat and the goal point. 
• Radius coefficient to control the egg laying radius. 
• Number of k-means clusters. 
 
4.2.5: Proposed COA-GA Algorithm for Clustering  
A new algorithm is developed by hybridising COA and GA. Figure 4.2 shows the flowchart 
of the COA-GA algorithm. First, the COA chooses the best population (pop 1) as discussed in 
Section 4.2.4, and the profit value (fitness value) is calculated for this population. 50% of the 
chosen population undergoes the crossover operation, which is intended to prevent premature 
convergence as it creates more solutions in a given population [169]. After crossover, a 20% 
mutation is applied to the population, which increases the chance of discovering a better 
solution by maintaining diversity within the population. Crossover and mutation are important 
aspects of GA, increasing the possibility of exploring untouched areas of the solution space in 
each iteration of the algorithm, which COA alone could not reach. The output of these 
processes is termed population 2 (pop 2), and the profit value is determined for this 
population. 
Pop 2 and pop 1 profit values are compared, and the population with the higher profit value 
is retained (population with better positioning) and input into the next iteration of the 






Figure 4.2: Flowchart of COA-GA. 
4.3: Gene Ranking and Selection  
As it was discussed in Section 3.6, gene selection is an essential task in microarray data 
analysis, due to the fact that only small numbers of genes are informative for each cancer 
type, and the presence of other genes reduces the classification accuracy. In this chapter, in 
order to facilitate a quick search and therefore reduce the computational time, the filter 
method of gene selection is used to score the genes. In this method, gene scoring is performed 
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by utilising a signal-to-noise ratio (SNR) criterion. The general expression for SNR is shown in 
Equation 4.6. 







There are several SNR-based ranking methods such as the signed Fisher discriminant ratio 
(Signed.FDR), Fisher discriminant ratio (FDR), symmetric divergence (SD), and T-statistics 
that can be used for gene ranking [118, 188, 189]. A summary of these methods is provided 
below. 























































































𝑖 are the mean and standard deviation respectively of the class (I) of gene 𝑖, 
and 𝜇
−
𝑖  and 𝜎
−
𝑖  are the mean and standard deviation of the class (II) of gene 𝑖 respectively. 
𝑁 and 𝑁s are the number of samples in class (I) and class (II) respectively. 𝑟+𝑖
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In this chapter, after clustering is performed the genes in each cluster were ranked using 
symmetric divergence method (See Equation 4.9) which is a filter based ranking technique. 
The total number of best genes to be selected from all clusters is set to be 𝑁
	
𝑔 = 25. The 
number of best genes to be selected from each cluster is calculated using Equation 4.13. 



















+ 1 (4.13) 
where 𝑁𝑘𝑔	is the number of best genes selected from cluster 𝑘, 𝑁
	
𝑔 is the total number of best 
genes to be obtained from all clusters,	𝑞 is the number of clusters, 𝑚 is the total number of 
genes, 𝑚
	




𝑖, 𝑡  is the criterion used for gene 
ranking (Equation 4.9). In this study, at least one gene is selected from each cluster. In this 
respect, the number of clusters is subtracted from the total number of required genes and 
then the number of genes in each cluster is added by one [165]. 
4.4: Classification and Performance Evaluation  
In most cases, before classification the data is divided into two partitions: test and training 
sets. For both the training and test data, hold out validation is applied to get accurate 
classification result. After partitioning the data, the classifier trains itself by using the training 
data, and then tests its prediction power across the test data. Finally, the prediction outcome 
is compared to the testing target, and as a result the accuracy of the classifier is calculated. 
4.4.1: Classification Methods 
In this study, the SVM (see Section 3.5.1) and MLP (see Section 3.5.2) artificial neural 
networks are used as the classifiers. In the case of the SVM classifier, the build of the 
hyperplane is based on the structural risk minimisation principle. The error rate of the learning 
machine for the test data is bounded by the training error rate, as well as one term that 
depends on the Vapnik-Chervonenkis (VC) dimension [177,178]. The input data is first 
mapped in the feature space, in relevance to the kernel function. Then the system 
automatically searches for an optimised linear division [179].  
In the case of MLP, the classifier has 25 inputs that are fed by the 25 selected genes; one 
hidden layer consisting of 30 neurons, and one output. Sigmoid and pure linear activation 
functions are used for the hidden and output layers respectively as the activation functions. 
The Levenberg–Marquardt algorithm [180] is used for training purposes, and the maximum 
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number of iterations is set to be 100. 70% of the data is used for training and 30% is used 
for testing the classifier performance. In order to reduce the effects of random selection on 
the training and testing data, the neural network has been trained and tested 100 times, 
where in each iteration, different training and testing data sets were used. 
4.4.2: Performance Evaluation 
After the classification task, the performance of both classifiers is evaluated. The evaluation 
is carried out in the forms of sensitivity, accuracy, and specificity. There are 4 possible 
outcomes from the classifier. The first possibility is a true positive (TP), which refers to the 
case that a diseased sample is correctly diagnosed. The second possibility is a false positive 
(FP), in which a healthy sample is incorrectly identified as a diseased case. The third possibility 
is a true negative (TN), which indicates the case where a healthy sample is correctly spotted. 
The final possibility is a false negative (FN), which refers to the case that the diseased sample 
is incorrectly identified as healthy [165]. The percentage value for the evaluation criteria 













𝑛' + 𝑛 + 𝑛Ù' + 𝑛Ù
×100 (4.16) 
 
where 𝑛', 𝑛, 𝑛Ù and 𝑛Ù'  correspond to the number of 𝑇𝑃, 𝑇𝑁, 𝐹𝑁 and 𝐹𝑃 respectively 
as a result of the classifier test stage.  
 
4.5: Investigating the Effects of Conventional Clustering 
Methods on Classification Performance 
4.5.1: Methods  
The general methodology used in this section is illustrated in Figure 4.3. The gene 
expression data for prostate and leukaemia cancer was used for this investigation. First, the 
data was indexed by using the available information on the classes of data (e.g. healthy vs 
cancerous). The data was indexed in two groups and stored separately in two matrixes 
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referred to as IndexClass1 and IndexClass2. After the genes were indexed, 3 conventional 
clustering methods (K-means, fuzzy C-means, and hierarchical) were utilised to partition 
genes based on their similarity. The number of clusters was pre-defined.  
For each dataset, the following steps were performed six independent times, each time 
choosing a different number of clusters (𝑘 = 1, 2,3,4,5,6). If data is clustered into one, this 
means no clustering was performed.  
 
1. Data is clustered into k cluster. 
2. Symmetric divergence (see Equation 4.9) was used for gene ranking. 
3. The top 25 ranked genes were selected using Equation 4.13. 
4. The selected genes were then fed to the SVM (see Section 3.5.1) and MLP (see Section 
3.5.2) classifiers. 
5. Classification performances for both classifiers were evaluated in terms of sensitivity, 
accuracy, and specificity as explained in Section 4.4.2.  
 
Note that the performance of clustering is assessed based on their effect on the classification 
performance. Changing the number of clusters results in selection of different genes due to 
the method of gene selection (Equation 4.13) which is affected by the gene ranking within 
each cluster and the number of genes in each cluster. Therefore, each clustering method will 
















Basic information on the datasets used in this research is listed in Table 4.1, including the 
number of genes, samples, and the two classes.  
Table 4.1: Basic information of microarray data. 
Dataset Number of genes Samples Class1 Class2 
Leukaemia 7,129 72 48 (ALL) 25 (AML) 
Prostate 12,600 102 50 (Normal) 52 (Cancerous) 
 
At the first stage of microarray analysis, data was clustered in order to find any hidden 
connections throughout it without any annotations. In order to investigate how each clustering 
algorithm distributes genes into different clusters, the number of clusters was set to two. After 
running each clustering algorithm, the number of genes in each cluster was observed (see 
Table 4.2). It is noteworthy that genes are not equally partitioned, and each clustering method 
partitions genes differently. The differences between the numbers of genes across two 
clusters are more pronounced when the K-means and fuzzy C-means algorithms are used. In 
contrast, the information suggests that hierarchical clustering divides genes into clusters more 
equally.    
Table 4.2: Number of genes in each cluster when data is clustered into two groups 
 K-Means C-Means Hierarchical 
Cluster 1 Cluster 2 Cluster 1 Cluster 2 Cluster 1 Cluster 2 
Number of genes for 
Prostate 117 12483 184 12416 6189 6411 
Number of genes for 
Leukaemia 140 6989 135 6994 1603 5526 
 
In order to investigate the effects of clustering on classifier performance, different 
conventional clustering methods (K-means, fuzzy C-means, and hierarchical) were used. For 
each type of clustering, the classifier performance has been tested by partitioning data into 
different amounts of clusters (1, 2, 3, 4, 5, and 6 clusters), where 1 cluster means no clustering 
was used. After clustering, the top 25 genes were selected using the filter method of gene 
selection (Equation 4.13) and fed to the classifiers. 
To investigate the performance of the MLP classifier for the selected genes, the selected 
genes (25 genes) were fed to the MLP and mean sensitivity, specificity, and accuracy were 
calculated. Also, standard deviations for these terms were calculated. In the case of the 




Table 4.3, when no clustering (1 cluster) was used, sensitivity, specificity, and accuracy 
are found to be 81.1%, 83%, and 89.8% respectively. This yielded more accurate results 
compared to when clustering was used, apart from the case of K-means clustering when data 
was partitioned into 6 clusters, and 82.1%, 83.5%, and 90.1% were acquired for sensitivity, 
specificity and accuracy respectively. In respect to the prostate cancer dataset (See Table 
4.4), in some clustering cases such as using K-means with 3 clusters, C-means with 2 clusters, 
and hierarchical with 5 clusters, a slightly better classification performance for the MLP 
classifier was observed. This was compared to the case when no clustering was used, in which 
84.9%, 89.1%, and 87% were acquired for sensitivity, specificity, and accuracy respectively. 
The results from both datasets suggest that clustering may not necessarily enhance the MLP 
classifier performance.   
 
Table 4.3: MLP classifier performances including the mean sensitivity, specificity, accuracy, and 
standard deviation (SD) for leukaemia. 
 Number of clusters 
1 2 3 4 5 6 
Mean/SD Mean/SD Mean/SD Mean/SD Mean/SD Mean/SD 
K-m
eans 
Sensitivity 81.1/15.2 80.3/16.4 80.9/16.2 79.1/17.3 81/15.0 82.1/13.3 
Specificity 83/12.9 82.7/13.5 82.6/13.7 82.8/14.0 82.5/13.6 83.5/12.2 
Accuracy 89.8/8.2 87.6/8.9 89.1/8.5 88.9/9.3 89.6/8.3 90.1/7.9 
C-m
eans 
Sensitivity 81.1/15.2 81/15.4 80.4/16.4 80.9/16.0 81.1/15.2 79.9/17.9 
Specificity 83/12.9 82.9/12.9 82.1/13.3 82.5/13.1 82.9/13.0 82.3/13.7 
Accuracy 89.8/8.2 89.3/8.4 89.1/8.9 88.4/9.4 88.9/9.1 88.4/9.4 
H
ierarchical 
Sensitivity 81.1/15.2 81/15.4 80.9/16.4 80.2/16.9 79.9/17.0 80.5/16.6 
Specificity 83/12.9 82.3/13.4 82.9/13.0 83/12.9 82.6/13.2 81.9/14.2 









Table 4.4: MLP classifier performances including the mean sensitivity, specificity, accuracy, and 
standard deviation (SD) for prostate cancer. 
 Number of clusters 
1 2 3 4 5 6 
Mean/SD Mean/SD Mean/SD Mean/SD Mean/SD Mean/SD 
K-m
eans 
Sensitivity 84.9/12.1 84.7/12.5 85.1/11.6 84.7/12.5 84.2/12.8 83.6/13.1 
Specificity 89.1/9.1 88.6/10.4 89.8/8.7 88.5/10.5 88.9/10.1 88.3/10.9 
Accuracy 87/10.9 86.7/11.3 87.1/10.7 86.9/11.0 84.6/12.3 86.8/11.5 
C-m
eans 
Sensitivity 84.9/12.1 85.2/11.5 84.2/12.6 84.3/12.5 83.6/13.0 83.9/13.4 
Specificity 89.1/9.1 89.7/8.9 87/11.3 88.6/10.1 89.1/9.2 87/11.3 
Accuracy 87/10.4 87.1/10.3 85.2/11.5 86.5/11.0 85.1/11.6 85.9/11.1 
H
ierarchical 
Sensitivity 84.9/12.1 84.3/12.6 84.2/12.9 84.8/12.2 85/11.5 83/13.7 
Specificity 89.1/9.1 88.1/10.6 89/9.4 87.5/11.1 90.3/8.1 89/9.4 
Accuracy 87/10.4 86.9/10.5 86/11.0 86.5/10.7 87.8/9.9 86.4/10.6 
 
 
In the next step, in order to investigate the effects of clustering on the SVM classifier, the 
selected genes (25 genes) were fed to the SVM classifier, and mean sensitivity, specificity and 
accuracy were calculated. Table 4.5 gives information on the sensitivity, specificity, and 
accuracy of the SVM classifier when different clustering methods were used, and the data was 
partitioned in different amounts of clusters for the leukaemia dataset. It can be seen from 
Table 4.5 that when data clustering is not applied (1 cluster), sensitivity, specificity, and 
accuracy were calculated 95%, 97.7%, and 98.1% respectively. An improvement of 0.7% and 
0.8% in accuracy was observed when data was clustered into 4 partitions via K-means and C-
means respectively compared to the case when no clustering was used. Furthermore, in the 
case when data was clustered into 3 partitions using C-means, improvement in all performance 
criteria was achieved compared to when no clustering was utilised. In the case of the prostate 
cancer dataset, as can be seen from Table 4.6 when clustering was not applied (1 cluster), a 
higher classification performance was achieved excluding two cases where C-means clustering 





Table 4.5: SVM classifier performances including the mean sensitivity, specificity, accuracy, and 
standard deviation (SD) for leukaemia.  
 Number of clusters 
1 2 3 4 5 6 
Mean/SD Mean/SD Mean/SD Mean/SD Mean/SD Mean/SD 
K-m
eans 
Sensitivity 95/5.1 94.9/5.0 94.3/5.7 95/5.1 94.4/5.9 93.5/6.8 
Specificity 97.2/4.1 97/4.2 96.8/4.5 96.8/4.3 96.8/4.5 96.5/4.9 
Accuracy 98.1/3.4 98/3.6 97.1/4.3 98.8/3.1 97.5/4.1 97.7/3.9 
C-m
eans 
Sensitivity 95/5.1 94.6/5.4 95.5/4.6 95/5.4 94.9/5.1 94.6/5.5 
Specificity 97.2/4.1 97.1/4.1 97.8/3.8 96.7/4.6 96.5/4.8 96.9/4.1 
Accuracy 98.1/3.4 97.8/3.7 98.7/3.1 98.9/2.9 97.2/3.9 97.4/3.8 
H
ierarchical 
Sensitivity 95/5.1 95/5.3 94.8/5.6 94.5/5.9 94.9/5.0 94.6/5.4 
Specificity 97.2/4.1 97.1/4.2 97.2/4.1 96.9/4.3 96.3/4.9 96.8/4.5 
Accuracy 98.1/3.4 97.7/3.7 97.9/3.4 97.7/3.4 98.1/3.2 97.6/4.0 
 
Table 4.6: SVM classifier performances including the mean sensitivity, specificity, accuracy, and 
standard deviation (SD) for prostate cancer. 
 Number of clusters 
1 2 3 4 5 6 
Mean/SD Mean/SD Mean/SD Mean/SD Mean/SD Mean/SD 
K-m
eans 
Sensitivity 89.4/8.3 88.6/9.1 88.8/9.1 89.1/9.2 89.1/9.2 89.3/8.4 
Specificity 93/6.8 92.8/6.9 92.9/6.9 92.1/7.3 90.5/8.8 92.7/7.2 
Accuracy 90.1/7.6 89.8/7.8 89.6/8.0 89.3/7.9 89.7/7.8 90/7.6 
C-m
eans 
Sensitivity 89.4/8.3 89/9.1 89.9/8.1 88.6/9.1 89.7/9.0 89.4/9.3 
Specificity 93/6.8 92.6/7.1 93.3/6.5 92.6/7.1 93.1/6.7 92.9/6.9 
Accuracy 90.1/7.6 89.2/8.2 91.4/7.1 89.6/7.9 91.2/7.2 89/8.4 
H
ierarchical 
Sensitivity 89.4/8.3 89.1/8.9 89/9.2 89.1/8.9 88.9/9.3 88.5/9.5 
Specificity 93/6.8 92.8/7.0 93/6.8 92.1/7.3 93/6.3 91.8/7.6 




Figure 4.4 illustrates a comparative performance between SVM and MLP for the leukaemia 
and prostate cancer datasets when no clustering was applied. It can be seen that the SVM 
classifier has a better sensitivity, specificity, and accuracy compared to that of the MLP 
classifier in both datasets.  
 
 
Figure 4.4: MLP vs SVM performance without clustering. 
4.6: Proposed Gene Selection Based on Shuffle Technique  
4.6.1: Methods  
In the previous section, the impact of conventional data clustering on classification 
performance was investigated, and it was determined that conventional clustering may not 
have any significant effect on classification performance. In order to fully investigate the effect 
of data clustering on classification performance, this section investigates the effect of 
optimisation based clustering methods on the performance of the SVM and MLP classifiers 
compared to conventional methods. A novel gene selection approach called shuffling is 
proposed to enhance the selection of the most informative genes 
 
• Novel shuffle technique to enhance gene selection 
 
 In cancer classification, using clustering based gene selection (grouping genes before gene 
selection) and changing the number of clusters, both result in selection of different sets of 

























differences in the selected genes could occur because the initial centroid protocol for clustering 
is not specified, but selected randomly [181]. Since the clustering outcome is highly dependent 
on the initial centroids, it often transpires that better results would have been achieved with 
other initial points. The standard solution is to try the algorithm a few times with different 
initial points [182]. As demonstrated in Section 4.5.2, differences in the selected genes can 
influence the classification performance, so by creating a method to reinforce the selected 
genes a more robust classification can be performed. 
To overcome this problem, a technique called shuffling is proposed in this study. This 
requires that the data is clustered 6 times, setting different numbers of clusters, ranging from 
1 to 6 in each case. As a result, the number of clusters in the first run is set to one, implying 
no clustering is used, hence the algorithm goes straight to the gene selection step and selects 
the top 20 genes. In the second run, data is partitioned in two clusters, while the clustering 
algorithm iterates 100 times to minimise the cost function to achieve clusters that are more 
accurate. After 100 iterations of the clustering algorithm, gene selection is carried out 
according to the number of clusters and the population in each cluster. Therefore, depending 
on the number of clusters, different sets of genes are selected. A similar procedure to the 
second run carries on until the final run, in which data is clustered into six partitions.  
The reason for merging the outputs of a clustering algorithm when the number of clustered 
varied from 1-6 was to assure reinforcement for the selected genes by the clustering 
algorithm. To shed light on this lets assume we choose 20 genes when K-mean clustering is 
used and the number of clustered is equal to two. If we run the K-mean again while the 
number of clusters are three, a slightly different set of 20 genes will be selected which is due 
to the nature of selection criteria across different clusters that depends both on the number 
of genes in the cluster and the ranking of genes in that cluster (see Equation 4.13).  If run 
the algorithm for four clusters, again a different set of 20 genes will be selected. It should be 
noted that although a different set of genes are selected each time, some genes could be 
repeatedly selected while changing the number of clusters. Since in the proposed shuffle 
technique the gene selection is done six times when changing the number of clusters from 1-
6, and each time 20 genes are selected, a total 120 genes are acquired. However, some of 
the 120 genes are similar and repeatedly selected while varying the number of clusters by the 
same clustering algorithm. These 120 genes are then ranked based on their repetitions of 
being selected by the clustering algorithm. Therefore, when choosing the 25 most repeated 
genes we reinforce the selected genes that are chosen by the algorithm and do not rely solely 
on one outcome of the algorithm. In another word, this introduces a more robust gene 
selection. The number of final selected genes were chosen 25 to correlate with the number 
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of selected genes in Section 4.5.1. Furthermore, as it was discussed in Section 4.4.1 the MLP 
classifier contains 25 input neurons and the 25 selected genes also correlate to this. This was 
done to ensure the same setup for classifiers in Sections 4.5 and this section (4.6). After 
selecting 25 most repeated genes, these genes were fed into the MLP and SVM classifiers. 
Finally, sensitivity, accuracy, and specificity for both SVM and MLP are calculated. 
The proposed methodology that incorporates the shuffle technique and the new 
optimisation algorithm, COA-GA, that was explained in Section 4.2.5, is illustrated in Figure 
4.5. 
 
Figure 4.5: Proposed shuffle method. 
4.6.2: Results 
Basic information relating to the datasets used in this study is listed in Table 4.7, including 
the number of genes, number of samples, and the two classes for each dataset. 
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Table 4.7: Basic information of the microarray data used in this study. 
Cancer  Genes Samples Class1 Class2 







24(germinal centre B-DLCL) 
50 (Normal) 
23 (active B-DLCL) 
52 (Cancerous) 
 
 In order to investigate the effects of clustering on the classifier performance, different 
clustering methods have been used with the shuffle method. These were compared to 
classification accuracy when no clustering was used, in order to determine the factor providing 
the greatest increases in classification. In that case, the data was scored based on Equation 
4.9, and the 25 genes with the highest scores were extracted for the purpose of classification. 
Table 4.8, Table 4.9, and Table 4.10 compare how different clustering algorithms with the 
shuffle method affect the classification accuracy, sensitivity, and specificity of SVM and MLP 
classifiers for leukaemia, lymphoma, and prostate cancers respectively. 
 
Table 4.8: The mean sensitivity (SE), specificity (SP), accuracy (AC), and standard deviation (SD) 
of classification results for MLP and SVM classifiers when integrating different clustering algorithms in 
the shuffle technique for the leukaemia dataset.  
 MLP SVM 
Method SE/SD SP/SD AC/SD SE/SD SP/SD AC/SD 
K-means 80.1/16.3 81.0/14.9 86.2/10.8 97.2/3.6 99.8/1.9 98.7/3.2 
C-means 82.6/13.6 83.2/13.2 86.7/10.4 96.8/4.3 99.6/2.1 98.8/2.3 
Hierarchical 82.8/13.1 82.0/14.2 90.0/7.6 94.6/5.3 96.8/3.8 96.0/4.1 
GA 98.2/3.7 87.4/9.1 91.0/6.3 99.0/2.1 99.6/1.9 99.5/2.0 
PSO 91.0/7.1 84.2/10.9 90.5/7.8 99.6/1.9 99.4/2.1 99.3/2.2 
COA 95.2/5.7 85.8/10.1 93.9/6.2 99.5/1.9 99.5/1.9 99.5/1.9 
COA-GA 95.6/5.3 84.9/10.6 93.9/6.6 99.6/2.1 99.9/0.8 99.7/1.1 
No cluster 82.0/13.1 83.4/12.9 90.0/7.8 96.0/3.9 98.0/2.5 98.9/2.1 
 
 
It is noted that in all datasets, the SVM classifier has a higher accuracy, specificity, and 
sensitivity compared to the MPL classifier. In the case of leukaemia when using the SVM 
classifier when no clustering was used, sensitivity, specificity, and accuracy were 96%, 98%, 
and 98.9% respectively, which is comparable to the results when K-means, C-means and 
hierarchical clustering were used. However, K-means clustering slightly outperforms the C-
means and hierarchical clustering by reaching a sensitivity of 97.2% and specificity of 99.8%.  
Interestingly, in all cases in which optimisation algorithms were used, a higher classification 
accuracy, sensitivity, and specificity were reached. For both classifiers, COA-GA shows a better 
performance compared to other optimisation methods. For instance, in the case of SVM, by 





Table 4.9: The mean sensitivity (SE), specificity (SP), accuracy (AC), and standard deviation (SD) 
of classification results for MLP and SVM classifiers when integrating different clustering algorithms in 
the shuffle technique for the lymphoma dataset cancer. 
 MLP SVM 
Method SE/SD SP/SD AC/SD SE/SD SP/SD AC/SD 
K-means 86.3/10.2 96.2/4.4 86.4/10.0 90.3/7.5 100/0.0 88.3/8.9 
C-means 88.3/8.8 96.7/4.2 87.5/9.1 89.3/7.8 100/0.0 88.5/8.8 
Hierarchical 85.9/10.9 97.1/3.9 87.8/8.8 89.6/7.6 100/0.0 88.8/8.7 
GA 89.4/7.6 98.7/2.5 90.9/7.3 91.2/6.8 100/0.0 92.4/5.2 
PSO 89.1/7.9 98.5/2.8 90.3/7.2 91.8/6.2 100/0.0 92.9/4.9 
COA 91.2/6.9 98.9/2.2 91.6/6.8 92.3/5.3 100/0.0 93.1/4.2 
COA-GA 92.1/6.1 99.5/1.8 92/5.9 93.2/4.9 100/0.0 93.9/3.8 
No cluster 87.4/9.2 96.6/3.9 87.7/9.1 90.1/7.9 100/0.0 88.9/8.6 
 
 
Similar trends appear across all three data sets, whereby optimisation based clustering 
yields a better classification accuracy, sensitivity, and specificity. For instance, in the case of 
lymphoma when SVM is used and COA-GA is applied for clustering data, an accuracy of 93.9% 
is achieved, compared to 88.9% when no clustering is used (see Table 4.9). For the same 
dataset, it can be seen that a specificity of 100% is achieved with all algorithms for the SVM 
classifier. For prostate cancer, as presented in Table 4.10, the classification accuracy, 
sensitivity, and specificity when utilising traditional clustering methods are comparable to the 
case in which no clustering is used. In contrast, an improvement of 5.1% is seen for SVM 
accuracy, and 5% for MLP accuracy when COA-GA is used compared to when no clustering is 
applied. 
 
Table 4.10: The mean sensitivity (SE), specificity (SP), accuracy (AC), and standard deviation (SD) 
of classification results for MLP and SVM classifiers when integrating different clustering algorithms in 
the shuffle technique for the prostate dataset cancer. 
 MLP SVM 
Method SE/SD SP/SD AC/SD SE/SD SP/SD AC/SD 
K-means 86.1/10.3 90.7/7.1 89.9/7.9 90.1/7.6 94.3/4.5 91.4/6.4 
C-means 84.2/11.1 90.9/6.9 89.6/8.1 90.9/7.1 94.6/4.3 91.2/6.8 
Hierarchical 86.0/10.3 90.3/7.4 89.0/8.8 91.0/6.8 93.3/4.9 90.4/7.3 
GA 90.8/7.1 92.1/5.9 92.1/5.9 95.9/4.2 96.0/3.8 94.3/4.6 
PSO 90.5/7.3 92.9/5.3 92.8/5.4 94.6/4.4 96.8/3.7 94.4/4.5 
COA 91.5/6.5 93.1/4.9 93.4/4.7 96.1/3.9 98.6/2.8 95.9/4.1 
COA-GA 92.4/5.9 94.6/4.1 94.2/4.3 96.9/3.6 99.5/2.1 96.6/3.8 




Figure 4.6 and Figure 4.7 illustrate the differences in classification accuracy, sensitivity, and 
specificity when no clustering is used compared to COA-GA clustering for the MLP and SVM 
classifiers respectively. It can be seen that SVM outperforms the MLP classifier in all cases. 
Furthermore, the performance is enhanced for both classifiers when the shuffle method 
integrated with COA-GA is used, compared to that when no clustering is applied prior to gene 
selection. These results suggest that the shuffle technique with the proposed algorithm (COA-
GA) can improve cancer classification performance, and better results could be achieved if 




Figure 4.6: Accuracy and sensitivity of MLP classifier results for three cancer datasets when no 












































Figure 4.7: Accuracy and sensitivity of SVM classifier results for three cancer datasets when no 
clustering is used, compared to using the shuffle technique with COA-GA for clustering. 
Figure 4.8, Figure 4.9, and Figure 4.10 show the cost function minimisation for COA-GA, 
COA, GA, and PSO over 100 iterations for leukaemia, lymphoma, and prostate cancer 
respectively. 
For the leukaemia dataset, GA has reached its minimum by the 91st iteration, and the best-
cost value reached is 1.500 ×106. By contrast, PSO has reached its minimum by the 85th 
iteration, and the best-cost value reached is 1.943×106, indicating that GA has outperformed 
PSO as it further minimises the cost function. However, the COA algorithm reaches its 
minimum 2.429×105 at 13 iterations, whilst COA-GA could minimise the cost value to 
2.400×105 at 13 iterations. It can be seen that all four methods reached their minimum after 
some itterations.  However, COA and COA-GA notably outperform GA and PSO, finding a 
better minimum for the cost function, as well as having faster convergence, whilst COA-GA 
performed the best among the four algorithms. 
A very similar trend in cost minimisation capabilities for all algorithms is observed for the 
cases of and lymphoma (Figure 4.9). It is notable that in the lymphoma dataset, the COA-GA 
algorithm significantly outperforms other algorithms, and when compared to COA 
performance, COA-GA continues to minimise the cost function after the 11th iteration, while 
COA reached its minimum at this iteration. In the case of prostate cancer (Figure 4.10), it can 
be seen that COA-GA and COA show the best performance, where COA-GA outperforms COA. 




































However, it is clear that in this case, PSO significantly outperforms GA opposite to the case of 
leukaemia and lymphoma where GA outperformed PSO. 
 
Figure 4.8: Cost minimisation for four algorithms over 100 iterations for leukaemia. 
 






Figure 4.10: Cost minimisation for four algorithms over 100 iterations for prostate cancer. 
4.7: Summary 
In this chapter, the effects of data clustering prior to gene selection on classification 
performance was investigated. To this end, first the effects of conventional data clustering 
methods on classification performance for cancer datasets were investigated. This approach 
included three steps (i) clustering, (ii) gene selection, and (iii) classification. Three different 
methods, K-means, fuzzy C-means, and hierarchical clustering; and two classification 
methods, support vector machine (SVM) and multi-layered perceptron (MLP) neural networks 
were studied. The results obtained suggest that conventional clustering methods may not 
impact the classifier performance. This has been observed in the case of both classifiers. The 
results also suggest that the performance of the SVM classifier is better than that of the MLP 
artificial neural networks.  
In the next step, in order to fully examine the effect of data clustering on classification 
performance, the effect of optimisation based clustering algorithms on the performance of the 
SVM and MLP classifiers were investigated and compared to conventional methods. A novel 
approach to enhance gene selection called the shuffle technique was proposed, in which a 
new hybrid algorithm, COA-GA, was implemented for clustering microarray data. The 
performance of the proposed algorithm was tested against other well-known optimisation 
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algorithms including PSO, GA, and COA. The results suggested that data clustering with 
optimisation based clustering methods prior to gene selection via the proposed method 
significantly enhance the performance of both classifiers.  However, clustering data via 
conventional clustering methods did not have any impact on any of the classifiers’ 
performances that were used in this investigation. It was also explained that when no 
clustering was used, the results were comparable with the cases where conventional clustering 
methods were used. Comparative analysis between the proposed hybrid algorithm, COA-GA, 
with other optimisation algorithms like PSO, GA, and COA, suggested that COA-GA significantly 
outperforms other algorithms at reaching a better minimum in fewer iterations. In the final 
part of this chapter, better classification performance was achieved when SVM was used 

































Chapter 5: Two Stage Gene Selection for Cancer 






It is now well established that early diagnosis of tumours can greatly increase the rate of 
cancer survival by providing the right treatment at early stages. However, methods such as 
X-ray imaging and computed tomography (CT) usually detect such tumours in later stages of 
cancer formation. Nevertheless, invasive methods such as surgery could detect malignancies, 
with the downside of potential severe side effects, and therefore such methods are not 
recommended for benign cases [183]. In this respect, over the last few decades gene 
expression profiling using microarray technology has attracted many scientists towards the 
early detection and classification of cancer [184,185]. 
However, as discussed in Chapters 1 and 2, due to the so-called ‘curse of dimensionality’ 
problem, the prognosis and classification tasks remain challenging to date. High classification 
accuracy is of the utmost importance for personalised medicine. Since there are two important 
factors that can enhance the classification performance, gene selection and classifier method, 
computer scientists have proposed different methods to increase the efficiency of each factor.  
With regards to the gene selection factor, numerous studies have been carried out with 
the objective of increasing the classification accuracy [146,186]. For example, Golub et al., 
[26] proposed a signal-to-noise ratio method, which was also used later in different studies 
[187]. Cho et al. [188] investigated several methods such as Pearson’s correlation, Euclidean 
distance, information gain, and mutual information to select the most informative genes 
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among different cancer types including colon, lymphoma, and leukaemia. In the above 
methods, genes are first ranked based on the relevant criterion, and then the top 𝑛 genes are 
selected for classification purpose. Several classification methods have been proposed for such 
analysis, and LDA, k-NN, SVM, and MLP artificial neural networks were discussed in Section 
3.6. Most of these gene selection approaches, known as filter methods, have greatly 
contributed to early detection and classification of cancer by providing useful information for 
medical experts. Nevertheless, the downside of the filter methods, which is ignoring feature 
dependencies and interaction with classifiers, can lead to poor classification accuracy.  
To address this problem, evolutionary algorithms such as GA and PSO have been applied 
for the purpose of gene selection. These methods essentially are heuristic optimisation 
algorithms that find the optimum subset of features to achieve the best classification accuracy, 
which is feasible as these methods are combined with the classification step in the form of a 
hybrid setup. For instance, Lee et al. proposed a gene selection method using an adaptive 
genetic algorithm combined with a KNN classifier to achieve a good classification accuracy for 
colon cancer datasets [189]. Shen et al. proposed a method combining discrete PSO and SVM 
for the selection of the most informative genes. The result of this study suggested that the 
SVM performance was significantly enhanced when PSO is used (91.7%) compared to the 
case when no gene selection was applied (83%) for a colon cancer dataset[179]. Since finding 
the local optimum is challenging for most optimisation algorithms, some studies proposed 
hybrid optimisation methods to overcome this problem. For example, Li et al. proposed a 
hybrid method combining PSO and GA that used SVM as the classifier [154]. This method was 
applied to different cancer datasets, and the result suggested that their proposed method can 
select the most informative genes that enhance classification accuracy.   
The vast majority of these studies focus on increasing the classification accuracy rather 
than the number of selected genes. Biomarker identification is another area of ongoing 
research, where it is important to identify a small number of genes in order to spot patterns. 
For instance, choosing a few genes that are all differentially expressed across different 
samples [190,191]. Works of research argue that the ideal classification task should result in 
the highest classification accuracy with less genes [192]. Therefore, it is essential to create a 
model for cancer classification that meets both objectives for tumour classification. To date, 
it has been possible to achieve the highest classification for some cancer datasets. However, 
even in these cases, several genes are needed to be used to achieve the highest classification. 
Therefore, in this chapter, the main objectives are to select the optimum number of most 
informative genes that can best distinguish between two cancer types to achieve the highest 
classification accuracy. To accomplish these objectives, a new optimisation algorithm which 
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combines the cuckoo optimisation algorithm (COA) and harmony search (HS), is proposed 
(COA-HS), which will be used in a two-stage gene selection method. 
5.2: Proposed Method 
The general methodology used in this study is illustrated in Figure 5.1. First, the data was 
discretised into nine states. After this pre-processing stage, the top 100 genes which are the 
most relevant and least redundant were selected using the minimum redundancy and 
maximum relevance (MRMR) feature selection (a filter method [193]). The selected genes 
were fed to a wrapper setup that consisted of the COA-HS algorithm and SVM classifier, to 
choose the minimum number of genes that provide 100% accuracy. Using two-stage gene 
selection combines the advantages of both filter and wrapper methods of gene selection. 
Finally, the classification performance for the selected genes was measured in terms of 
accuracy via the leave-one-out cross validation method (LOOCV). In order to validate the 
performance of COA-HS, the results were compared to those established with other 
evolutionary algorithms, such as the genetic algorithm (GA), particle swarm optimisation 
algorithm (PSO), harmony search algorithm (HS), and cuckoo optimisation algorithm (COA).  
Microarray data for three cancer types (leukaemia, prostate, and lymphoma) was used in 
this study. Gene expression data for leukaemia [26] and prostate cancer [30] was obtained 
from the Broad Institute (www.broadinstitute.org); Gene expression data for lymphoma [28] 
was obtained from the Lymphoma/Leukaemia Molecular Profiling Project (llmpp.nih.gov). 
Basic information relating to the datasets used in this study is provided in Table 5.1, including 
the number of genes, the number of samples and the two classes for each dataset. 
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Figure 5.1: Schematic of the general methodology for gene selection. 
 
5.3: Discretisation of Data 
Discretisation is the process of converting continuous values into discrete counterparts, and 
this technique is frequently used as a pre-processing step in the analysis of biological data for 
several reasons. For instance, some gene selection and classification methods only accept 
discrete values as their input. Although the representation of data is changed through this 
process, it is assumed that the biological information within the data is preserved. In fact, 
several studies suggest that using discrete values can lead to more efficient learning processes 
[194–196]. Furthermore, Peng et al. investigated the performance of continuous and discrete 
values of microarray data in classification performance, and suggested that discrete values 
lead to a better classification performance [193].  
In the context of microarray gene expression data, there are several discretisation methods 
that can be applied, which can be categorised into supervised and unsupervised methods. In 
the supervised method, gene expression data is discretised while taking into consideration the 
class information of each gene (healthy vs cancerous). In contrast, in unsupervised methods, 
gene expression values are discretised without any impact from their class label. In this 
chapter, the unsupervised approach is the focus. In unsupervised cases, there exists two 
100 
 
pathways. One method is discretising data based on absolute values of gene expression, and 
another is discretising based on variation between time points [197,198].   
In this chapter, data is discretised  using absolute values of gene expression in order to 
reduce the noise in the gene expression data, and to enhance the accuracy of classification 
results [199]. Gene expression values for each gene were categorised into a nine-state 
variable based on the mean value (μ) and standard deviation (σ) for that gene. For each gene, 
the nine states showed whether the gene was not expressed (state zero) or if expressed, how 
much it was over-expressed (states +1 to +4) or under-expressed (states -1 to -4). Table 5.2 
details the different states utilised in the discretisation of data.  
 
Table 5.2: Discretisation of gene expression data. 
Data States Data States 
μ <d< μ-1/2 σ 0 μ <d< μ+1/2 σ 0 
μ-1/2 σ <d< μ-σ -1 μ+1/2 σ <d< μ+σ 1 
μ-σ <d< μ-3/2 σ -2 μ+σ <d< μ+3/2 σ 2 
μ-3/2 σ<d< μ-2σ -3 μ+3/2 σ<d< μ+2σ 3 
d < μ-2σ -4 d > μ+2σ 4 
 
As mentioned earlier, Peng et al. (2005) concluded that discrete values lead to a better 
classification performance for microarray data. A study by Gallo et al., (2015) suggests that 
although the number of states in a discretisation task depends on the inference of the 
algorithm that the data is prepared for, there is a trade-off between computational complexity 
and the loss of information when choosing the number of states. On the one hand, by 
increasing the number of states one can better preserve the information. On the other hand, 
by increasing the number of states the computational complexity also significantly increases 
[198]. In this study data was discretised into nine states. To visualise the effects of 
discretisation, the frequency plots before and after discretisation for lymphoma (see Figure 











Figure 5.2: Frequency plots before (a) and after (b) discretisation for lymphoma dataset. 
 
Figure 5.3: Frequency plots before (a) and after (b) discretisation for prostate dataset. 
 







5.4: First Stage Gene Selection Using Minimum Redundancy 
Maximum Relevance (MRMR) 
The goal of feature selection in a classification task is to identify a subset of features that 
best characterise the statistical significance of the classification task [46]. Since utilising 
wrapper methods for gene selections are computationally expensive when dealing with gene 
expression data due to existence of thousands of genes, filter methods are usually used for 
gene selection or applied to reduce the dimension of the data before applying a wrapper 
technique. Feature entropy is an appropriate metric to identify such informative genes.  
Entropy refers to the initial uncertainty of the output class [200], and can be calculated using 
Equation 4.1.  
 





where {𝑃; 𝑎 	|	𝑎 = 1, 2, … , 𝑁;}	  is the probability density for different classes. A conditional 
entropy is used to define the mean uncertainty with respect to the feature vector, which can 
be calculated via following expression: 
 








where 𝑏 is the input feature vector with 𝑁S samples and 𝑃; 𝑎|𝑏  is the conditional probability 
of class 𝑎 from feature vector 𝑏. Initial entropy is usually larger than conditional entropy; 
however, in the case of total independence between the output class and feature, both 
entropies have equal values. Mutual information that quantifies the mutual dependencies of 
two variables 𝐴 and 𝐵 can be defined based on Equation 4.3. 
 
 I	 A; B = 	H A − H A|B  (4.3) 
 
This equation can be rewritten as: 
 








where 𝑝(𝑎)	and 𝑝(𝑏) are the probability density functions of variables 𝐴 and 𝐵 respectively, 
and 𝑝	(𝑎; 	𝑏)	is the combined probability density function of both variables. Mutual information 
between two variables 𝐴 and 𝐵 defines how much information about variable 𝐵 one can gain 
by only looking at variable 𝐴. 
Minimum redundancy maximum relevance feature selection (MRMR), which is a filter 
method, uses mutual information to select those genes that were mutually maximally 
dissimilar, but with the highest relevance to the target class [193]. First, in order to choose a 
subset of genes that best represents the entire dataset, the minimum redundancy was 
calculated using the following equation.  
 







where 𝑇 denotes the total number of important genes that were required to be extracted, and 
𝐼(𝑔a; 𝑔b) represents the mutual information of gene 𝑖 and gene 𝑗. Next, the mutual information 
between genes (𝑔a) and the corresponding classes (𝐶), 𝐼 𝑔a; 𝐶  were calculated to quantify 
the relevancy of each gene with regards to its class. Subsequently the maximum relevancy 
was acquired using Equation 4.6. Maximum relevancy selected the top 𝑇 genes in the 
descending order of 𝐼 𝑔a; 𝐶  [193]. 






Since both conditions 𝑊 and 𝑉 were equally important, MRMR combines both. This 
combination could be carried out by two methods, namely MRMRMIQ and MRMRMID, which 
combine both conditions as Equation 4.7 and Equation 4.8 respectively. In this study, MRMRMIQ 
was used, which is formulated as Equation 4.9. 
 
 












In the proposed method for the first stage selection, by using Equation 4.9, the top 100 
genes which were mutually maximally dissimilar were extracted and fed to the second stage 
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of selection, which used an evolutionary algorithm to select the minimum number of genes 
that gives the maximum accuracy for the SVM classifier.  
5.5: Second Stage Selection Using Evolutionary Algorithms  
Fundamentally, optimisation is the process of finding the best solution among all possible 
solutions. Population based optimisation algorithms initially choose a random set of solutions 
(initial population), and this population is enhanced via an iterative process. For each iteration, 
a cost function is established to quantify the outcome of the optimisation task. Since the 
problem in this study is defined as classification of microarray data while achieving higher 






+ NOG (4.10) 
 
where 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 is the accuracy of SVM classifier measured by the LOOCV method and ranges 
from 0 to 1, 𝑁𝑂𝐺 is the number of selected genes which ranges from 1 to 100, and 𝑎 is a 
coefficient. Since the accuracy was more important than the number of selected genes, 𝑎 was 
set to 1000 in order to give the accuracy more weight in the cost function. Therefore, by 
minimising the cost function, the number of selected genes is minimised while the accuracy 
is maximised.  
It should be noted that both terms in Equation 5.10 are important for the cost function. 
For instance, if an algorithm selects 20 genes and gives 0.98 for accuracy, this would result 
in a cost value of 1040.4. If in another case this algorithm chooses 8 genes and give 0.97 for 
accuracy, this would result in a cost value of 1038.99. In this scenario, the latter would be 
more preferable for the algorithm although the accuracy of the preferred case is less. 
However, if scenario changes such that 0.98 accuracy is acquired by 17 genes, which leads 
to a cost value of 1037.4, then the algorithm prefers this option than the case of 0.97 with 8 
genes. The value for 𝑎 was chosen 1000 as it was observed that this will result in better 
outcomes. For instance, if 𝑎 was chosen 100 and 35 genes were selected by an algorithm that 
resulted in 0.9 accuracy this would give a cost value of 146.1. If 3 genes were selected and 
the accuracy for the 3 genes was 0.7, this results in a cost value of 145. In this scenario, the 
algorithm would prefer the latter case although in the latter case the accuracy is only 0.7. as 




In respect to LOOCV method, one sample is treated as a test sample, whilst the remaining 
samples are used for training the SVM, and the accuracy is calculated. If there are 𝑁 samples, 
this procedure is repeated 𝑁 times, each time with a different sample, and the average 
accuracy is calculated for the selected genes. SVM was used for the classification of selected 
genes, as the SVM classifier is a powerful classification algorithm and has been demonstrated 
to exhibit excellent performance in a variety of biological classification tasks [201]. The LOOCV 
method was chosen as it can overcome data overfitting [202].  
A new hybrid optimisation algorithm, COA-HS, was developed by combining the recently 
invented COA [24] and HS algorithms. The results were compared with the GA, PSO, COA, 
and HS algorithms. Details of GA, PSO, and COA algorithm can be seen in Section 4.2.2, 
Section 4.2.3, and Section 4.2.4 respectively. Details of HS and the proposed COA-HS will be 
described in the following subsections.  
5.5.1: Harmony Search Algorithm (HS) 
The harmony search (HS) is a musically-inspired optimisation algorithm [203].  In jazz, 
musicians improvise their instruments’ pitch in order to find a perfect harmony, which can be 
achieved through three options. The first option is to play a pitch from memory. The second 
option is to play a random pitch within the acceptable range of available pitches. Finally, they 
can play a pitch adjacent to a pitch in their memory. In the HS algorithm, these options are 
respectively referred to as harmony memory (HM), pitch adjustment rate (PAR) and harmony 
memory consideration rate (HMCR). Figure 5.5 illustrates the analogy of the musical 
improvisation process and optimisation process. 
 
Figure 5.5: Analogy between musical improvisation process and optimisation process. 
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The HS algorithm has been successfully applied to various optimisation problems, such as 
feature selection [204], discrete design variables [205], and continuous optimisation problems 
[206]. 
The harmony search algorithm follows a number of steps as demonstrated below. The cost 
minimisation plot is acquired to visualise how HS minimises the cost function over 100 
iterations. 
 
1. Initialise HMCR and PAR. 
2. Initialise harmony memory (HM).  
3. Improvise a new harmony memory.  
4. Update harmony memory (HM). 
5. If the number of iterations is less than 100, go to step 3. 
6. Save the best harmony memory as the ‘best answer’. 
 
It is noted that HMCR and PAR values affect the performance of the HS algorithm. For 
instance, HMCR is important in the convergence of the algorithm as this parameter is used to 
warrant the best fitted solutions are considered as the features of new solutions. The value 
for this parameter ranges between 0 to 1. It is recommended to choose a value in a range of 
[0.70 - 0.9] to make ensure enough exploitation [207,208]. This parameter act as crossover 
rate in genetic algorithm. For instance, if its value is 0.8 this means there is 80 % probability 
that the value of variables in HM will be chosen for new solutions. PAR is also very important 
parameter in improvisation process and act like the mutation parameter in the genetic 
algorithm. This parameter defines whether the variables of the new solutions should be altered 
to the value of its neighbour variable. PAR value also ranges from 0 to 1, and determines the 
probability of changing the variable values. The recommended range of values for PAR is [0.1 
- 0.3] [208,209]. In order to ensure the optimum values for HMCR and PAR are selected for 
the cost function and related datasets, the recommended ranges for HMCR and PAR were 
investigated. To this end the HS algorithm was ran 100 iterations and the final cost value was 
obtained for leukaemia, prostate, and lymphoma datasets (See Table 5.3). It was observed 
that the optimum values for HMCR and PAR across all datasets were 0.9 and 0.3 respectively 







Table 5.3: Results of using HS with different PAR and HMCR values. 
HMCR PAR Leukaemia  Prostate Lymphoma 
0.7 0.1 1031 1054 1028 
 0.2 1028 1053 1027 
 0.3 1030 1052 1027 
0.8 0.1 1029 1055 1032 
 0.2 1031 1057 1030 
 0.3 1032 1052 1029 
0.9 0.1 1027 1056 1027 
 0.2 1022 1050 1027 
 0.3 1021 1045 1023 
 
5.5.2: Proposed Algorithm COA-HS 
For this study, a new algorithm was developed by combining the COA and HS algorithms 
(see Figure 5.6). As discussed, in the COA algorithm (Section 4.5.3), each egg in a nest 
represents a solution, and each cuckoo represents a new solution. Therefore, in the analysis 
of gene expression data, a solution refers to a gene. The COA-HS algorithm starts with the 
initialisation of the cuckoos. After the initial population lay eggs, the profit values of the eggs 
are calculated by evaluating the cost function. These solutions (eggs) are then fed to the HS 
algorithm in order to explore more solutions. These can be provided by the improvisation 
process through HMCR and PAR, which were set to 0.9 and 0.3 respectively.  As a result, a 
better solution can be achieved by preventing premature convergence of the COA.  
After the HS algorithm stops, the profit value for the solutions suggested by the HR are 
calculated through the cost function. Then the profit values of the solutions suggested by the 
COA and HS are compared, and the solution (egg) with the higher profit value is chosen to 
survive. Afterwards, these eggs grow and become cuckoos and the survival rate of each 
cuckoo is calculated. Then all cuckoos move towards the nest with the highest survival rate 
and lay eggs within the ELR of the best nest (best position). This means that the space of 
solutions is refined towards the best solution, concluding one iteration of the COA-HS 
algorithm. This process is repeated 100 times, and each time the cuckoos lay eggs in a further 












To select the minimum number of genes that can best distinguish between two classes of 
cancer, first the number of candidate genes was reduced to 100 using MRMR. These 100 
genes were then fed to our proposed algorithm COA-HS to select the best genes while 
maintaining the highest accuracy. The SVM classifier was used for classification where the 
Gaussian kernel was employed. The accuracy of the SVM classifier was measured after cross 
validating using the LOOCV method.  
In order to account for possible overfitting, the gene expression samples in each dataset 
were split into two sets of 25% and 75%. In the splitting task the ratio of class I and class II 
data (each dataset had two classes) was considered to ensure in each set both classes are 
presented. The set with 75 % of data was used for training and cross validating the classifier 
model. Once an optimisation algorithm select the best genes based on the cost function in the 
second stage of gene selection, the trained model that was used to select the final genes was 
then used to classify unseen data where the set of 25% of data was used. 
Figure 5.7 illustrates the accuracy of the SVM classifier for the top 100 genes selected via 
MRMR. Initially, as the number of genes increases up to 5-6 genes, the accuracy increases. 
After initial increase, in some instances the classification accuracy was reduced as the number 
of genes increased. For example, in the case of the prostate cancer dataset, the classification 
accuracy for the first 8 genes is 97%, but the accuracy reduces as the number of genes 
increases, attaining values of 91-93% when 90-100 genes are used. 
 
Figure 5.7: Accuracy of SVM for selected genes by MRMR. 
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The selected 100 genes from MRMR were input to different optimisation algorithms which 
used the cost function defined in Section 5.5. Each optimisation algorithm was ran 20 times. 
In each run, the algorithm was iterated 100 times. So in each run after 100 iteration, the 
trained classifier’ model for the final selected genes was used to examine the performance of 
the SVM model on unseen data (on the set of 25%) and the performance was measured in 
terms of sensitivity, specificity, and accuracy. These values were recorded and after 20 run, 
the means and standard deviations for these values were computed. Tables 5.4, 5.5, and 5.6 
give information on the performance of each optimisation algorithms after 20 run (each run 
100 iteration) for prostate, leukaemia, and lymphoma cancer datasets respectively. 
Furthermore, in the following tables, the means and standard deviations of the selected genes 
by each algorithm are provided.  
 
Table 5.4: Means and standard deviations for the number of selected genes, sensitivity, 











Mean SD Mean SD Mean SD Mean SD 
GA 41.80 3.22 98.40 1.80 98.72 1.08 97.35 2.08 
PSO 35.90 5.03 97.57 2.43 98.96 1.45 97.40 2.61 
HS 28.20 4.53 98.73 1.99 98.72 1.36 98.09 2.63 
COA 16.70 4.83 98.85 1.79 99.06 1.29 98.70 2.68 
COA-HS 8.40 3.12 99.33 1.96 99.92 1.36 98.97 2.37 
 
Table 5.5: Means and standard deviations for the number of selected genes, sensitivity, 
specificity, and accuracy of SVM classifier for 20 runs of optimisation algorithms for 










Mean SD Mean SD Mean SD Mean SD 
GA 29.30 2.86 99.32 1.42 99.51 1.12 98.20 1.61 
PSO 14.50 3.40 99.17 1.87 99.33 1.24 98.85 1.92 
HS 31.10 3.73 99.64 1.57 99.54 1.19 98.41 1.67 
COA 8.00 2.93 99.31 1.34 99.87 1.04 99.29 1.54 
COA-HS 6.50 2.72 99.42 1.18 99.61 1.23 99.36 1.36 
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Table 5.6: Means and standard deviations for the number of selected genes, sensitivity, 
specificity, and accuracy of SVM classifier for 20 runs of optimisation algorithms for 










Mean SD Mean SD Mean SD Mean SD 
GA 28.80 2.81 99.40 0.87 99.51 0.78 98.70 1.12 
PSO 13.40 2.98 99.49 0.93 99.64 0.88 98.92 1.19 
HS 29.70 3.33 99.17 1.87 99.33 0.92 98.05 1.94 
COA 7.70 2.16 99.36 1.74 99.61 1.16 99.27 1.84 
COA-HS 5.10      1.99     99.91 0.90 99.87 0.71 99.45 1.04 
 
 
Overall, COA-HS and COA outperformed GA, PSO, and HS in that these two algorithm 
selected significantly less number of genes while achieving better means for accuracy, 
sensitivity and specificity. In respect to prostate cancer dataset, as can be seen if Table 5.4 
after 20 run of COA-HS a mean of 8.4 genes was selected to achieve a mean of 98.92 % for 
accuracy which is the highest accuracy acquired across different algorithms employed in this 
research. However, it is noted that in this dataset, GA had smaller standard deviations for 
accuracy and specificity when compared to other algorithms.  Regarding leukaemia dataset, 
COA-HS outperformed other algorithms in most cases apart from the mean specificity and its 
standard deviation, where COA had a better performance (See Table 5.5). Finally, in Table 
5.6 it can be seen that COA-HS achieved slightly better results when compared COA in all 
criteria and had significantly higher performance when compared to HS, GA, and PSO. It is 
noted that although GA had a mean of 28.8 for the selected genes, this algorithm had small 
standard deviations for all three classification performance measures when compared to PSO, 
GA and COA.  
It was observed that in each run of an optimisation algorithm different combination of 
genes were selected and each algorithm tend to select different number of genes. In respect 
to the proposed algorithm, COA-HS, the final selected genes after each run were recorded 
and after 20 run the genes were ranked based of how many times they were repeated for 
each dataset. In the following the genes which were selected at least 10 times after 20 run of 





In respect to prostate cancer, 37639_at and 38087_s_at were selected. 37639_at was a 
probe-set for Hepsin gene, also known as HPN, is a gene that encodes a type II 
transmembrane serine protease. Expression of the encoded protein is associated with the 
growth and progression of prostate cancer [210]. Klezovitch et al., [211] demonstrated that 
hepsin was highly expressed by 10 fold in prostate cancer. 38087_s_at is a probe-set for S100 
calcium binding protein A4 gene. This gene is a protein coding gene and its gene ontology 
annotation associated with poly (A) RNA binding and identical protein binding. This gene has 
been selected as a signature for prostate cancer classification in many studies [212–214]. 
Regarding leukaemia dataset, Zyxin gene was found to be selected at least 10 times out 
of 20 runs of COA-HS algorithm. This gene is a focal-adhesion-associated phosphoprotein that 
involves in the control of actin assembly. Literature suggests that in the signal transduction 
pathway this gene could act as a messenger that control the adhesion-stimulated changes in 
gene expression [215]. Several studies have identified this gene as prominent in leukaemia 
cancer classification [26,216–218].  
For lymphoma dataset one gene was found that at least was selected 10 times out of 20 
runs namely GENE1296X gene. This gene is known as MCL1 gene which is a protein coding 
gene that encodes an anti-apoptotic protein that is a member of the Bcl-2 family. It is known 
that Bcl-2 plays an important role in some cancers such as leukaemia and lymphoma [219]. 
This gene has previously been selected for its discriminatory power in lymphoma cancer 
classification [220].  
5.7: Summary 
In this chapter, a two-stage gene selection process using MRMR and the COA-HS 
algorithm was proposed in order to minimise the number of genes that could provide high 
accuracy in cancer classification. To this end, first MRMR was used to reduce the number of 
genes to 100, so that the computational time could be reduced for an optimisation algorithm. 
The 100 candidate genes were then used as an input for the second stage of gene selection, 
during which COA-HS was combined with the SVM classifier and acted as a wrapper gene 
selection method. The LOOCV method was used to evaluate the performance of our proposed 
method, and the results were compared to other optimisation algorithms such as PSO, GA, 
HS, and COA. To account for overfitting, 75 % of data was used for training and cross-





Each optimisation algorithm was ran 20 times and in each run the algorithm iterated 100 
times. The means and standard deviations fore sensitivity, specificity, and accuracy of SVM 
classifier for each algorithm were computed. The results suggested that the COA-HS 
outperforms other optimisation algorithms in reaching a higher classification performance 








































Chapter 6: Gene Expression Analysis using RNA-
Seq Data  
 
 
In this chapter, first an overview of RNA-Seq data analysis will be explored in Section 6.1. 
Then in Section 6.2 a state-of-the-art pipeline for RNA-Seq analysis will be investigated.  
6.1: Overview of RNA-Seq Data Analysis 
As it was discussed in Chapter 1, RNA-Seq overcomes several limitations of microarray 
technology when measuring gene expression and more recently, has therefore become a 
popular choice for measuring gene expression. There are several steps towards a successful 
RNA-Seq data analysis, including experimental considerations in design, pre-processing and 
quality assessment, alignment, building a count table, normalisation, and downstream 
analysis.  
6.1.1: RNA-Seq Experimental Considerations 
In order to accurately answer a biological question, adequate information should be 
provided within a RNA-Seq experiment. For this reason, several experimental considerations 
need to be addressed, such as sequencing depth and the number of replicates. Sequencing 
depth for a sample refers to the number of reads that have been sequenced for the sample. 
Research suggests that there is a direct relation between the number of transcripts that can 
be discovered, and the depth of sequencing [75]. However, the biological question is the main 
factor in defining the adequate number of reads for a valid analysis. For instance, around five 
million mapped reads would be sufficient to identify the highly expressed genes, compared 
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with a range of 100 million reads that might be adequate if low expressed genes needed to 
be quantified [239]. Furthermore, for some studies, a few thousand reads is adequate, such 
as the 20 thousand reads that were used for splenic tissue to successfully differentiate the 
cell types [240].  
There are two types of replicates in RNA-Seq, technical and biological replicates. In general, 
the number of replicates depends on both biological and technical variability. Although some 
studies show that increasing the depth of sequencing can improve transcription identification 
[241] and quantification of gene expression [242], others suggest that by sequencing less 
reads and increasing the number of replicates in an experiment, a greater statistical power 
can be achieved [243].  
In order to design RNA-Seq experiment, an optimum number of replicates and sequencing 
depth should be calculated, where tools like Scotty fulfil this objective [244]. Scotty calculates 
the variability between replicates and the frequency at which new RNAs are quantified by 
utilising prototype data. T-test is used to estimate the power and sample size. Furthermore, 
empirical distributions can also be taken from publicly available datasets that are pre-loaded 
in Scotty [244]. To model the power first empirical observations are used to select theoretical 
distributions. These distributions are then used to fit the observed data. The software 
estimates the variance between different replicates from same condition which essentially is 
the determinant factor on deciding the number of replicates required. Busby et al., [244] 
argue that although there exists a substantial heterogeneity among different experiments such 
that biological variation is less that technical variations, the estimate for sample size is more 
accurate if users supply Scotty with their own data. 
6.1.2: Pre-Processing of RNA-Seq Data 
As discussed in Sections 2.3.4 once the RNA-Seq short reads are sequenced by an NGS 
platform, the output of such platform is usually in a FASTQ format. The first step upon 
receiving FASTQ files is pre-processing, which is vital for removing technical and biological 
contaminations from the data, so that one can investigate more interesting variations from 
the datasets. Technical contaminations include low quality reads and technical sequences, 
such as adaptors. Concerning the read quality, the PHRED score is used as a standard 
measurement, and ranges between 0-40. In general, read quality increases towards the 5’ 
end of the reads, and bad quality reads are observed towards the 3’ ends. For a valid analysis, 
reads with a Phred score of less than 20 should be removed, as these reads introduce errors 
and lead to noise in read counts. Three popular tools to aid in the visualisation of read quality 
and other important metrics for NGS data are the FASTQC [245], NGSQC [73], and HTQC 
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[246] software. In order to remove bad quality reads, one can use software such as FASTX 
[247], Cutadapt [248], or Trimmomatics [249] to trim out the bad quality reads based on a 
given threshold. 
With regards to technical sequences like adaptors, it is also essential to remove these 
sequences before the mapping step, especially if the reads are mapped to a reference 
genome. This is due to the fact that adaptors contain sequences from similar nucleotides to 
that of the organism sequences that are introduced artificially, which therefore could hinder 
the ratio of mappability and consequently create artefacts in the downstream analysis. 
Mappability refers to the state of being mappable for the reads that can be mapped to a 
reference genome. It is important to note that in the case of RNA-Seq data, duplicate reads 
are often observed. This is normal, as they can be the results of highly expressed genes, and 
not due to a PCR amplification step. Therefore, it is safe to ignore the duplication level in the 
RNA-Seq quality control step. Biological contaminations include the presence of polyA tails, 
rRNA, and mtDNA. Since up to 95% of RNA is rRNA, it is essential to carefully remove rRNA 
and concentrate on the remaining 5% of mRNA, which can result in a meaningful downstream 
analysis.  A popular tool to remove rRNA content is the SortMeRNA toolkit [250]. 
6.1.3: RNA-Seq Alignment 
In RNA-Seq, in order to find the locations of short reads, the sequenced reads must be 
aligned to a reference genome or a transcriptome assembly [251]. Mapping RNA-Seq reads is 
particularly challenging, as in most cases the reads are formed from mRNA and not DNA, 
which means some reads might overlap an exon-exon junction, at which the location’s intron 
has been removed [89]. If RNA-Seq reads are aligned to a reference genome, it provides more 
information to discover novel transcripts and isoforms. However, in this method, reads should 
be able to be split, as some reads might be mapped to two exons (see Figure 6.1). This 
method is done by spliced-aware aligner software, either by using prior information of 
exon/intron boundary annotations, which are usually available to download in a GTF format 
from the Ensembl website, or without this information which is known as de novo spliced 





Figure 6.1: Junction reads [253].  
If transcription discovery is not the objective of RNA-Seq, the sequenced reads can be 
aligned to a reference transcriptome, which is fast and useful for transcript quantification and 
is limited to identifying known exons and junctions. This method is done by unspliced aligner 
software, which aligns the reads to a reference transcriptome without allowing any large gaps. 
Finally, if a reference genome or transcriptome are not available, the alignment can be done 
by de novo assembly of the transcript sequences using de Bruijn graphs [254].  Figure 6.2 
summarises different methods for RNA-Seq alignment.  
 
 
Figure 6.2: RNA-Seq alignment methods. 
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6.1.4: Creating a Count Table  
After reads are successfully mapped to a reference, the read alignment information is 
usually presented in a SAM format, which stands for sequence alignment/map. However, this 
information is then converted into BAM format, which is the binary version of the SAM format, 
in order to reduce the file size and index its content better. Since a BAM file only contains the 
genomic locations of the reads, in order to count how many reads are mapped to unique 
regions, a list of genomic features (e.g. genes or exons) containing the start and end positions 
of such regions are required. 
One simple method is to count the number of reads for every exon of each gene [21,75]. 
However, this method can ignore the reads that are mapped to other places than annotated 
exons [251]. Another method to quantify the reads is to count the reads along the total length 
of the gene, so that all reads from the coding sequences will be counted [255]. A number of 
R/Bioconductor packages, such as GenomicAlignments [256], Rsubread [257], and 
EasyRNASeq [258] can be utilised to obtain the count table. Furthermore, a popular python 
based software called HTSeq [259] can be used to achieve this objective. As a result, a matrix 
is formed in which each column corresponds to a sample, and each row corresponds to a 
genomic feature and its corresponding counts. The first column specifies a list of genomic 
features, and the rest of the columns specify the number of counts for genomic features (see 
Figure 6.3). 
 
Figure 6.3: Count table for RNA-Seq. 
As the number of reads that overlap a gene is directly related to the length of transcripts, 
all of these methods can encounter the same problem due to initial random RNA 
fragmentation. Therefore, a normalisation step based on transcript length and sequencing 
depth is essential, which will be discussed in the next section.  
6.1.5: Normalisation  
In order to remove biases and artefacts that can affect the downstream analysis the 
normalisation step is an essential task to be carried out on the RNA-Seq count table. Gene 
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length bias is the first issue that should be accounted for in the normalisation task. For 
example, if the number of counts for gene 𝑛 is 30 reads, and for gene 𝑚 is 60, at first it can 
be inferred that gene 𝑚 is expressed more than gene 𝑛. However, if genes 𝑛 and 𝑚 have 
lengths of 30 and 60 bp respectively, it should be noted that both genes actually have the 
same level of expression.  
The next bias is the library size, which corresponds to the total number of reads for each 
sample. As illustrated in Table 6.1, if the total number of reads for replicate two is double 
those of replicate one, although each gene in replicate 2 might appear to have an expression 
twice those of gene 1, in fact none of these genes are differentially expressed.  
 
Table 6.1: Library size affect. 
   Replicate 1 Replicate 2 
Gene 1 10 20 
Gene 2 20 40 
… … … 
Gene n 30 60 
Total Reads 1000 2000 
 
A simple method to correct such a bias is to plot both replicates against each other and 
calculate the slope. Ideally the slope of such a plot should be 1, however if it deviates from 
1, one can normalise such biases by using the obtained slope number. Other biases such as 
GC content and batch effect are also important to take into consideration. 
In order to overcome these biases, several normalisation methods have been proposed, 
including reads per kilobase per one million mapped reads (RPKM) [75], DESeq [260], quantile 
(Q) [261], total count (TC), upper quantile (UQ) [262], trimmed mean of M-value (TMM) 
[263], and median normalisation methods. The most commonly used method for single-end 
reads is RPKM. In the case of paired-end reads, a similar approach called FPKM (fragments 
per kilobase per one million mapped fragments) is used, so that the two reads that come from 
one fragment are counted as one [264].  RPKM simply normalises the reads for each gene 










Dillies et al., performed a comparative analysis between different normalisation methods 
[265] in terms of their power in intra-variance (group variance), count distribution, clustering, 
and false positive rate. In their study the performance of different methods was reported in 
terms of not satisfactory, satisfactory, and very satisfactory (see Table 6.2). The results 
suggest that the RPKM and TC methods are not very suitable if large differences exist in library 
size (count distribution). In contrast, DESeq and TMM methods provided very satisfactory 
results. These two methods are used in two popular R/Bioconductor packages called DESeq 
[260] and EdgeR [266] respectively.   
 
Table 6.2: Summary of results for seven normalisation methods; 0 indicates not satisfactory, 1 
indicates satisfactory, and 2 denotes very satisfactory (modified from [265]). 
Method Distribution Intra-
Variance 
Housekeeping Clustering False 
Positive Rate 
TC 0 1 1 0 0 
UQ 2 2 1 2 0 
MED 2 2 0 2 0 
DESeq 2 2 2 2 2 
TMM 2 2 2 2 2 
Q 2 0 1 2 0 
RPKM 0 1 1 0 0 
 
Overall, if one wishes to find differentially expressed genes within the same sample, RPKM 
can provide satisfactory results and is more simple. However, if the objective is to find 
differentially expressed genes across different samples, the DESeq and TMM methods can 
provide very satisfactory results.  
6.1.6: Modelling Raw Counts, Dispersion and Differential Gene Expression 
From a biological view point, a very interesting question is ‘which genes are differentially 
expressed across different conditions?’ One way to investigate this question is to look at the 
number of counts for each genomic location, for example genes, isoforms, or transcripts. 
Research suggests that the number of counts for a gene is a good indication of the abundance 
of that gene. However, when comparing this between different conditions (healthy vs 
cancerous), the observed counts are done separately. In this respect, statistical tests should 
be performed to see if the differences in read counts between two conditions are actually 
significant, or observed due to natural random variation. It is noted that if reads are sampled 
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independently, the number of observed reads would follow a multinomial distribution that is 
known to be well approximated by Poisson distribution. Several studies have used this model 
to identify differentially expressed genes [267,268] 
The Poisson model provides a useful tool for estimating the probability that a read from 
condition one could map to a given gene, as well as estimating the probability that a read in 
condition two could map to the same gene. Consequently, one can tell in which condition the 
probability of observing more reads for a given gene is higher, which leads to the concept of 
differential gene expression. In the Poisson distribution model, the variance is equal to the 
mean, and this makes this model very simple as there is no need to estimate the variance 
[267]. However, it is important to investigate whether this distribution is feasible for RNA-Seq 
datasets or not, due to the fact that several sources of noise exist in such datasets. One source 
of noise is referred to as shot noise, and denotes the existence of variance in counts [260]. It 
is known that this follows a Poisson distribution. Standard deviation (𝜎) of such noises is equal 
to the square root of the mean count (𝜇). Another source of noise is the sample noise that 
includes biological and technical noises. Research suggests that the Poisson model performs 
well for technical replicates, as the variance is equal to the mean [21]. However, this research 
suggests that in the case of biological replicates, actual variance could be predicted 
inaccurately by the Poisson distribution model, since genes with higher mean counts have a 
higher variance than the mean, which can lead to an increase in false discovery rates (type1 
errors). This phenomenon is referred to as an overdispersion problem in the literature 
[269,270].  
Negative binomial distribution has more recently been used in order to overcome the 
overdispersion problems that the previous model encountered [260,266]. This model includes 
an extra parameter that accounts for dispersion, and can be seen below. 
 
𝑦 = 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑎𝑏, 1/𝑎	)	 (6.2) 
 
where 𝑎𝑏 is the mean (𝜇), and (1/𝑎) is the dispersion parameter (∅). In this distribution, 
variance can be calculated by the following expression: 
 
𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑦 = 𝑣 + 𝑣V∅ (6.3) 
  
In the above expression, 𝑣 accounts for shot noise, which is related to Poisson sampling 
noise, and 𝑣V∅ accounts for technical and biological noise. Usually the first step towards 
differential expression analysis when dealing with biological replicates is to estimate these 
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parameters. In order to have a good estimation for these parameters, all methods that are 
proposed for identifying differentially expressed genes make some assumptions about the 
form of underlying distribution. This is due to the fact that the number of samples are small, 
and without assumptions, the correct estimation would be impossible [271].   
Two of the well-known R/Bioconductor packages that use the negative binomial approach 
are edgeR [266] and DESeq [260]. However, these methods differ by which the dispersion 
parameters are estimated, as well as using different hypothesis testing approaches to find 
differentially expressed genes.  
In DESeq, the number of reads for gene 𝑖 in sample 𝑗 (𝑅ab) is modelled via negative binomial 
distribution as shown by following expression:  
 
𝑅ab = 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝜇ab, 𝜎abV 	)	 (6.4) 
 
where 𝜇ab is the mean and 𝜎abV  is the variance. Initially, 𝜇ab is calculated, which is proportional 
to a size factor (𝑆b) that accounts for the sequencing depth, multiplied by a variable that 
accounts for the gene expression number for gene 𝑖 in sample 𝑗 (𝑄ab). Next, the variance is 
calculated by the following expression: 
 
𝜎abV = 𝜇ab + 𝑆bV𝑣a,(b) (6.5) 
  
where 𝑣a,(b) is the per gene raw variance and is the smooth function of 𝑄ab. As the general 
form of a negative binomial, the above expression also accounts for shot noise and biological 
variations.  
In the edgeR Bioconductor package [266], data is also modelled via negative binomial 
distribution, as shown by the following expression:  
 
 
𝑌a = 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑀a𝑃b,∅	)	 (6.6) 
 
 
where 𝑀a is the read counts, 𝑃b is the relative abundance of gene 𝑔 in condition 𝑗 to which 
sample 𝑖 belongs, and ∅ is the dispersion. 𝑀a𝑃b is equal to the mean (𝜇a), and the variance 
can be calculated as follows: 
 





Once the parameters of mean and variance are modelled, a generalised linear model (GLM) 
is fitted into the data to get the variance-mean dependence. Figure 6.4 illustrates the fitted 
line for mean and variance by the Poisson (purple line) model, DESeq (orange line), and edgeR 
(dashed orange). Generally, in all fitted lines in Figure 6.4 as the mean count increases, the 
variance also increases. However, the fitted line from Poisson model is linear which fits well 
only for the lower mean counts and poorly estimates mean and variance for the higher mean 
counts. In contrast, the fitted lines by edgeR and DESeq are nonlinear and fit well for all 
ranges of mean and variance [260]. 
 
Figure 6.4: Variance-mean dependence adapted from [260]. 
In order to identify differentially expressed genes, the null hypothesis of 𝜇3 = 𝜇V is 
investigated, where 𝜇3 and 𝜇V	are the mean expression values for conditions 1 and 2 
respectively. For both conditions 1 and 2, the summation of reads across all replicates (𝑘a3	and 
𝑘aV) for each gene is calculated. The overall sum is equal to 𝑘a3 + 𝑘aV. Finally, the probability 
of observing the actual sum is calculated using a Wald test. The Wald test provides p-values 
for each gene, and based on a threshold, one can determine differentially expressed genes. 
Most packages now implement the Benjamini-Hochberg procedure to control the FDR.  
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6.1.7: Alternative Splicing Analysis  
So far, the statistical methods for differential gene expression were investigated. However, 
RNA-Seq data provides information that sheds light on differential analysis at the transcript 
level and alternative splicing. Each gene contains several transcripts, and each transcript from 
a gene can differ from other transcripts from the same gene in its starting and ending sites, 
as well as differing from the inclusion of exons. The translation of different transcripts results 
in different protein structures and functions, which leads to the importance of the transcript’s 
expression for the phenotype of cells and investigating diseases. The advances in informatics 
approaches have paved the way to look into differential exon usage and differential isoform 
expression. 
A pioneering approach to identify differential exon usage is the DEXSeq [272] method, 
which is implemented in a R/Bioconductor package. Simply put, the differential exon usage 
approach identifies the exons that are expressed differently across different conditions within 
each gene. In this method, the relative usage of each exon is used in order to identify the 







DEXSeq has a similar approach to the DESeq package in finding differential exon usage, 
where the main steps are count normalisation, dispersion estimation, and differential testing 
that returns a p-value. However, one of the major differences is preparing annotations that 
can allow counting reads that overlap exons. For this reason, after the reads are mapped to 
a genome reference, an annotation file with exon coordinates is used to count the number of 
reads in each exonic location. Since some exons can be seen more than once in an annotation 
file due to their inclusion in multiple transcripts, they can overlap each other. In such cases, 
in order to make sure each exon is counted only once, DEXSeq uses a flattened form of 
annotation file in which exons from the same coordinates are flattened into counting bins 




Figure 6.5: Flattened exons’ locations. 
In contrast to differential exon usage, where the focus is at the exon level, in differential 
isoform expression, the unit of study is the isoform and the objective is to identify isoforms 
that are expressed differently across conditions for the same gene. Zheng and Chen [273] 
proposed a method based on the hierarchical Bayesian model called BASIS to provide a 
platform for differential expression at the isoform level across two conditions. A more popular 
tool that allows differential analysis at the transcript level for more than two samples is Cuffdiff 
[274].  Similar to DESeq and DEXSeq, Cuffdiff also hypothesises that the number of reads that 
are mapped to a transcript is propositional to its abundance, and uses a negative binomial 
model for read counts. Furthermore, in the Cuffdiff method, a scaling factor is used to correct 
the sequencing depths across different samples, and the Benjamini-Hochberg method is used 
to control for FDR. This method produces very accurate results, as both biological and 
technical variations are taken into consideration in its statistical model to look for differential 
isoform expression [274,275]. More recently, a new approach has been proposed that allows 
the identification of differential gene expression and differential isoform expression at the 




Figure 6.6: RNA-Seq data analysis.  
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6.2: Pipeline for Analysis of RNA-Seq: a Case Study 
In this Section, a state-of-the-art pipeline for RNA-Seq analysis will be investigated. Figure 
6.7 illustrates the steps in this pipeline. Whilst there have been numerous studies to improve 
RNA-Seq data manipulation, quality control, and downstream analysis, the analysis of RNA-
Seq when examining gene expression remains challenging compared to microarray data. Since 
the methods to analyse NGS data in general are essentially statistical approaches, 
R/Bioconductor, a free source software, has become a popular tool to implement such 
analysis. There are several reasons for the popularity of performing NGS analysis in 
R/Bioconductor. For example, this software is easily accessible due to its affordability. 
Furthermore, it is a platform assisting with the statistical challenges of NGS data, and can be 
used for annotation and handling large datasets.  
There are numerous Bioconductor packages to use for RNA-Seq analysis. This has led to 
the suggestion of several pipelines for this kind of analysis. However, due to the  rapidly 
developing nature of statistical approaches for RNA-Seq, the proposed pipelines have also 
undergone several changes to improve their results. In this chapter, we investigate a state-
of-the-art pipeline for pre-processing and analysis of RNA-Seq that can pave the way to extract 
biologically relevant results from large datasets. Figure 6.7 illustrates the steps required for 
this pipeline. Usually RNA-Seq data is in the format of FASTQ, and the first step towards a 
successful downstream analysis is the pre-processing step. The pre-processing step is divided 
into four processes that are shown in orange in Figure 6.7. Once the qualities of reads are 
satisfactory, the alignment step follows. Finally, different downstream analysis, such as 
differential gene expression, differential exon usage, GO and pathway analysis, and 




Figure 6.7: RNA-Seq analysis workflow.  
6.2.1: Utilised RNA-Seq Data 
It is observed that a mutation in the aryl hydrocarbon receptor interacting protein (AIP) 
gene occurs in familial isolated pituitary adenoma (FIPA). This leads to early onset acromegaly 
in patients, and in most cases, invasive pituitary adenoma forms as a result. It is established 
that patients with positive for AIP have bigger body sizes than normal. Ascertaining 
pathogenicity of missense mutations is an abstruse task and to date around 70 AIP variants 
have been identified. However, it is still unclear how pituitary tumorigenesis can be caused by 
AIP inactivation. In this study, we used RNA-Seq data produced by Aflorei [277] at the 
Genome Centre of Queen Mary University of London.  
Drosophila was investigated as a subject of interest by Aflorei [277]. The Drosophila AIP 
orthologue (CG1847) gene encodes a protein that resembles the human AIP. In brief, CG1847 
defective flies were generated through in vivo RNAi knockdown to get a putative null allele of 
CG1847. In order to investigate the differentially expressed genes and underlying molecular 
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mechanisms as a result of the loss of AIP, RNA-Seq data was produced from mutant (3 
samples) versus control (3 samples) male larvae.  
To produce this RNA-Seq data, Aflorei first isolated total RNA using Qiagen RNeasy 
MicroKits and the samples were purified by the DNase I. Nanodrop was used to measure the 
RNA samples and Agilent 2100 bioanalyzer was used to examine the quality of the extracted 
RNA. Then, the RNA samples were normalized to 500 ng/μl and the normalised samples from 
both mutant and control were used to produce the cDNA libraries for the Illumina HiSeq 1500 
platform. In this platform one lane was used to sequence all libraries and as a result around 
30 million reads for each sample was acquired [277]. Each sample contained two files which 
corresponded to forward and reverse strands of short RNA-Seq reads. 
6.2.2: Pre-processing 
All analyses shown below are performed in Mac OS X with 16 GB of ram and an 8 core 
processor. The first step after receiving the RNA-Seq data (usually in FASTQ format) is to 
perform quality control assessments like examining the overall sequence quality, 
overrepresented reads, and the GC content of the data. A popular software to illustrate this 
information is FASTQC. To run FASTQC, all FASTQ files should be saved in one folder, and 
then the directory of the terminal is changed to that folder. Afterwards, FASTQC can be run 
for FASTQ files by using terminal. For the purpose of demonstration, the pre-processing steps 
are only shown for one sample here, and the same procedure can be repeated for all samples. 
fastqc -t 8 ForwardRead.fastq ReverseRead.fastq 
-t 8 option takes advantage of multicore processor capability to speed up the time for analysis. 
Two files (a zip and an HTML file) are created for each FASTQ file as a result of this command. 
By opening the HTML files, different analysis metrics such as basic statistics, per base 
sequencing quality, per base sequence content, per base GC content, per sequence GC 
content, sequence duplication level, overrepresented sequences, and Kmer content can be 
observed. Details for each metric are well-explained on the developer’s website [245]. Four 





Figure 6.8: Initial FASTQC output.  
First, one should consider quality trimming and adaptor removal if required based on 
FASTQC results. From the per base sequencing quality graph (Figure 6.8 B), it can be 
discerned that all reads have a quality higher than 20 based on the Phred score, therefore 
there is no need for removing any reads. However, if bad quality reads are observed, one can 
use software such as FASTX [247], Cutadapt [248], or Trimmomatic [249] to trim out the bad 
quality reads based on a given threshold. Since in the data that we received, adaptors had 
already been removed by the Genome Centre, the FASTQC metric on adaptor contamination 
indicates no contamination. In the presence of adaptors, the graph related to the adaptor 
contamination would identify the sequence of adaptor. By using software like FASTX and 
supplying the relevant sequence of the adaptor, one could remove them.  
From Figure 6.8 C, it can be seen that there is a presence of noise in the first 10-12 
nucleotides, which is in fact a universal bias from the Illumina RNA-Seq data. Since we are 
interested in differential gene expression and these biases are universal, these biases would 
cancel each other, and therefore one can safely ignore them. However, if the objective was 
to quantify gene expression, it would be essential to trim these nucleotides.  
Figure 6.8 D shows the distribution of GC content per read. In this figure, the blue line 
presents the theoretical distribution of GC content by FASTQC, and the red line indicates the 
actual distribution of GC content. Ideally, the actual distribution should follow the theoretical 
distribution. However, as shown in this figure, the actual distribution presents a shoulder on 
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the left side of the graph. Practical observations suggest that if a shoulder is presented on the 
left side of the actual distribution, it is more likely to be due to the enrichment of A/T content. 
However, a shoulder on the right side is more likely caused by the presence of rRNA. 
Nevertheless, due to the nature of RNA-Seq data generation, rRNA will often be present. 
Therefore, in the next step, a software called SortMeRna [250] is used to account for rRNA 
molecules. SortMeRna performs the removal of rRNA in three steps. First, the forward and 
reverse reads of a given sample should be merged together as shown below: 
 
merge-paired-reads.sh ForwardRead.fastq ReverseRead.fastq MergedReads.fastq 
 
Then the resulting MergedReads.fastq can be used in the main command of SortMeRna as 
follows: 
sortmerna --ref $SORTMERNA_DB --reads MergedReads.fastq --aligned MergedReadsWithrRNA --
other MergedReadsWithoutrRNA --paired_in --fastx 
 
where SORTMERNA_DB is the environmental variable for the SortMeRna database, and should 
be saved prior to the command. Argument “--reads” indicates the merged reads, “--aligned” 
indicates the reads which contain rRNA, “--other” represents those reads which are rRNA free, 
the “--paired_in” argument makes both paired reads goes to a single file, and “--fastx” 
indicates that the output file should be in the FASTQ format. In the next step, the merged 
reads (MergedReadsWithoutrRNA) that are rRNA free should be unmerged using the following 
command.  
 
unmerge-paired-reads.sh MergedReadsWithoutrRNA.fastq ForwardRead.fastq ReverseRead.fastq 
 
After this step, another assessment on the read quality should be made by the FASTQC 
software, in order to make sure satisfactory results are acquired through the following 
command:  
 
fastqc -t 8 ForwardRead.fastq ReverseRead.fastq 
 
It is noted that by using SortMeRna, the shoulder on the left side of figure 7.2 D has been 
reduced to less than 400,000 from 460,000 before using SortMeRna (see Figure 6.9). 
However, other metrics remained the same as expected. In this step, the initial total reads 
before applying SortMeRna was 31,497,483; and after SortMeRna the total number of reads 




Figure 6.9: Per GC content for mutated sample after SortMeRna  
Although the rRNA content has been removed, there is still a shoulder on the left side of 
the GC for the distribution. In this situation, it is advisable to check the overrepresented 
sequences in “Blast”, which is an NCBI utility [278] in order to reveal the nature of these 
sequences. By blasting these sequences, it becomes clear that these overrepresented 
sequences are mostly related to mitochondrial sequences. Since we will be mapping the reads 
to the Drosophila genome, the reads originated from mitochondria will not be mapped. 
Therefore, this step should be satisfactory for the pre-processing step.  
6.2.3: Alignment of the Reads to a Reference Genome 
After the pre-processing step is completed, and the quality of reads has been assessed to 
be satisfactory, the reads can be aligned to either a reference genome or transcripts. In this 
demonstration, the goal is to map the reads to a reference genome. Although several aligner 
software have been developed so far, there are two approaches that can be used to do the 
alignment task, which are the Burrows-Wheeler transformation (BWT) [279] and maximum 
exact matches (MEM) [280]. Since the objective is to align RNA-Seq to a reference genome, 
it is essential to use a spliced-aware aligner like TopHat [255] or STAR [281].  
In this research, STAR, which is an ultrafast universal RNA-Seq aligner based on MEM 
protocol, is chosen to aid in the alignment process. First, a genome index should be generated 
so that the STAR software is aware of exon-exon junctions when doing the alignment. In 
order to generate the indexed genome, a reference genome in FASTA format, and a genome 
annotation file in a GTF format are required. The corresponding files for Drosophila are 
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downloaded from the Ensemble website [282]. The command to generate the indexed 
genome is shown below.  
 
STAR \ 
--runMode genomeGenerate \ 
--genomeDir StarGenome \ 
--genomeFastaFiles Drosophila_melanogaster.BDGP5.dna.toplevel.fa \ 
--sjdbGTFfile Drosophila_melanogaster.BDGP5.dna.toplevel.gtf \ 
--sjdbOverhang 100 
 
The first parameter (--runMode) specifies the mode in which STAR should be run. The 
second parameter (--genomeDir) defines the output directory. The third and fourth 
parameters point STAR to the FASTA file and GTF file respectively. The last parameter 
(sjdbOverhang) denotes the sequencing read length, and a default value of 100 is used. Once 
this step is done, the genome index is saved in the directory specified by the second parameter 
(--genomeDir). This folder is used in the next step to align the reads to it as shown below.  
 
STAR \ 
--runMode alignReads \ 
--genomeDir StarGenome \ 
--readFilesIn ForwardRead.fastq ReverseRead.fastq \ 
--sjdbGTFfile Drosophila_melanogaster.BDGP5.dna.toplevel.gtf \ 
--outSAMtype BAM  
 
where the third parameter (--readFilesIn) directs STAR to do forward and reverse reads of 
the sample, and the last parameter (--outSAMtype) specifies the output should be in the 
format of BAM. Once this command is successfully finished, several files will be created, 
including a file whose name ends with Aligned.out.bam that contains the alignment in BAM 
format. It is essential to sort this file by sequencing position and then index it for further 
analysis by using a tool called samtools [283] as shown below. 
samtools sort -n Aligned.out.bam 
samtools index Aligned.out.bam 
This step concludes the alignment phase. The steps required for differential analysis at the 
gene, exon, and isoform levels differ from the point of counting the number of reads for each 
genomic location. This is due to the fact that different models are required to count the reads 
for different downstream analysis. Therefore, the analysis of differential expressions is divided 
into the three separate sections described in the next section.   
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6.2.4: Differential Gene Expression  
Differential gene expression is divided into four subsections, which are counting reads over 
genes, normalisation, dispersion estimation, and testing for differential gene expression. The 
R/Bioconductor code written for this analysis can be found in appendix 1.  
 
6.2.4.1: Counting Reads Over Genes  
In order to count the number of reads over each gene, in addition to the aligned reads, a 
gene model is required and can be accessed in the GTF or GFF3 format on Ensembl website 
[282].  The latest release of the GTF file for Drosophila was acquired from the Ensembl website 
for this analysis (Drosophila_melanogaster.BDGP5.76.gtf). A transcript database (TxDb 
format) called TxDbFromGFF was then created from this GTF file using the GenomicFeatures 
package (makeTxDbFromGFF command). This database can be utilised to create a separate 
file for the genomic locations of interest that is ranged-based and includes genes, exons, and 
transcripts. Since we are dealing with exons in RNA-Seq, a list of exons for each gene 
(GRangesList format) is then created using exons with a command from the GenomicFeatures 
package, and saved as an ExonByGenes object. Each gene in the GRangesList is stored in the 
Granges format. The length of the observed GRangesList for Drosophila is 15682; and a 
snapshot of the list acquired via R/Bioconductor is shown below.  
 
 
Figure 6.10: Exons grouped by gene in GRangesList format. 
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Once the previous step is done, a count table was created by using the summarizeOverlaps 
function from the GenomicAlignments package and saved as a RangedSummarizedExperiment 
object. This function can count the reads for each gene for all samples simultaneously, as this 
function accepts a file path to all of the BAM files that need to be processed. As a result, this 
function creates a file (RangedSummarizedExperiment format) containing three main 
components (see Figure 6.11), including samples’ information, actual count matrix, and 
genomic ranges, which can be accessed using the colData, assay, and rowRanges commands 
respectively. The resulting count matrix has a dimension of 6 (samples) by 15682 (genes) for 
Drosophila datasets. Samples’ information is primarily an empty component, and can be 
supplied using samples’ information, such as samples’ names and corresponding conditions in 
a character vector format.  
 
Figure 6.11: RangedSummarizedExperiment format. 
Analysis of the literature suggests that the DESeq2 package is mostly used for differential 
gene analysis, and therefore this package is chosen as the preferred method for this analysis 
[284]. In order to use DESeq2, the RangedSummarizedExperiment format should be 
converted into a DESeqDataSet class object that provides extra manoeuvrability in datasets, 
as the DESeqDataSet class has an argument called design formula that accounts for the group 
condition of a sample for further analysis.  
6.2.4.2: Sample Normalisation and Visualisation  
In order to make a valid conclusion about data through visualisation methods like PCA 
plots, the variations due to gene length and sequencing depth should be taken into account, 
which is done during the normalisation step. Based on the comparative analysis from Section 
6.6, DESeq normalisation provides very satisfactory results, and therefore will be used for this 
purpose. As discussed in Section 6.1.5, a size factor that is directly related to the ratio of 
library sizes is utilised in the DESeq package to normalise the data. This means if all samples 
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are sequenced at the same level, a size factor equal to one will be allocated to all of the 
samples.  
In order to calculate the size factors for all samples, the estimateSizeFactors function from 
the DESeq2 package was used on the DESeqDataSet object. Table 6.3 shows the information 
on the estimated size factor for each sample.  
 
Table 6.3: Estimated size factor for each sample using DESeq. 
 Control5 Control7 Control8 Mutated5 Mutated6 Mutated7 
Size factor 1.09 1.06 0.97 1.00 0.87 1.03 
  
In order to check whether the normalisation method is satisfactory, the density of mean 
counts for each sample was plotted, and if it is observed that the densities from all samples 
almost overlap each other, that is a good indicator for a successful normalisation outcome 
(see Figure 6.12).  
 
Figure 6.12: Density of mean counts for each sample. 



























Another way to validate a proper normalisation is to investigate the probability of observing 
a given number of counts from the datasets, which can be identified using an empirical 
cumulative distribution function (ECDF).  Similar to density graphs, in ECDF graph samples 
should almost overlap each other in order to conclude that samples are normalised to provide 
satisfactory results.  Figure 6.13 shows the observed probabilities for different mean counts 
from the ECDF function. It can be seen from Figure 6.13 that the observed probability for a 
given number of counts is almost similar for all samples, which provides evidence for a 
successful normalisation.  
 
Figure 6.13: Probability of observing a given number of counts for all samples. 
In order to see the similarities and differences between samples at this stage, a principal 
component analysis (PCA) can be very informative. However, PCA and other statistical 
approaches such as clustering are applied to homoscedastic data, which refers to a group of 
datasets in which the variance is the same for different ranges of mean values within a sample 
[285]. Due to the nature of RNA-Seq data, the variance increases with the mean value. In 
order to illustrate the difference in variance for different numbers of counts, two samples 
(control7 and control8) were plotted against each other (see Figure 6.14). In Figure 6.14, 
























each dot refers to a gene and it can be seen that genes with a higher number of counts have 
higher variances.  
 
 
Figure 6.14: Natural scale for sample-sample visualisation. 
One method to overcome this issue is to use a logarithmic scale instead of the normalised 
counts. As illustrated in Figure 6.15, this method provides a more constant variance across 
different ranges. However, by using this method, higher variation can be observed in the 
lower counts region. The variation in lower counts can be the result of Poisson noise for genes 
with lower counts, it can also be accounted for by the fact that the differences for genes with 
lower counts are maximised when a logarithm is applied. 
 
Figure 6.15: Log2 normalised counts scale for sample-sample visualisation. 


































The regularised logarithm transformation (rlog) and variance stabilising normalisation (vst) 
methods are useful approaches to correct for the variation in the lower counts region [284]. 
For genes with higher counts, rlog and vst act like a normal logarithm, however for lower 
counts of genes the values shrink. Figure 6.16 shows the effect of an rlog transformation on 
the counts. It can be seen that the rlog method stabilises the variance at different levels of 
the mean, and provides a satisfactory data format that prevents biases from affecting further 
analysis.   
 
Figure 6.16: rlog scale for sample-sample visualisation. 
Now that the datasets adhere to the characteristics for homoscedastic data, PCA can be 
applied to visualise the samples relations to each other. It can be seen from Figure 6.17 that 
a clear separation of two group conditions (control and mutated) is presented by using a PCA 
plot, which validates the experimental design for two conditions. In this plot, each dot 
represents a sample.  
 
Figure 6.17: PCA plot for all samples. 































6.2.4.3: Dispersion Estimation for Differential Gene Expression 
As previously discussed in Section 6.6, DESeq uses negative binomial distribution to 
calculate the dispersion parameter with results from biological variations in order to test for 
differential expression. Figure 6.18 illustrates the dispersion acquired by the 
estimateDispersions function from DESeq2 package. The black dots are the estimated 
dispersion for each gene, the red line presents the fitted line which is derived from a 
generalised linear model. The black dots are then shrunken towards the fitted line to form the 
blue dots, which are the final estimates of dispersion for each gene. The black dots that are 
surrounded by blue circles present the dispersion outliers that refer to genes which have very 
high dispersion estimates. The final estimates that are shown in blue are then used for 
hypothesis testing [284]. 
 
 
Figure 6.18: Dispersion estimates versus the mean normalised count from DESeq2. 
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6.2.4.4: Differential Gene Expression Test  
A Wald test is used in order to check for differentially expressed genes. A function called 
nbinomWaldTest in the DESeq2 package uses the dispersion estimates and the calculated size 
factors to test for the significance of the coefficient in a negative binomial generalised linear 
model. Then the results of this test can be extracted by the results function, in which the 
Benjamini-Hochberg method is used to return the adjusted p-value. Using the above functions, 
and filtering out those genes with an adjusted p-value grater that 0.1, 4591 genes were 
identified as being differentially expressed across two conditions. A snapshot of the results is 
shown in Figure 6.19.  
 
 
Figure 6.19: Results of DESeq2. 
One of the useful methods for visualising the results is an MA plot [286]. The X-axis of an 
MA plot shows the mean normalised counts, and the Y-axis represents the log2 fold changes 
in normal vs mutated samples (see Figure 6.20). Each dot in the MA plot represents a gene, 
and those shown in red are identified as differentially expressed genes using an adjusted p-
value of 0.1 as the threshold. It shows that genes with lower mean normalised counts that 
present high variability are accounted for using a shrinkage method to prevent those genes 




Figure 6.20: MA plot of results using adjusted p-value > 0.1.  
In order to take a more conservative approach to testing for differentially expressed genes, 
we select those genes that have log2 fold changes of at least double or half of that between 
two conditions, and then filter the results based on an adjusted p-value of 0.1. Using this 
approach, 186 genes were identified as differentially expressed genes and are depicted in the 
MA plot in Figure 6.21. 
 
 
Figure 6.21: MA plot of results using adjusted p-value > 0.1 and log2 fold changes of at least 
double or half. 
































Another useful way to visualise differentially expressed genes is a heat map. To this end, 
first differentially expressed genes from the previous step (186 genes) should be sorted based 
on their adjusted p-value. Since homoscedastic data should be used in order to have a valid 
statistical approach to calculate the distance between the genes, the data from the rlog 
transformation step should be utilised. By having the gene names form the sorted genes, the 
relevant dataset is extracted from the rlog matrix. Using an R/Bioconductor package called 
pheatmap for the top 25 differentially expressed genes, the heat map in Figure 6.22 is 
acquired. A clear trend can be seen from the heat map, in which the genes on the upper part 
of the heat map are highly expressed in control samples, while those genes in the lower part 
are highly expressed in the mutated samples. 
 




































































The information on the used packages and their versions is listed in Figure 6.23: 
R/Bioconductor session information for differential gene expression. 
 
 
Figure 6.23: R/Bioconductor session information for differential gene expression. 
6.2.5: Differential Exon Usage Analysis 
After aligning the RNA-Seq short reads similar to those in Section 6.1.3, one can investigate 
which exons are expressed differently across two conditions (normal vs mutated). As 
discussed in Section 6.1.7, to create a valid exon model in which an exon is only counted 
once, it is required to work with a flattened annotation file (GTF file). However, after creating 
this file, similar steps to differential gene expression are followed, including counting reads 
over genes, normalisation, dispersion estimation, and testing for differential exon usage. The 
R/Bioconductor code written for this analysis can be found in appendix 2.  
6.2.5.1: Preparing the Flattened Annotation File  
In order to create a flattened file (GFF format) from the annotated file (GTF file), first the 
relevant GTF file for Drosophila (the same version that was used for aligning reads using 
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STAR) is downloaded from the Ensembl website (Drosophila_melanogaster.BDGP5.76.gtf). 
Then using Unix terminal and a python file provided by the DEXSeq package 
(dexseq_prepare_annotation.py), one can easily create the flattened file as shown below: 
 
Python DEXSeq/python_scripts/dexseq_prepare_annotation.py --aggregate=no Drosophila_melanogaster.BDGP5.76.gtf 
Drosophila_melanogaster.BDGP5.76.gff 
 
where the argument --aggregate specifies if an exon cannot be assigned to a unique gene, it 
should be ignored.  
6.2.5.2: Counting Reads Over Exon Bins and Creating a DEXSeq Object 
The DEXSeq package provides a python file (dexseq_count.py) that uses a HT-Seq 
functionality (htseq-count) that has been modified to count the number of reads over exons. 
Using Unix terminal, a .txt formatted file can be created that contains these counts as shown 
below: 
 
DEXSeq/python_scripts/dexseq_count.py --format=bam --paired=yes --stranded=no Drosophila_melanogaster.BDGP5.76.gff 
control7.bam control7.txt 
 
   The above command should be run for each alignment file, separately changing the last 
two arguments’ names to correspond to the sample name under process. Since the aligned 
files are in BAM format, paired end, and not strand specific, this information is supplied by 
argument --format, --paired, and --strand respectively. After running the above command six 
times, each time for different samples, six .txt formatted files are acquired that are used for 
further analysis after being imported into R/Bioconductor.   
By using the DEXSeqDataSetFromHTSeq function from DEXSeq package, the required data 
frame for DEXSeq is then created. This function includes four arguments that need to be 
provided. The first argument accepts a character formatted file containing the directory path 
to count files (.txt files). The second argument is the sample information, which includes 6 
rows and 2 columns. Each row corresponds to a sample, the first column is the sample names 
and the second column contains information on sample conditions, which is similar to the 
sample information provided in Section 6.2.4.1. The third argument is the design formula that 
specifies we are looking for exon expression differences based on different conditions. Finally, 
the last argument is a character formatted file that contains the directory to the GFF files that 
was created using the python command.  
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The resulting file from the DEXSeqDataSetFromHTSeq function is saved as 
DEXSeqDataFrame which is in the DEXSeqDataSet format, and its information can be accessed 
similarly to that of the DESeqDataSet format explained in Section 6.2.4.1. The resulting 
DEXSeqDataFrame file for the six Drosophila samples has a dimension of 77026 by 12. The 
rows of the matrix correspond to the exon IDs, and several rows can be related to a given 
gene depending on the number of exons for that gene. The first six columns correspond to 
six samples, each column contains the number of reads assigned to the respective exon ID in 
a given gene, and we refer to them as the group 𝐴 columns. The next six rows provide 
information on the sum of reads that are assigned to other exons within the same gene, and 
we refer to them as the group 𝐵 columns. The DEXSeq package compares these two groups 
in order to identify an exon as being differentially expressed or not. Figure 6.24 illustrates the 
first 5 rows of this matrix for five exons that originate from two genes.  
 
 
Figure 6.24: Count table in DEXSeqDataFrame. 
6.2.5.3: Normalisation of Counts  
Similarly to differential gene expression analysis, it is also essential to account for the 
variation in the sequencing depths across different samples in differential exon usage. Using 
the estimateSizeFactors function of DEXSeq on DEXSeqDataFrame, the corresponding 
normalisation factors for samples can be calculated (12 columns as above). The table below 
gives the information on the estimated size factors for each sample.  
 
Table 6.4: Estimated size factors for each sample using DEXSeq. 
 Control5 Control7 Control8 Mutated5 Mutated6 Mutated7 
Size factors 
for Group A 
column 
1.07 1.05 0.94 1.01 0.87 1.10 
Size factors 
for Group B 
column 




To find out if the calculated size factors are satisfactory for further analysis, two plots were 
investigated, including the density of mean counts plot (see Figure 6.25) and the ECDF plot 
(see Figure 6.26). Two clear distributions can be seen from Figure 6.25 that correspond to 
both the group A and B columns, and since the line graphs for samples in each group almost 
overlap, it can be concluded that a satisfactory normalisation was performed. A similar trend 
is observed in the ECDF plot that provide further evidence to support this conclusion. 
 
Figure 6.25: Density of mean counts for all samples including group A (1-6) and B (7-12). 











































Figure 6.26: Probability of observing a given number of counts for all samples including group A 
(1-6) and B (7-12). 
6.2.5.4: Dispersion Estimation for Differential Exon Usage 
For differential exon usage, it is also essential to account for biological variations across 
samples, so that more interesting variations can be addressed. Figure 6.27 depicts dispersions 
obtained by the estimateDispersions function from the DEXSeq package, which is actually the 
same function as that of DESeq2, and the resulting figure can be interpreted as such.  

































Figure 6.27: Dispersion estimates versus the mean normalised count from DEXSeq. 
6.2.5.5: Testing for Differential Usage of Exons 
A likelihood ratio test (chi-squared distribution) is then used to test for differential exon 
usage [272]. This test is performed using the testForDEU function from the DEXSeq package, 
which uses the calculated dispersions and size factors and returns a p-value. Adjusted p-
values are also provided using the Benjamini-Hochberg method that can be used for multiple 
testing. Then the log2 fold changes and the exon usage coefficient are calculated using the 
estimateExonFoldChanges function. The results of these steps are saved as meta data for the 
DEXSeqDataFrame object, and can be accessed using the DEXSeqResults function. By filtering 
the data using an adjusted p-value of 0.1, 1053 exons were identified as being differently 
used across the control and mutated samples that correspond to 622 genes. A snapshot of 





Figure 6.28: Results of DEXSeq. 
 The figure below shows an MA plot in which the red dots represent the exons that are 
differently used across two conditions and identified as significant using an adjusted p-value 
of 0.1. It is shown that most of the exons that are identified as significant have a higher 
number of counts.  
 
Figure 6.29: MA plot for differential exon usage.  
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The results of DEXSeq can be visualised using the plotDEXSeq function. Figure 6.30 
illustrates the mean expression level for the exons of the FBgn0000382 gene that has the 
lowest adjusted p-value from the result of the analysis. The transcript models that can be 
used to visualise isoform expression of this gene are also included.  
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The information on the used packages and their versions is listed in Figure 6.31. 
 
 
Figure 6.31: R/Bioconductor session information for differential exon usage. 
6.2.6: Gene Annotation and Biological Relevance of Selected Genes 
It is essential to annotate the differentially expressed genes by adding the Entrez ID or 
gene symbol, which can be done using the AnnotationDbi package. A list of all of the 
differentially expressed genes (186 genes) including their symbol names can be seen in 
Appendix 3. First, the biological relevancies of the differentially expressed genes were 
investigated using the Web tool DAVID (database for annotation, visualisation, and integration 
discovery) [287]. Three gene ontology (GO) terms including biological process, molecular 
function, and cellular component were selected.  
Table 6.5 gives information on GO terms and the corresponding gene names within each 
term. With regards to terms for biological processes, ten genes (see Figure 6.32) contribute 
to the metabolic process of chitin.  One of the main substances in the exoskeletons of insects 
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is chitin [288], and all of the genes that contributed to the metabolic process of chitin are 
highly expressed, which results in the production of more chitin. Since it is known that AIP 
positive leads to a bigger body size, enrichment of this term as a result of these 10 genes 
would suggest that these genes contribute to body size and are linked to CG1847. Another 
main substance that contributes to the exoskeletons of insects is cuticle [288], which is also 
shown as an enriched term in the biological process of GO analysis. Ten genes (see Figure 
6.33) that are all highly expressed lead to the enrichment of this term in the biological process. 
In a previous study, it was shown that a mutation of TwdlD that is in the same family of 
proteins as TwdlG, TwdlV, and TwdlZ changes body shape in Drosophila [289]. These two 
biological process terms (chitin and cuticle) also appeared in the molecular function of GO 
analysis with the lowest p-value observed. Proteolysis and the lipid catabolic process are both 
known to contribute to the breakdown of protein and lipids respectively. 
 
Table 6.5: GO analysis.  
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structural constituent of chitin-based cuticle 
serine-type endopeptidase activity 
transferase activity, transferring acyl groups 
lipase activity 




























Figure 6.33: Log 2 fold change of genes contributing to chitin-based cuticle development. 
Using the functional annotation chart of DAVID for pathway analysis, two terms from the 
KEGG pathway [290] were enriched, including glycerolipid metabolism and folate biosynthesis. 
Research suggests that glycerolipid metabolism can control cell growth and cellular function 
[291].  Three genes including CG4582, CG5665, and CG6753 were identified to 






















the enrichment of the folate biosynthesis pathway. Folate is known to be important in the 
formation of new cells and their maintenances [292].     
 
6.2.7: Classification  
In order to apply a similar methodology to that of microarray for classification purpose of 
RNA-Seq data, it is essential to normalise RNA-Seq data as explained in Section 6.2.4.2. Since 
it was observed that the rlog transformation performed better compared to other methods 
like vst, in this pipeline the rlog of the count is used for classification purposes. Once the 
transformed count matrix is acquired, those features that have zero counts are removed. The 
resulting matrix can then be treated like microarray gene expression, and the standard 
procedure for classification analysis such as feature selection, designing a classifier, and 
classifier validation can be followed.  
Our proposed method for feature selection and classification in Chapter 5 (MRMR-COA-HS) 
was utilised for RNA-Seq classification. Figure 6.34 illustrates the steps to be performed for 
the proposed method. In brief, RNA-Seq data is first discretised into nine states (see Section 
5.3). Then, the top 100 features were selected using the MRMR filter method of feature 
selection (see Section 5.4) in the first stage of selection. This was done in order to reduce the 
computational time for the second stage of selection. In the second stage, the proposed COA-
HS was utilised in a wrapper setup with the SVM classifier to minimise the number of selected 
features, while maintaining a high accuracy for classification. A cost function similar to that in 
Section 5.5 was used for COA-HS, and the LOOCV model of validation was used to assess the 
performance of the SVM classifier.  
 
Figure 6.34: Schematic of the general methodology for RNA-Seq classification.  
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Following the proposed method (See Figure 6.34), 100 features were selected in the first 
stage of gene selection. In the second stage of gene selection these 100 features were used 
as input for COA-HS algorithm that is wrapper method and uses SVM to evaluate the features 
in terms of their power to discriminate between two experimental conditions. After 100 
iterations of COA-HS, six genes were selected which led to 100% classification accuracy. The 
selected genes include CG9021, CG14960, TwdlG, Osi24, CG6741, and CG9154. Figure 6.35 
illustrates comparative performance assessments of the SVM classifier for the selected six 
features, and those 100 features that were selected after the first stage of selection using 
MRMR. It can be seen that when 100 genes were used for classification purposes, an accuracy 
of 95.8% was achieved compared to 100% SVM classifier accuracy using the selected six 
genes as its input.  
 
 
Figure 6.35: Accuracy of SVM classifier. 
 
As mention in Section 6.2.4.4, when DESeq Bioconductor package was used to determine 
differentially expressed genes, 186 genes were selected based on an adjusted p-value of 0.1 
and log2 fold changes of at least double or half of that between two conditions. In the 
classification analysis using MRMR-COA-HS when normalised counts were used, in fact four 
genes (CG9021, CG14960, TwdlG, and Osi24) out of the six selected genes by the classification 
method were also among the 186 genes selected by DESeq Bioconductor package. CG6741 
and CG9154 genes that were selected by the classification method and were not found to be 
differentially expressed by DESeq, were then investigated to determine whether they have 
biological relevance for the dataset under investigation. It was found that the CG9154 gene 
is a protein coding gene, and its biological process is the positive regulation of transcription 
156 
 
from the RNA polymerase II promoter. The CG6741 gene is also a protein coding gene, and 
its biological process is involved with compound eye development. To date, there is limited 
amount of information available in the literature in regard to the selected genes. However, 
further exploration in the roles of these genes could shed more light on the function of these 
genes. 
6.2.8: Summary 
In this chapter, first an overview of RNA-Seq data analysis was given. Then a state-of-the-
art pipeline for RNA-Seq analysis was investigated.  
In respect to the overview of RNA-Seq data analysis, different steps required for successful 
RNA-Seq analysis were explored (see Figure 6.6). First, the importance of experimental 
consideration in the design of RNA-Seq was pointed out with regards to sequencing depth and 
number of replicates. Then the sources of possible contaminations in such experiments were 
explored, including technical and biological contaminations, and how one can eliminate such 
contaminations as a pre-processing step towards a successful RNA-Seq downstream analysis. 
It was discussed that the first step after pre-processing is aligning the short reads, either to 
reference transcripts or a reference genome. The aligner software should be spliced-aware if 
short reads are mapped to a reference genome, to account for exon-exon junctions. Examples 
of such aligners are STAR and TopHat. The aligner software usually creates a BAM file, which 
contains the genomic coordinates that reads are mapped to, and from this file a count matrix 
is then formed that summarises the number of reads for each genomic feature depending on 
the objective of the study. Several software was introduced to create the count table. Then 
different normalisation methods including RPKM were explored that aid in accounting for gene 
length and library size biases. In Section 6.1.6, statistical methods for modelling raw counts 
and estimating overdispersion that present in RNA-Seq data due to biological variation were 
investigated including the negative binomial model.  Finally, the concept of differential 
expression at gene and transcript levels were examined, and some of the well-known software 
for such analysis were identified. 
In respect to the state-of-the-art RNA-Seq analysis pipeline, details of this pipeline were 
outlined (see Figure 6.7). To perform the analysis, RNA-Seq data from Drosophila, including 
three normal and three AIP positive samples were used. Since there are many different 
R/Bioconductor packages, a state-of-the-art pipeline was implemented to perform the RNA-
Seq analysis for differential gene expression, differential exon usage, sample classification, 
annotation, and pathway analysis. Initially all samples were quality checked, and when 
required, pre-processing steps were performed to eliminate noise and low quality RNA-Seq 
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reads. Then the data was mapped to the Drosophila genome using the STAR aligner. These 
steps were carried out using OSX terminal. Afterwards, the data was imported into the 
R/Bioconductor software, and the initial differential gene expression analysis was carried out. 
Several steps were required for this analysis, including counting reads, normalisation, 
dispersion estimation, and differential gene expression tests, all of which were explored in 
detail. As a result, 186 genes were identified as differentially expressed. Furthermore, the 
relevancies of these genes were investigated using gene annotation and tools like DAVID. It 
was observed that the selected genes play an active role in biological processes, such as chitin 
and cuticle development. It is noted that both of these substances are related to the main 
structure for Drosophila body size. It is also known that cases that are AIP positive usually 
lead to bigger body sizes. Therefore, the selected genes could be used as a biomarker for 
such cases. Furthermore, a differential exon usage analysis was performed to identify any 
exon that is expressed differently across two conditions. Similar steps to that for differential 
gene expression were performed. It was observed that 1053 exons were differently used 
across control and mutated samples that correspond to 622 genes, with gene CG3954 
(FBgn0000382) having the smallest p-value. Finally, the use of machine learning for RNA-Seq 
data was investigated. To this end, the proposed method for microarray data in Chapter 4 
was implemented for RNA-Seq data classification. Initially, the count matrix was normalised 
and transformed using the rlog method, so that the data could have the characteristics of 
those in homoscedastic data. The transformed count matrix then underwent a two-stage 
feature selection in order to select the most informative features. As a result of classification, 
six genes were identified that achieve 100% classification accuracy for the SVM classifier. Four 
out of six genes were previously identified as differentially expressed. However, features 























Recent advances in gene expression have paved the way for investigating it on a genome-
wide scale. This has been possible with the help of technologies such as microarray and next 
generation sequencing, which in principle are very different one from another. This is because 
the resulting datasets from each technology require different approaches for a successful 
analysis. This thesis presented an investigation into the analysis of gene expression from both 
technologies, and provided new methods towards a more successful analysis for multi-
category diseases. 
7.1: Analysis of Microarray Data 
With regards to microarray technology, cancer classification is of the utmost importance. 
It improves personalised medicine by providing information for better treatment decisions by 
doctors. However, highly accurate disease classification remains challenging due to the curse 
of dimensionality in these datasets. Therefore, one of the main objectives of this study was 
to design solutions to enhance the classification accuracy of microarray data.  
Different steps were required to achieve a high classification accuracy, such as gene 
selection, clustering, and different classifiers, which were explored. It was noted in Chapter 3 
that in order to have a successful analysis, several aspects should be considered prior to the 
analysis such as the design of the microarray experiment and pre-processing, in order to 
remove systematic errors that present in microarray data. A detailed investigation into 
unsupervised methods such as K-mean, C-mean, hierarchical clustering, SOM, Bi-CoPaM, and 
UNCLES were carried out, and the importance of these methods in the visualisation and 
interpretation of experimental results was pointed out. With regards to the gene selection 
step, different methods such as filter and wrapper approaches were examined, and two 
classifiers, SVM and the MLP artificial neural network were studied. Several cancer datasets 
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including leukaemia, prostate cancer, and lymphoma were used to test the proposed methods 
for enhancing classification performances.  
Several original contributions have been made to this thesis that enhanced the accuracy of 
cancer classification. For example, a novel gene selection method, in which optimisation based 
clustering algorithms were utilised in order to cluster microarray data prior to gene selection 
was developed. This method incorporated a shuffling technique to choose the most 
informative genes and consequently led to a better classification performance. In this method, 
a new optimisation algorithm, COA-GA, was also proposed, for which a comparative 
performance assessment with other optimisation algorithms suggested that the proposed 
algorithm outperforms other optimisation algorithms such as PSO, GA, and COA in reaching a 
better minimum in fewer iterations. This ultimately resulted in better classification. However, 
it was noted that traditional clustering methods such as K-means, C-means, and hierarchical 
may not have any effects on the classification performance. Furthermore, from a comparative 
analysis between SVM and MLP, it was observed that the SVM classifier performs better than 
MLP for microarray cancer classification.  
Another method with regard to microarray technology was developed that is called MRMR-
COA-HS, which selects the most informative genes in two stages and provides high 
classification accuracy for cancer datasets under investigation. In the proposed method, 
initially the most relevant genes were selected using MRMR, which is a filter method, to reduce 
the computational time for the second stage of the selection process. In the second stage, a 
novel optimisation algorithm called COA-HS was proposed, and the cost function was designed 
so that the number of selected genes would be minimised while maximising the accuracy of 
the SVM classifier. The LOOCV method was used to examine the performance of the proposed 
method, and the results were compared to other algorithms such as PSO, GA, HS, and COA. 
Overall, this approach resulted in a high classification accuracy for all optimisation algorithms 
mentioned above. However, it was observed that COA-HS outperformed other methods, by 
both achieving a higher classification accuracy for all datasets, and selecting a lower number 
of genes to achieve its accuracy compared to other optimisation methods. Since each 
algorithm was ran 20 times, those gene that were selected at least 10 times out of 20 runs 
where then further investigated and found to be biologically relevant to each cancer dataset.  
This part of the thesis provides new approaches that enhance prognosis and classification 
of cancer using microarray data that provides reliable classification results, which can lead to 
more informed decisions by doctors.   
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7.2: Analysis of RNA-Seq Data 
With regards to next generation sequencing (RNA-Seq), the required primary analysis for 
successful downstream analysis includes several steps such as pre-processing, alignment of 
short reads to a reference genome, creation of a count table, and normalisation. However, 
depending on the downstream analysis, the statistical modelling of the count table and 
normalisation can differ. Since the introduction of RNA-Seq, the preferred platform for the 
analysis of such a dataset has been R/Bioconductor, and therefore numerous packages have 
been proposed to aid in a successful analysis. This has led to an overwhelming number of 
choices that one can opt for, and many studies have proposed pipelines to use specific 
software to perform such analyses from start to downstream analysis of choice. However, due 
to advances in statistical methods that applied to RNA-Seq, these pipelines have undergone 
several changes. This thesis investigated a state-of-the-art pipeline that uses more cited, 
recently developed software, and can be used for different steps towards downstream 
analysis, such as differential gene expression and differential exon usage. Nevertheless, there 
has not been enough research to apply classification for RNA-Seq thus far, as the focal point 
for this dataset is finding the features, including genes, exons, and isoforms that are being 
used differently across different conditions. Therefore, as a part of the proposed pipeline, the 
classification approach that was used for two-stage gene selection with microarray was utilised 
to pave the way for using statistical methods from microarray in next generation sequencing 
for classification purposes. 
To investigate this pipeline, RNA-Seq data from AIP deficient Drosophila that was produced 
in house at Queen Mary University of London was used. Initially, a differential gene expression 
analysis was performed, and important steps including counting reads, normalisation, 
dispersion estimation, and differential gene expression tests were investigated, and the 
required packages for these steps were pointed out. As a result of the differential gene 
expression analysis, 186 genes were identified as differentially expressed. By examining the 
functions of the differentially expressed genes, it was discovered that these genes are 
essential in biological processes such as chitin and cuticle development, both of which are 
important factors for Drosophila’s body size. Since AIP-deficient cases can lead to a bigger 
body size, the selected differentially expressed genes were deemed to play a direct role in the 
case study under investigation, and can be used as biomarkers. 
Differential exon usage was then investigated to provide information for alternative 
splicing, in which similar steps to that for differential gene expression were identified to be 
important for a successful analysis, while the differences in modelling count were also pointed 
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out. As a result of this analysis, 622 genes were identified to have exons that are differently 
expressed across control and mutated samples (1053 exons). 
Finally, the classification was successfully performed for RNA-Seq data. The count table 
was normalised and then treated as a microarray matrix for classification. For classification 
purposes, the MRMR-COA-HS method that was proposed in Chapter 4 for microarray data was 
used. As a result, six genes were selected that led to 100% classification accuracy for SVM. 
Two out of six of the selected genes by MRMR-COA-HS were not found to be differentially 
expressed when performing differential gene analysis.  
7.3: Suggestions for Future Work 
Future work for this research can be divided into two parts. The first part concerns 
microarray data analysis, and the limitations of the proposed methods being that they are 
designed for a two-class classification task. However, this can be expanded on for multi-class 
classifications in number of ways. For instance, a library for SVM is proposed to achieve this 
objective that is known as LIBSVM [293], and can be used instead of simple SVM. The 
proposed methods for classification in Chapter 4 and Chapter 5 can be used for extra 
microarray datasets to further validate these methods, and upon successful validation, these 
methods could be used as a benchmark for cancer classification. The proposed optimisation 
algorithms can be used for other optimisation-based problems too, as they outperform other 
algorithms such as GA, PSO, HS, and COA at achieving a better minimum in fewer iterations. 
This can reduce the computational time significantly, while providing better results at the 
same time. Finally, gene selection also plays an important role in achieving high classification 
accuracy. Therefore, it is worth investigating new feature selection methods that have recently 
been proposed for other scientific fields like text classification, for the purpose of cancer 
classification.  
The second part relates to RNA-Seq data. As mentioned in Section 6.2.7, once the count 
table is normalised appropriately, statistical approaches that used for microarray data can be 
applied in a similar fashion. Therefore, as a future study, one could investigate different 
clustering methods to identify hidden patterns within RNA-Seq data that could not be observed 
with other analyses. Furthermore, differential isoform analysis has recently attracted many 
researchers, and the objective is to observe which isoforms are expressed differently across 
different experimental conditions.  The most cited tool for differential isoform analysis to date 








#TO USE PARALLEL COMPUTING 
library("BiocParallel") 
register(MulticoreParam(5)) 
#***********************1. READING DATA INTO R**************************************************** 
#==============================dir to datasets 
dir="/Users/Main-Data" 
#==============================dirs to bam files 
AlignedFiles <- list.files(dir, ".bam$", full.names = TRUE) 
#==============================dir to gtf file 
GTFfile <- file.path(dir, "Drosophila_melanogaster.BDGP5.76.gtf") 
#==============================read in bamfiles by Rsamtools 
library(Rsamtools) 
BAMFileList <- BamFileList(AlignedFiles,yieldSize=10^5) 
#============================== create sample table 
     SampleInfo = data.frame( 
      row.names =       c("Control5","Control7","Control8","Mutated5","Mutated6","Mutated7"), 
  condition = c("Control","Control","Control","Mutated", "Mutated","Mutated")) 
      
#**************************2. COUNT THE READS ***************************************************** 
library(GenomicFeatures) 
TxDbFromGFF <- makeTxDbFromGFF(GTFfile, format="gtf") 
ExonByGenes <- exonsBy(TxDbFromGFF, by="gene") 
length(ExonByGenes) 
summary(elementNROWS(ExonByGenes)) 
setSessionTimeLimit(cpu = Inf, elapsed = Inf) 
library(GenomicAlignments) 





###add column data 
colData(RangedSummarizedExperiment ) <- DataFrame(SampleInfo) 
## Visualizing sample-sample distances 
plot(assay(RangedSummarizedExperiment)[,2:3]) 
********************3 CREATE OBJECT FOR DESEQ2 ************************************************* 
### Creating a DESeqDataSet object 
library(DESeq2) 











multidensity( counts(DESeqDataFrame, normalized = T), 
              xlab="mean counts", xlim=c(0, 1000)) 
 
multiecdf( counts(DESeqDataFrame, normalized = T), 
           xlab="Mean counts", xlim=c(0, 1000)) 
#============exploratory data analysis 
loggeomeans <- rowMeans(log(counts(DESeqDataFrame))) 
hist(log(counts(DESeqDataFrame)[,1]) - loggeomeans,  
     col="grey", main="", xlab="", breaks=40) 
log.norm.counts <- log2(counts(DESeqDataFrame, normalized=TRUE) + 1) 
log.norm <- normTransform(DESeqDataFrame) 
rs <- rowSums(counts(DESeqDataFrame)) 
mypar(1,1) 
# not normalised 
boxplot(log2(counts(DESeqDataFrame)[rs > 0,] + 1))  
# normalised 
boxplot(log.norm.counts[rs > 0,]) 
plot(log.norm.counts[,2:3]) 
### rld transformation  
rld <- rlog(DESeqDataFrame) 
plot(assay(rld)[,2:3]) 
### vsd transformation  
vsd <- varianceStabilizingTransformation(DESeqDataFrame) 
plot(assay(vsd)[,2:3]) 
#The principal components (PCA) plot  
plotPCA(rld, intgroup="condition") 
 
#**************** 5 Differential gene expression****************************************************** 
DESeqDataFrame <- estimateDispersions(DESeqDataFrame) 
plotDispEsts(DESeqDataFrame) 
#test for differential analysis 
DESeqDataFrame <-  nbinomWaldTest(DESeqDataFrame) 
DESeq2Results <- results(DESeqDataFrame, pAdjustMethod = "BH") 
summary(DESeq2Results) 
table(DESeq2Results$padj < 0.1) 
DESeq2ResultsFoldChange <- results(DESeqDataFrame, lfcThreshold=1) 
table(DESeq2ResultsFoldChange$padj < 0.1) 
#####FIND DIFFERENTIALLY EXPRESSED GENES####### 
#The top "n" high and low expressed genes by adjpval: 
n = 5 




     DiffExprGenes <- DESeq2ResultsFoldChange[ which(DESeq2ResultsFoldChange$padj < 0.1 ), ] 
dim(DiffExprGenes) 
#all differentially expressed genes 
DiffExprGenesbyPadj<- DiffExprGenes[ order( DiffExprGenes$padj ),] 
      write.csv( as.data.frame(DiffExprGenesbyPadj), file="Diff-Exp-Genes.csv" ) 
#sort it by the log2 fold change estimate 
      DiffExprGenesSortedByfoldChange <- DiffExprGenes[ order( DiffExprGenes$log2FoldChange ), ] 
#TOP UP and DOWN:   
      DiffExprGenesbyPadjFold <- rbind(head(DiffExprGenesSortedByfoldChange,n),tail(DiffExprGenesSortedByfoldChange,n)) 
DiffExprGenesbyPadjFold 
      write.csv( as.data.frame(DiffExprGenesbyPadjFold), file="Diff-Exp-Genes-TOP30.csv" ) 
DiffExprGenesbyPadjFold[c(1:5,(2*n-4):(2*n)), c('baseMean','log2FoldChange','padj')] 
 
#****************6 VISUALISING THE RESULTS *************************************************** 
 




      plotMA(DESeq2ResultsFoldChange, main='Control vs. Mutated', ylim=c(-4,4)) 
#============================== Plot top gene 
# Examine the counts for the top gene 
mypar(1,2) 
      plotCounts(DESeqDataFrame, gene=which.min(DESeq2ResultsFoldChange$padj), intgroup="condition") 
#the gene which had lowest expression log-fold0change 
      plotCounts(DESeqDataFrame, gene=which.min(DESeq2ResultsFoldChange$log2FoldChange), intgroup="condition") 
#the gene which had which had highest expression log-fold0change 




DiffExprGenesbyPadj<- DiffExprGenes[ order( DiffExprGenes$padj),] 
SortedGenes <- DiffExprGenesbyPadj 
      topgenes <- head(rownames(SortedGenes),25) 
topgenes <- rownames(SortedGenes) 
#topgenes <- head(rownames(DiffExprGenesDoubleOrHalf),) 
# matrix from rld for the selected genes  
mat <- assay(rld)[topgenes,] 
 
#Fourth, we subtract the rowMeans from this matrix to have a uniform plot 











#********************6 RESULTS *********************************** 
#============================== Export results into CSV 
write.csv( as.data.frame(resSort), file="results.csv" ) 
#============================== Annotation 
#simply add symbol to the genes 
DiffExprGenes$SYMBOL <- mapIds(org.Dm.eg.db, 
                               keys=row.names(DiffExprGenes), 
                               column="SYMBOL", 
                               keytype="FLYBASE", 
                               multiVals="first") 
#simply add entrez to the genes 
DiffExprGenes$ENTREZID <- mapIds(org.Dm.eg.db, 
                                 keys=row.names(DiffExprGenes), 
                                 column="ENTREZID", 
                                 keytype="FLYBASE", 
                                 multiVals="first") 
dim(DiffExprGenes) 
write.csv( as.data.frame(DiffExprGenes), file="Annotation.csv" ) 
getwd() 





























Appendix 2: R-code for diffrential exon usage 
  
 
#TO USE PARALLEL COMPUTING 
multicoreWorkers() 
BPPARAM = MulticoreParam(workers=5) 
 
#**********************1. PREPERATION ************************************* 
######Done in TERMINAL  
#######1.1 Preparing the annotation 
#following should be run once to create flattened gff from gtf file. 
 
python/Library/Frameworks/R.framework/Versions/3.3/Resources/library/DEXSeq/python_scripts/dexseq_prepare_annot    
ation.py --aggregate=no Drosophila_melanogaster.BDGP5.76.gtf Drosophila_melanogaster.BDGP5.76.gff 
# 
######1.2.  counting reads 
#following should be run for all samples 
# gff_file is the output file from perevious command 
gff_file=Drosophila_melanogaster.BDGP5.76.gff   
#change "bam_file" in sequence with desired bam file for all samples (note that the samples should be sorted by name         





format=bam --paired=yes --stranded=no $gff_file $bam_file $out 
 
 
#**********************2. READING DATA INTO**************************************************** 
 
dir="/Users/Main-Data" 
CountFilePaths = list.files(dir, pattern="txt$", full.names=TRUE) 
basename(CountFilePaths) 
class(CountFilePaths) 
flattenedFilePath = list.files(dir, pattern="gff$", full.names=TRUE) 
basename(flattenedFilePath) 
#sample table 
SampleInfo = data.frame( 











#**********************3. CREATE OBJECT************************************************* 
 
library("DEXSeq") 
DEXSeqDataFrame = DEXSeqDataSetFromHTSeq( 
  CountFilePaths, 
  sampleData=SampleInfo, 
  design= ~ sample + exon + condition:exon, 
  flattenedfile=flattenedFilePath ) 
 
#**********************3. NORMALIZATION ************************************************** 
 
#measure relative sequencing depth using SizeFactor 




multidensity( counts(DEXSeqDataFrame, normalized = T), 
              xlab="mean counts", xlim=c(0, 1000)) 
multiecdf( counts(DEXSeqDataFrame, normalized = T), 
           xlab="Mean counts", xlim=c(0, 1000)) 
dev.off() 
 
#Dispersion estimation (second line to parallel so quick) 
DEXSeqDataFrame = estimateDispersions( DEXSeqDataFrame, BPPARAM=BPPARAM) 
plotDispEsts( DEXSeqDataFrame ) 
 
DEXSeqDataFrame = testForDEU( DEXSeqDataFrame, BPPARAM=BPPARAM) 
DEXSeqDataFrame = estimateExonFoldChanges(DEXSeqDataFrame, fitExpToVar="condition", BPPARAM=BPPARAM) 
# results table 
DEXSeq_Results = DEXSeqResults( DEXSeqDataFrame ) 
plotMA(DEXSeq_Results, cex=0.8) 
 
table (DEXSeq_Results$padj < 0.1 ) 
table(tapply(DEXSeq_Results$padj<0.1,DEXSeq_Results$groupID,any)) 
 
DifferntialExons <- DEXSeq_Results[ which(DEXSeq_Results$padj < 0.1 ), ] 
dim(DifferntialExons) 
 
#you added next 3 line for extra... 
TopGenesSorted <- DifferntialExons[ order( DifferntialExons$padj ), ] 
dim(TopGenesSorted) 
 
TopGeneSortedNames <- rownames(TopGenesSorted) 
TopGeneSortedNames 
 








#draw the fitted expression levels of each of the exons of gene FBgn0010909 for each condotion 
plotDEXSeq( DEXSeq_Results, "FBgn0000382", legend=TRUE, cex.axis=1.2, cex=1.3, lwd=2 ) 
 
# visualize the transcript models, which can be useful for putting differential exon usage results into the context of  
isoform expression. 
plotDEXSeq( DEXSeq_Results, "FBgn0000382", displayTranscripts=TRUE, legend=TRUE, cex.axis=1.2, cex=1.3, lwd=2 ) 
 
#the count values from the individual samples. The counts are normalized by dividing them by the size factors 
plotDEXSeq( DEXSeq_Results, "FBgn0000382", expression=FALSE, norCounts=TRUE, legend=TRUE, cex.axis=1.2,  
cex=1.3, lwd=2 ) 
 
#create browsable, detailed overview over all analysis results, allowing a more detailed exploration of the results. 
#saved in getwd() 
setwd("~/Desktop") 
DEXSeqHTML( DEXSeq_Results, FDR=0.1, color=c("#FF000080", "#0000FF80"),BPPARAM=BPPARAM) 
 






























Appendix 3: Diffrentially expressed genes 
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